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ABSTRACT
This thesis describes our own approach for the construction of turn 
mimetics (y- and inverse y-tum) and for an a-helix constraint, based on the 
heterocyclic skeleton of 4-amino-3-isoxazolidinone.
A review of the types of secondary structures and turns found in peptides, 
and their putative importance for bioactivity is described. This is followed by an 
account of the different types of peptide mimetics that have been synthesised and 
incorporated into bioactive peptides for structural-activity studies.
A detailed study of the imidoyl-X function in the dihydroisoxazole ring 
(where X = Cl, Br, OS02Me and 0 S 0 2CF3) as a possible route to incorporate 
amino esters is reported. The generation and the incorporation of the 
3-chloro-4-amino-4,5-dihydroisoxazole as a potential heterocyclic constrained 
glycine mimetic, into the C-terminus of a peptide chain has been achieved. 
Conformational studies by NMR have been applied to examine the "constrained'’ 
peptide for a y- and inverse y-tum feature.
Work applied to the synthesis of the more constrained variants; cis-fused 
bicycle II (as an inverse y-tum mimetic), bridged bicycle HI (as a new type of 
constraint) and spiro-fused bicycle IV (as an a-helix constraint) is also described.
Finally, the potential use of chloromethoxyphthalimde and N,N'- 
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1. Importance o f Constrained Peptides
Over recent years there has been intense interest in determining the 
relationship between three dimensional structure (conformation) and biological 
activity (binding and transduction) in small polypeptide hormones and 
neurotransmitters. This was sparked by the tremendous potential offered by not 
only gaining valuable understanding of the bioactive conformation of a peptide at 
its receptor/acceptor site but also from the use of this information to synthesise 
more stable and potent analogues as drug candidates. Early work centred on the 
substitution and deletion of amino acids in the peptide chain in order to determine 
the minimum active sequence required for bioactivity. This was then followed by 
systematic substitution of an L-amino acid by the corresponding D-amino acid 
which provided insight into the stereostructural requirement of a specific residue 
for peptide-receptor interaction. Side chain residues were similarly probed by 
replacement with a methyl group or by pseudoisosteric groups possessing different 
electronic properties. This enabled the examination of the importance of different 
side chains and their stereoelectronic properties for interaction with the receptor. 
These studies have also been greatly assisted by the use of rapid semi-automatic 
solid phase synthesizers, as a means of generating a wide variety of substrates in a 
straight-forward fashion.
An alternative way of minimising the conformational flexibility of a 
target peptide is by introduction of a constrained analogue. The premise for this 
approach was that an appropriate conformational constraint would restrict a 
residue, or a group of residues, to a small region of conformational space. Thus, 
when a peptide interacts with its receptor, or an acceptor molecule such as an 
enzyme, the conformation required for binding will bear a close relationship to that
-2-
seen in solution, given that there will be a high free energy barrier preventing 
alteration of a constrained conformation/2*
1.1 Examples o f Backbone Constraints Commonly Used
There are numerous types of constraints that can be applied to restrict 
peptide conformational flexibility. The most general approach involving the 
introduction of a non-covalent modification to the backbone of the polypeptide 
chain provides insight to conformational stability and the importance of secondary 
structures in polypeptides and proteins.
The simplest form of a backbone constraint involves the modification of 
the amide bond itself. This field has been extensively explored and is the subject 
of a comprehensive review by Spatola/1* The different types of constraints that 
are most widely applied to restrict flexibility and hence the conformational space 
that a peptide can occupy are illustrated below:
i. Substitution of (D) for the naturally-occurring (L)-amino acids. This 
common manipulation involves the inversion of stereochemistry of the 
a-carbon atom in an amino acid component of a peptide and results in the 
generation of a diastereomeric system.
ii. Methylation of the a-C or of the nitrogen of the peptide bond (CO.NH 
replaced with CO.NMe). This type of constraint reduces the hydrogen 
bonding capacity of nitrogen as well as increasing the steric bulk 
associated with the side chain.
iii. Desipeptide analogues where NH in CO.NH is replaced by O or S to give 
either an ester (CO.O) or a thioester (CO.S) linkage.
iv. Intercalation of methylene into the peptide backbone using a p-amino acid 
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by either NH-CH2-CHR-CO or NH-CHR-CH2-CO.
v. Carba replacement involves modification of the amide group itself. For 
example, CO.NH may be replaced by CH2CO, CH2NH, CH2CH2 or 
CH=CH. These modifications will alter the stability and conformational 
preference of structures containing important hydrogen bonded features.
vi. The use of retro-peptides which involves reversal of the amide bond 
(-CO.NH-to-NH.CO-).
vii. Other changes can be carried out on the a-amino group. This may 
involve replacing the functional group by analogues based on hydrazino 
(NH replaced with NHNH), aminoxy (NH replaced with NHO), and 
N-amine (NH replaced with NNH^.
For more details see Spatola^ and Hruby 2^^  and Scheme I.
These types of amide bond replacement provide insight into the importance of 
specific amide bonds and amino acid residues for ligand-receptor (acceptor) 
interactions. These modifications may also serve to stabilise peptide substrates 
against enzymatic degradation and are also of use in the design of novel protease 
inhibitors.
1.2 Allowed and Disallowed Conformational Space
One important way of visualising the influence of constraints on 
individual amino acids was pioneered by the group of Ramachandran and 
Sasisekharan/4) This group used hard-sphere approximations to calculate the 
non-bonding interaction between atoms as a function of the torsion angles (j) and y. 
In this method, atoms were assumed to be hard spheres of fixed radii (usually the 
van der Waals radius) and these spheres were not allowed to overlap. This 
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energetically ‘allowed’ and ‘disallowed’ conformational space. Structures having 
no hard-sphere overlap (no contacts) were considered as allowed conformations 
and those having hard-sphere overlaps (contacts) were considered disallowed. The 
allowed and disallowed conformational space of a particular molecule is expressed 
in what is known today as the Ramachandran Map. This is a two-dimensional 
graphical representation of a three-dimensional situation, where two variables (§ 
and \\f) are plotted against one another within an ‘allowed’ energy boundary 
(Figures 1A and IB). Figure 1A shows that 50% of the plot of possible 
conformational space is accessible to glycine (N-acetyl-Gly-N'-methylamide) and 
that addition of a single methyl group to the a-carbon (to generate alanine) to give 
N-acetyl-Ala-N'-methylamide decreases this accessible area to 16% (Figure IB).
The hard-sphere approximation method was later refined to include 
minimum energy conformational calculations. This approach is more 
representative of a real system, where spontaneous shifting from a higher energy 
state to a lower energy state can occur (if a pathway is available). There are 
various computational programmes available to calculate the energy minima of a 
peptide.^ By fixing both bond lengths and bond angles and by assuming that the 
peptide bond is in the s-trans configuration and with no account being made for 
rotation of side chain groups, the conformational energy of the peptide is 
calculated as a function of the torsion angles (j> and \jr. The conformational 
properties of the peptide can then be represented as an energy contour map, where 
torsion angles <J) and \j/ are plotted against one another and the conformational 
energy levels are represented by contours (Figures 2A and 2B). The local energy 
minima are usually marked by small dots and these are determined by separate 
minimization calculations. No contour lines are drawn in the energetically 
forbidden regions (above 11 kcalmol"1).
The contour maps shown in Figures 2A and 2B have similar features to
Scheme II
<0
<j> Is the torsion angle between Cj N2Q3C4
V Is the torsion angle between N2Q3C4N5
© Is the torsion angle between C^C^NgCg (amide bond) 
X  Is side chain dihedral angle
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those obtained by the hard-sphere approximation method (Figures 1A and IB). 
The former are, however, more informative by showing that an amino acid residue 
can exist in several low energy minima states, rather than just one predominant 
structure.
The notation used for torsion angles 6 and \\f to describe the backbone of a 
peptide chain was defined by IUPAC-IUB in 1969^ and is represented in Scheme 
IL
Even though the hard sphere approximation method may be considered to 
be primitive and an over simplification, the results are nonetheless instructive, as 
secondary structural units, such as turns, sheets and helixes, are found to be in 
regions of allowed conformational spaced  This indicates that the interresidue 
hydrogen bonds present in these ordered structures may be established, without 
having to overcome unfavourable steric contacts between adjacent residues (Figure 
3).
1.3 Secondary Structures and Turns in Peptide and Proteins
One should be aware of the different types of secondary structures and 
turns that a peptide chain can exhibit.^ The most commonly occurring secondary 
structure found in polypeptides and proteins is the a-helix. An a-helix is used to 
describe a single strand of peptide chain, twisted in either a right-hand (RH) or a 
left-hand (LH) direction to form a helical structure, with 3.6 amino acid residues 
per turn and a hydrogen bond between the C=0 of residue n with the NH of residue 
n+4 (Figure 4). The nomenclature for describing the basic structure of polypeptide 
a-helix is 3.613-helix, where 13 is the number of atoms in the hydrogen-bonded 
loop. The backbone conformation for a RH a-helix may be described by <J>=-60° 
and y=-60° and for the LH a-helix, <J>=+60° and \jr=+60°. The 310-helix can also
Fig. 5
Anti-parallel p pleated sheet
Fig. 6
Parallel p pleated sheet
Fig. 7 L-PRO
Structure o f  the cyclic pentapeptide cycUMGIy-Pro-Gly-u-Ala-l’ro) 
from X-ray diffraction (Karlc, 1978)
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occur and these units are found extensively in globular proteins. This feature has 3 
residues repeating and hydrogen bonding occurring at residue n+3 instead of n+4 
and has a backbone conformation <j>=-60° and y=30°. This is also a "tighter" helix 
with only 10 atoms in the hydrogen-bonded loop.
The second type of secondary structures found in polypeptides and 
proteins are p-sheets. These consist of straight or extended chains with alternating 
side chains and hydrogen bonding occurring between adjacent parallel and 
anti-parallel chains, known respectively as parallel or anti-parallel p-sheets. The 
p-sheets are also "pleated" with successive a-carbons falling either slightly above 
or below the plane of the sheet. The anti-parallel p-sheet has hydrogen bonds 
perpendicular to the peptide strand with narrowly spaced bonding pairs alternating 
with widely spaced pairs (Figure 5). The parallel P-sheets have evenly-spaced 
hydrogen bonds at angles between the strands (Figure 6). The backbone 
conformation for an anti-parallel p-sheet is describe by <j>=-139° and \j/=+135° ^ d  
that of a parallel p-sheet by <J>=-119° and \j/=+l 13°.
A turn structure found in peptides has been defined as "a site where a 
polypeptide chain reverses its overall direction"/8* Proline is often found at these 
bends/8* because the pyrrolidine ring fixes the proline torsion angle <}> at a value of 
-60° or +60° for the (D) or (L)-configuration respectively. The values allowed for 
the corresponding \jf torsion angle are approximately -55° and 130° (D-proline) and 
55° and -130° (L-proline). The torsion angles <J)=-60° and \j/=-55° lead to partial 
reversal in the direction of the peptide chain and, as a result, proline is often used 
as a constraint, to induce a "turn" in a polypeptide chain (Figure 7).
There are two main types of turns that we need to consider which are 
known as p-tums and y-tum s. A p-tum is established when hydrogen bonding 
occurs between the C=0 of residue i with the NH of residue i+3 (via a ten
Fig. 8
Type I Type I'
Type H Type 11'
p-Turns
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membered ring). A y-tum and its inverse y-turn occurs when a hydrogen bond is 
formed between the C=0 of residue i with the NH of residue of i+2 (via a seven 
membered ring) (Figure 9).
There are three main types of p-tums: I, II and III with corresponding 
mirror images I', II' and IH'. These structural features were first described by 
Venkatachalan in 1968^ from theoretical conformational analysis and the 
dihedral/ torsion angles (<j> and y) of these types of turns were later determined by 
Nemethy and Printz (1972)<10) (Table I). A Type m  p-tum has repeating values of 
<}> and \|f angles of -60° and -30° and is described as a helical turn similar to the 310 
helix/6) Type I and II P-tums are non-helical and the peptide chain is folded back 
onto itself, so that the first and fourth a-carbons are only 5A apart (Figure 8). 
Type I and Type II differ from one another by rotation of the central peptide unit 
by a 180° flip.
A new category was devised to accommodate the types of turns observed 
that were of a combination of the above three main types of p-tums/11,6) A type 
IV turn is used to describe bends that have at least two of the four torsion angles 
with values >40°. Type V and V' turns correspond to torsion angles values of a 
seven membered hydrogen bonded ring conformation ie. y(Ceq7 ) or inverse y(Cax7 ) 
turn and is often described as a combination of two y-tums. A Type VI bend 
consists of a cis peptide link between residues i+1 and a proline residue at i+2 in 
the polypeptide chain. Finally, the Type VII turn is used to describe a peptide 
chain where the first and fourth a-carbon are <7 A apart and where a large torsion 
angle at Vi+i(~180°) is coupled with a low value of <j)i+2 (<60°) or where a low 
value of Vi+i(<60°) is coupled with a large valve of <j>i+ 2  (~180°) is observed. 
These often occur as ‘kinks’ in polypeptide chains and therefore are not true 
reverse turn structures.
Fig. 9
y Turn Inverse 7  Turn
Y Turns
Table I
Types Turns ^♦1 YU1 $1*2 Y|+2
P turns 
Type 1 -60° -30° -90° 0
Type I* +60° +30° +90° 0
Type II -60° +120° +80° 0
Type if +60° -120° -80° 0
Type III -60° -30° -60° -30°
Type Ilf +60° +30° +60° +30°
Type V -80° +80° +80° -80°
Type Via -60° +120°
oo9
0
Type Vlb -120° +120° -60° 0
Y Turns
Turn 70-80° -60 to -70°





The second type of constraints, covalent modifications, involves the formation 
of cyclic peptides by tying the two end termini together or by cyclising a side chain 
onto the backbone of the peptide chain. Prior knowledge of the bioactive amino 
acid sequence is required before this technique can be applied and the formation of 
cyclic peptides of this type has been reviewed by Hruby et alS2,12^  and by Rose et 
alS8) These cover the methods available for synthesizing shorter cyclic peptides, 
together with modifications of the backbone of the peptide chain. In addition, with 
the aid of conformational analysis, the elucidation of the transduction processes 
and the synthesis of more stable peptide hormone analogues has been possible. 
One such example is somatostatin, a cyclic tetradecapeptide with the amino acid 
sequence Ala1-Gly2-Cy s3-Lys4-Asn5-Phe6-Phe7-Trp8-Lys9-Thr10-Phe1 ^ Thr12-
-Ser13-Cys14. This peptide is produced by the hypothalmus and by the endocrine 
glands and inhibits the release of glycogen, insulin, gastrin, secretin and growth 
hormone. Interest in somatostatin lies in its potential use to control diabetes. 
Verber et a/ 1^0,11,8) have systematically synthesised smaller and less flexible 
analogues of somatostatin and deduced the amino acid sequence that was essential 
for bioactivity which was shown to be Phe7-Trp8-Lys9-Thr10. By substituting 
D-Trp8 into this sequence, an increase in somatostatin bioactivity was observed. 
This, together with the use of NMR and computation conformational analysis, 
suggested the presence of a Type II' p-tum in the bioactive conformation of 
somatostatin. This effort led eventually to the synthesis of a highly potent cyclic 
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Cyclisation o f side chains to the backbone of the peptide chain has produced a 
wealth o f information regarding the range of turns and secondary structures found 
in bioactive peptides/8) The use of y, 5, e-lactams as a constrained glycine unit 
with a fixed tra n s  amide bond has been described. Freidinger has demonstrated 
the ease o f formation of 5, 6, and 7-membered lactams by intramolecular 
alkylation o f methionine dipeptide sulfonium salt (1) (Scheme III) to afford the 
y-lactam and by intramolecular cyclisation of the dipeptide omithine-lysine 
derivative (2) to the 8 and €-lactams (Scheme IV )/15) Since then, other routes to 
lactam constraints o f this type have been devised.(16a’b)
The y and 8-lactams are mainly used to promote a (3-turn conformation in 
a peptide chain, though there have been recent doubts cast over the validity o f  
these constraints/17a,b,c) Computational studies by Osguthorpe have shown that 
(3-tum conformations are not favoured for a y-lactam, unless the y-lactam is 
appropriately modified to contain a bulky substituent (ie.rm-butyl), on the 
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The first reported use of y-lactam as a conformational constraint was in 
studies relating to lutenising hormone-releasing hormone (LH-RH)^18) which is 
produced by the hypothalamus and regulates the levels of pituitary hormones, 
lutenizing hormone (LH) and follicle-stimulating hormone (FSH). The levels of 
LH and FSH in turn, regulate the reproductive processes of ovulation and 
spermatogensis. The potential use of LH-RH and its analogues lies in the
S ch em e V
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treatment of infertility and as contraceptive agents/19) LH-RH is a decapeptide 
with amino acid sequence Glu1-His2 -Trp3 -Ser4-Tyr5 -Gly6-Leu7 -Arg8 -Pro9- 
-Gly1 0-NH2. By examining systematic modification of each residue for biological 
activity, it was found that replacement of Gly6 -Leu7  for the constrained variant 
D-Ala6 -N-Methyl-Leu7  led to an increase in potency. From conformational energy 
calculations, this result was shown to be consistent with a p-tum as a biologically 
important conformation. To investigate the bioactive P-tum conformation, the 
y-lactam constraint as replacement for Gly6  in the amino acid sequence of LH-RH 
was examined (Scheme V). The constrained LH-RH analogue (3) was found to 
exhibit a greater potency than that of the parent hormone, for inducing the release 
of LH both in vivo and in vitro in adult rats primed with estradiol and 
progesterone/20^  The constrained LH-RH analogue was later shown to exhibit a 
Type n' P-tum conformation.
The different types of side-chain to side-chain, and side-chain to 
backbone linkages, to form cyclic peptides have been reviewed recently by 
Hruby 3^).
1.5 Peptide Mimetics o f  Secondary Structures and Turns
Since folding of polypeptide chains gives rise to the shape of a peptide or 
protein/6’21,22) turns in peptides have been proposed to be important loci for 
receptor binding and transduction, due to their intrinsic polar structure in a 
compact region of space/8) Hence, interests have developed in synthesising 
conformationally restricted peptide analogues of bioactive peptides that will 
exhibit these turn conformations. Turns are quasi-cyclic structures, where the 
orientation of side chain groups can be described as either axial or equatorial with 
respect to the backbone of the turn structure (Figure 11). Bioactivity should 
therefore not alter provided that the side chain groups are orientated in the same
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way as in the native molecule. One way o f inducing a turn conformation in a 
peptide chain is by the introduction of pseudopeptide mimetics and this area of 
work has been reviewed by Morgan and Gainor/14^  This review section will 
therefore concentrate only on the different types o f peptide mimetics that have 
been applied to induce a y-tum conformation in a peptide chain.
To date, there have been two reported cases of y-tum mimetics, compared 
with the vast number of peptide mimetics that induce or stabilise a P-tum 
conformation. The first was introduced by Kemp in 1981 ^  who reported the 
synthesis o f racemic l-acylamino-2-aminoalkyl-3-cyano-2-cyclopentene (Mcc) (6) 
(Scheme VII). The enaminonitrile moiety was chosen to mimic the amide bond, 
because this function is both compact and has a relatively weak tendency to form 




Racemic Mcc (5) was prepared from methyl-2(N-BOC-amino)-5-cyano- 
pentanoate (4) (Scheme VII) and coupled to amino esters in the presence of the 
weak acid, dichloroacetic acid. The resulting diastereoisomers were separable by 
chromatography but were found to epimerise in the presence of trifluoroacetic acid 
(25°C for lh) (Scheme VIII). X-Ray crystallographic analysis of diastereoisomer 
(7) revealed two main conformers, which differed by the orientation of the side 
chain benzyl group and in the puckering of the cyclopentene ring with the 
p-enaminonitrile function in a near-planar orientation (Figure 12).
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synthesis o f the more rigid bicyclic constraint, 4-alkylamino-3-cyano-6- 
-azabicyclo[3.2.1]oct-3-ene (BEN) (10), where Bredt’s rule prevents the 
epimerisation process/24®^ BEN was prepared from Barton cyano-ethylation of 
N-Cbz-(2S,4R)-hydroxyproline methyl ester (Scheme IX). This was followed by 
ring closure in the presence of potassium rm-butoxide. The bicyclic a-cyano 
ketone (8) was similarly treated with rm-butyl ester o f amino acids in the presence 
of dichloroacetic acid, but because this reaction was slow, competitive 















The vinyl chloride (9) was prepared as an alternative route for the 
incorporation of amino acids into the BEN skeleton and this was achieved by 
reaction of BEN with Ph3P/CCl4. Reaction of (9) with amino acids was, however, 
sluggish and extensive hydrolysis o f this reactive intermediate was also observed. 
However, this served to demonstrate the ability to couple amino acids to the 
constrained bicycle BEN, although the dipeptide variant BEN-(L)-Ile-OH was 
found to be unstable, decomposing on standing in solution. No further publications 

































The second y-tum mimic to be described in the literature was introduced 
by Huffmann.(25) A cycloheptene lactam (11) was suggested to represent 
constrained tripeptide analogues of the type y-(Gly-Gly-Phe), 
y-(Gly-D/L-Phe-Leu) and y-(D,L-Tyr-Gly-Gly), depending on the substituents R, 





General y turn y turn mimic
Compound Name R R! R2
(12) y(Gly-Gly-Phe) H H Bz
(13) y(Gly-D/L-Phe-Leu) H Bz !Butyl
(14) y (L,D-Ty r-G ly-G ly) Bz H H
The required cycloheptene lactam was prepared by Birch reduction of
4-methoxybenzyl alcohol, followed by selective ozonolysis o f the resulting enol 
ether. Reductive animation of the intermediate aldehyde, followed by cyclisation, 
afforded the desired lactam and the selective alkylation strategies that were used to 








<1)1 N NaOH.dioxane 







From X-ray crystallographic studies, the stereochemistry about Rj and R2 
(where R2=1Pr) were found to correspond to the (S)-configuration. In addition the 
overall shape of the cycloheptene lactam was virtually identical to that determined 
theoretically with a variety o f potential energy functions. The cycloheptene lactam 
was found to have torsion angles <J> and \y of similar values to that o f an ideal y-tum 
(Table 2).
TABLE 2
Vi <h+i Vi+i <t>i+2
Ideal y turn 128° 56° -67° -123°
Cycloheptene lactam 120° 80° -65° -120°
Cycloheptene lactam analogues (12), (13), (14) were then incorporated 
into leucine enkephalin, an important opioid hormone/19* as replacements for the 
Gly3-Phe4-Leu5 subunit and were subsequently tested for their affinity to opiate 
receptors. Only the peptide containing the cycloheptene lactam (14) showed a 
binding response but this was weak and it was concluded that the bioactive 
conformation o f leucine enkephalin at the p and 5 receptor sites did not contain a 
y-tum in the region occupied by these residues.
Very little success in incorporating peptide mimetics at the bioactive site 
of a peptide hormones or neurotransmitters has been reported, probably due to the 





1.6 Occurrence o f  y-Turns in Peptides and Proteins
In contrast to the large number of p-tums identified in peptides and 
proteins, y-tum conformations have not been widely reported/7,26) Though 
Milner-White^27) had published an article on the occurrence of y-tums in proteins, 
he concluded that alot more y-tums (particularly of the inverse type) could be 
identified if these units were allowed to contain a much weaker hydrogen bond. 
This was done by calculating the electrostatic energy of hydrogen bonds in 54 
known proteins and then grouping those that exhibited a possible y-tum geometry 
into two classes, strong and weak.
The strong y-(and inverse y) turn had an electrostatic energy >-1.0 kcal 
mol*1 with an interatomic distance of 2 .6 A for the crucial N-H—O hydrogen bond 
and the weaker y-(and inverse y) turn had an electrostatic energy of <-1 . 0  kcal 
mol"1, with an interatomic N-H--0 distance of 3.5A. The upper limit for a typical 
hydrogen bond has been judged to be 2.5A based on estimated van der Waals 
forces with electrostatic contributions/7) The weaker inverse y-tum was found to 
occur in greater abundance than those of the classic type. These weak inverse 
y-tums were found to be present in certain situations in the polypeptide chain. The 
weaker type tended to occur readily in the middle of strands of p-sheets and 
exhibited hydrogen bonding similar to that of a 2.27  helix (Figure 13). The 2.27  
helix was first proposed by Huggins in 1943 as a possible conformation for fibrous 
protein/28) This secondary structure was described as ribbon-shaped, though not 
fully extended, with a twist that is almost right handed. The stronger inverse 
y-tum tended to be sited at the N or C termini of a-helixes. A number of the 
stronger inverse y-tums have been postulated to be at the ligand binding and active 
sites of several metalloproteins and immunoglobins.
y-Tums have been implicated to be present in a series of pentapeptides of
Cyclo-(Pro-Gly-Pro-Gly-D-Ala)
Scheme XIII
2-amino-8-oxo-9,10-epoxydecanoic acid = Aoe
Compound Sequence
H.C - toxin cyclo [ L-Aoe-D-Tyr(OMe)-L-lle-L-Pro ]
Chlamydocin cyclo [ L-Aoe-Aib-L-Phe-D-Pro ]
Wf 3161 cyclo [ L-Aoe-D-Phe-L-Leu-L-Pip ]
Cyl - 2 cyclo [ L-Aoe-D-Tyr(OMe)-L-lle-L-Pip ]
Alb = a-am inoisobutyryl
Scheme IVX
C 3 ' - co, h
trans-His-Pro cis-His-Pro
n / ^ - co2h
-16-
structure cjc/0 -(Xxx-Pro-Yyy-D-Zzz-Pro), according to !H NMR conformational 
analysis/29^  Pease and Watson^30* were first to synthesise a cyclic pentapeptide 
cyc/<9 -(Pro1-Gly2 -Pro3 -Gly4 -D-Ala5) which contained the two different types of 
reverse turn structures in the same molecule and verified the structure by X-ray 
crystallographic analysis. The cyclic pentapeptide was found to consist of trans 
peptide bonds with two transannular intramolecular hydrogen bonds and, using 
X-ray crystallographic data together with other spectroscopic techniques, the 
authors postulated a structure with a type II' p-tum at Pro3 -Gly4 -D-Ala5, with a 
y-tum at Gly1-Pro2 -D-Ala5  (Figure 14).
NMR studies of short cyclic polypeptides of four or five residues have 
also been proposed to manifest y-tum conformations though none of these features 
have been reported to be either required or is responsible for bioactivityZ32^  A 
recently published article described the naturally-occurring cyclotetrapeptides
H.C-toxin/33) chlamydocin/34) W F-316l/35^  and cyl-2/36^  all possessing a 
peptidyl 12-membered ring with the amino acid, 2-amino-8-oxo-9,10- 
-epoxydecanoic acid (Aoe) as a common feature (Scheme XIII). These peptides 
have bioactivity both as plant toxins and in vitro as cytostatic and antimitogenic 
agents^37) and various side chain substitutions have established the importance of 
Aoe for bioactivityZ38^  Conformational analysis using various NMR techniques 
have demonstrated another common structural feature amongst these cyclic 
tetrapeptides. A cis-trans-trans-trans amide bond arrangement has been identified 
and this has been suggested to be required for bioactivity.(39)
The s-cis and s-trans isomerism of the His-Pro peptide bond (Scheme 
XIV) in angiotensin and thyroliberin analogues^40* by and 13C NMR has also 
been studied and the population of the s-cis isomer present in aqueous solution has 






















The occurrence of m-amide bonds in peptides are generally not favoured 
due to steric interactions between adjacent a-carbon substituents^41) (Figure 15). 
However, this feature has been observed in peptides containing proline^42) or 
N-methylated amino acids/43a,b) Recently, a number of bioactive peptides 
containing a c/s-peptide bond with neither of the above components have been 
reported/44^  This has lead to increased interest in the synthesis of constrained 
peptide analogues that would exhibit a constraint equivalent to a m-amide 
bond/45) There have only been two reported cases of peptide mimetics that fix the 
amide bond in this way. The 1,5-disubstituted tetrazole (CN4) (Figure 16) has 
been introduced as a synthetic probe for studies relating to cis-trans isomerisation 
of N-alkylamide bonds, as present in proline. This tetrazole has been successfully 
incorporated into the dipeptide cyc/o-[L-Phe-\|/(CN4 )-L-Ala], where the tetrazole 
ring has been shown to exhibit a strong geometric similarity to the c/s-amide 
bond/46a) The constrained tetrazole was prepared by addition of a dipeptide to a 
premixed solution of phosphorus pentachloride and quinoline, followed by the 
addition of hydrazoic acid (Scheme IVXa). Quinoline has been shown to be 
essential in order to prevent racemisation of the N-terminal amino acid residue.
Tetrazole dipeptide mimetics of the type Z-L-Ala6 y(CN4 )-L-Ala7 -NH2, 
Z-L-Ala6\jr(CN4 )-D-Ala7 -NH2  and Z-L-Pro2 \|r(CN4 )-L-Ala3 -NH2, have been 
successfully incorporated as constrained cw-proline conformers into the 2  and 6  
positions of bradykinin, a nonapeptide which has the amino acid sequence 
Arg1-Pro2 -Pro3 -Gly4 -Phe5 -Ser6 -Pro7 -Phe8 -Arg9. Bradykinin is one of the potent 
endogenous vasolidators and acts both as a depressor and as a myotropic 
substance. However, as yet no conclusive picture has emerged for the relative 
importance of available conformational states in relation to biological activity/8) 
When assayed upon isolated rat uterus the above three bradykinin analogues were 
found to be inactive^4611) suggesting that a c/s-amide conformer at either Pro2  or 






o-aminomethyphenylacetic acid = o-AMPA














Solution or solid phase
2)Cyclisation
N - T h r
-18-
O-Aminomethyphenylacetic acid (o-AMPA) (Figure 17) has been 
proposed to mimic a c/s-Gly-Gly unit/47) A cw-amide bond conformation at 
Phe-Pro had been speculated to be the bioactive conformation for cyclic 
hexapeptide cyc/o-(Pro1-Phe2 -D-Trp3 -Lys4 -Thr5 -Phe6)^ 48), a potent analogue of 
somatostatin for the release of growth hormone. The absence of activity in the 
peptide cyclo - (o-AMPA1 -Phe2 -D-Trp3-Ly s^Thr5) was speculated to be due to the 
lack of a side chain residue at o-AMPA^Thr5 and by the presence of a strong 
hydrogen bond between the NH and the carboxyl group in o-AMPA. The 
aminomethylene group was then N-methylated, followed by alkylation at the 
a-position of the carboxyl group in the o-AMPA (Scheme VX). Incorporation of 
this new constrained dipeptide unit (15), into the peptide chain 
(Phe-D-Trp-Lys-Thr), followed by cyclisation using diphenylphosphoryl azide, 
afforded the cyc/opeptide (16) as two separable diastereoisomers. While devoid 
of any biological activity in vitro, one diastereoisomer significantly inhibited the 
release of growth hormone in vivo, with an IC5 0  of 52^g/kg vs 62ng/kg for that of 
the parent somatostatin analogue. Here a much better case can be made for the 
requirement of a cw-peptide bond in the bioactive conformation of cyclic 
somatostatin analogues.
Given the published reports and reviews of turns in peptides, only 
bioactive peptides that have been postulated to exhibit a y turn conformation in 
solution, will be summarised here.
Pentapeptide Arg1-Pro2 -Asp3 -Val4 -Tyr5  ([Pro2 ]TP5), a biologically active 
analogue of the immunoregulatory peptide thymopentin, Arg1-Lys2 -Asp3- 
-Va^-Tyr5  (TP5), has been proposed to exhibit a Type II p-tum involving the first 
four residues with a y-tum at Asp3/ 49) Similarly, a p- and y-tum have been 
reported for elastin, a polypentapeptide of amino acid sequence
Fig. 18
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HCO-CVa^-Pro^Gly^Va^-Gly^-Val-OMe where n=18. Two p-turn structures 
are believed to be present between residues Va^-OO with Val4-NH (with 10 
atoms in the turn) and Gly3-NH with Gly5 -C=0 (with 11 atoms in the turn) with a 
y-tum at Gly3 -C=0 with Gly5 -N H ^  (Figure 18).
X-Ray crystallographic data of y-tums in bioactive peptides are however 
scarce and to date there are only two reported cases. The first was described by 
Flippen and Karle 5^1^  in the cyclic tetrapeptide dihydrochlamydocin, an analogue 
of the cytostatic peptide chlamydocin/34,37^  Dihydrochlamydocin has an amino 
acid sequence cyc/^-(Aoe1-DiMe-Gly2 -Phe3 -D-Pro4) and is characterised by two 
y-tums, together with four transoid amide bonds. This latter feature is so-called 
because the amide bonds are twisted by between 15° to 25° from planarity. 
Solution conformational analysis of chlamydocin, as determined by NMR 
techniques, was found to be in close agreement with that found by X-ray 
crystallographic analysis of dihydrochlamydocin (Figure 19)/52^
Cyclosporin A isolated from fungus species Tolypocladium inflatum 
Grams 5^3^  is an undecapeptide containing seven N-methylated amino acids and is a 
potent immunosuppressent, used clinically to suppress the rejection of transplanted 
human organs/54^  The amino acid sequence was first determined by X-ray 
crystallographic analysis of the iodo-derivative of cyclosporin A /55) The peptide 
was shown to contain an anti-parallel p-pleated sheet together with two 
intramolecular hydrogen bonds representing a p- and a y-tum. The overall shape 
of iodo-cyclosporin A has been described to be butterfly-shaped with the 
unsaturated amino acid, N-methyl-4-butenyl-4-methylthreonine (MeBmt), 
protruding out like that of an insects proboscis (Figure 20).
The structure of cyclosporin A was later refined and verified by 





features in cyclosporin A was revealed. The p-fragment, containing residues 11 to 
7, formed an anti-parallel p-pleated sheet and a Type II' p-tum at residues 3 and 4. 
Residues 7 to 11 formed the second structural feature, the so-called "loop”. The 
"loop" was found to contain a y-tum involving D-Ala8  and Me-Leu6  and a 
cw-amide bond was found between Me-Leu9  and Me-Leu1 0  (Figure 21). There 
are, however, a few discrepancies regarding the backbone conformation of 
cyclosporin A. A C5 bend between the NH-D-Ala8  with the adjacent peptide bond 
was indicated by NMR, but this feature was not observed in the solid state. The 
orientation of the side chain amino acid (MeBmt) was also found to be different to 
that predicted from solution phase analysis i.e. %=+60° (in solution) compared to 
X=-168° (in the solid state). The presence of MeBmt has been demonstrated to be 
important for the immunosuppressive activity of cyclosporin and
subsequent analogues of this side chain amino acid have been examined/58'60) The 
application of a 8 -lactam constraint to the p-tum in cyclosporin A has been 
investigated^61) but only weak immunosuppressive biological activity was 
observed.
Recent NMR studies^62) of substance P, neurokinin A and B have all 
suggested that there is a common y-tum structure in the peptide chain. These 
peptides are members of the trachykinin family and are neuropeptides that possess 






These peptides are of considerable interest due to their putative activity as 
neurotransmitters of pain and substance P and neurokinin A have also been shown 
to stimulate inflammation and vasolidation. A neurokinin antagonist is thus 
potentially useful as a non-narcotic analgesic and as an anti-inflammatory agent. 
Several neurokinin anagonists have since been prepared and this area has been 
reviewed by Vaugh/63) and by Logan/64) NMR studies of substance P carried out 
in methanol by Chassaing and coworkers/65) suggested an a-helical conformation 
between Pro4  and Phe8. This structure is thought to be comprised of a 1.5 helical 
turn, stabilised by hydrogen bonds between Phe7-NH and 0=C-Lys3 as well as 
between Phe8-NH with 0=C-Pro4, with a proposed y-tum involving Leu10. 
Indeed, a small amount of a-helix was also detected by Wu and Yang (in 25mM 
sodium dodecyl sulphate (SDS) solution) using circular dichroism 
spectrospcopy/66a‘c) Similarly, neurokinin A has been reported to possess a y-tum 
at sequence Lys2 -Asp4, stabilised by an internal salt bridge (His1 or Lys2  to Asp4) 
from NMR studies in DMSO/67) Loevillet has explored the conformation of 
neurokinin B and has suggested the presence of a y-tum at Met2  and that this 
structure was stabilised by a salt bridge between the carboxylate Asp1 and the 
imidazole of His3/ 62)
Although these results are speculative as conditions and the methods used 
were widely diverse, they nevertheless demonstrated the need for the different 
types of constrained units required to examine the different types of turns that are 
available in a bioactive peptide. This is especially true for y-turns, since these are 























1.7 The Use o f Peptide Mimetics to Initiate Folding in Polypeptide Chains
Hydrogen bonds in secondary structures have been thought to act as 
"seeds” for the folding of peptides/68* By understanding their role in protein 
folding it may ultimately lead to the design and synthesis of new proteins with 
tailor-made structural and functional properties. Recent achievements in protein 
design have been reviewed by Mutter and Vuilleumier*69* and only peptide 
mimetics that have been designed to initiate folding (i.e. a-helix or p-sheet 
formation) in peptides will be discussed in this chapter.
Two different types of secondary structural peptide mimetics, 
corresponding to a p-sheet and an a-helix, have been introduced by Kemp and 
co-workers.*70* Epindolidinone-peptide, containing a p-tum conformation 
(D-Ala-L-Pro), is thought to act as a template for p-sheet formation.*71,73* A 
reversal of peptide bonding sequence at the 2 -position of epindolidinone was 
recognised and this should give rise to a characteristic hydrogen bonding pattern 
similar to that of a parallel p-sheet (17) (Figure 22). As a route to anti-parallel 
p-sheet formation, an urea functionality was introduced into the peptide sequence 
to counteract this peptide bonding reversal (Figure 23). The overall synthesis of 
epinolidinone-peptide, fcw-2 ,8 [(N-ureido-Gly-L-Phe-NMe2 )-L-Pro-D-Ala-NH)]- 
epinolidinone (22) is outlined in Scheme XVI. Dimethyl dihydroxyfumarate (19) 
was reacted with 4-nitroaniline (18) to give the carbomethoxyquinolone (20). 
Thermal cyclisation generated 2,8-diamino-epinolidinone (21) and this diamine 
was then coupled with the corresponding amino acids (D-Ala-Pro), followed by 
ethyl isocyanoacetoacetate and Gly-L-Phe-NMe2  to give the template-peptide (2 2 ).
NMR conformational analysis on epinolidinone-peptide (22), established the 
structure as an anti-parallel p-sheet with a Type II' p-tum conformation/72,73*
Schem e XVI
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A; HCI, MeOH (64%): B; Dowtherm A,15 min 250°C (55%); 
C: SnCI2, HCI; D: AICI3-NaCI, 160°C, 1h;
E: Et3N, (B0C-D-Ala)20 , DMSO (97%);
F: TFA, then Et3N, BOC-L-Pro-OC6F5, in DMF (92%);
G: TFA, then Et3N, 0=C=N-CH2C 02Et in DMF (61%);
H: LiOH, THF-H20  (79%);




The a-helix peptide mimetic, (2S,5S,1 IS )-1-acetyl-l,4-diaza-3-keto-
5-carboxy-10-thiatricyclo[2.8.0]tridecane (26) has been specifically designed and 
synthesised with the three amide carbonyls having the same pitch and spacing as 
that present in an a-helix /74,76) This cluster was designed to act as the nucleation 
site to initiate a-helix formation when attached at the N-terminus of a linear 
polypeptide chain (Figure 24). The tricycle template was prepared by 
condensation of rra/w-l-(rm-butyloxycarbonyl)-2(S)-(methoxycarbonyl)-5(S)- 
-[(tosyloxy)methyl]pyrrolidine (23) with l-acetyl-2(S)-carboxy-4(S)-thio- 
pyrrolidine (24) to give the thioether (25), which was then cyclised under high 
dilution conditions (pyridine, 80°C) v ia  the active 4-nitrophenyl ester (Scheme 
XVII).*74,76)
Scheme XVII
HO TosO PhCH2Sr \  r \  -p^_» r \
\ n / ^ C O ^ H  \ N/ ^ C 0 2Me \ n / ^ C 0 2H
H Ac Ac (24)
A: SOCI2,MeOH (75%); B: Ac20,NaHC03-H20-dioxane (78%);
C: Tos-CI,py (64%); D: NaOH,H20  (87%); E: PhCH2SNa,DMSO (72%).
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L: Na/NH3; M: (23) In DMSO (73%); N: p-N02-C4H40H,DCC,CH2CI2 (85%); 











lH NMR conformational analysis of the tricyclic unit (26) found two 
principle conformations in solution, corresponding to the s-cis and s-trans 
1-acetamido function (Figure 25). The s-trans conformation exhibited nucleating 
properties, in that all three carbonyls are aligned in a helical array and the sulphur 
atom is positioned downwards facilitating hydrogen bonding to the acetamide 
carbonyl. In the s-cis conformer, the sulphur atom is positioned upwards and the 
acetoamido function is incapable of helical hydrogen bonding. This was thus 
assigned as the non-nucleating conformer. These results were in accordance with 
X-ray crystallographic analysis of the tricyclic acid, where the s-cis conformer was 
isolated.
Incorporation of the tricyclic template (26) into a series of peptide chains 
of the type, a-Temp-L(Ala)n-OR (where n = 1 to 6 , R = Me or *Bu and Temp = 
tricyclic template) and a-Temp-L-Ala-L-Phe-L-Lys-(eBoc)-L-Lys-(eBoc)-NHMe 
(where € indicates an unknown configuration at an asymmetric centre), have been 
studied by *H NMR for the presence of a helical conformation. The 
template-tetrapeptide complex was found to exhibit a distorted a-helix structure 
with a bifurcated hydrogen bond^ in acetonitrile^75^  (Figure 26). For 
a-Temp-(L-Ala)n-OR (n = 3,4,5 and 6 ) a helical conformation was observed in 
weakly polar organic solvents, such as chloroform and acetonitrile, whereas in 
more polar solvents (dimethylformamide and dimethylsulphoxide) a mixture of 
helical and non-helical peptides were observed. This was suggested as evidence 
that the attachment of the template to the alanine sequence serves to nucleate a 
helical structure from the N-terminus of the peptide chain. The helical nucleating 
capacity of the template was, however, destroyed by the addition of 
N-methylglycine at the junction between the template and the alanine amino acid 
sequence.^76)
Nucleation from the C-terminus of monomeric peptide chains of <20 units
-25-
has recently been published/77* Side chains of histidine and cysteine residues at 
positions i and i+4 of the peptide were used to interact with transition metal ions 
leading to a bidentate complex and which concurrently fixed the peptide backbone 
into an a-helix conformation.
2.0. A im of the Project and Proposed Routes
Our own approach to the synthesis of constrained heterocyclic units that 
would "induce" either a y-or an inverse y-tum in a peptide chain, is based on the 
heterocyclic skeletal structure of 4-amino-3-isoxazolidinone, more commonly 
known as cycloserine. We envisaged the incorporation o f an imidoyl halide 
(chloride) moiety within the 3-isoxazolidinone ring based on chemistry already 
established by workers involved in the synthesis o f AT-125 from tricholomic 





Kemp and Carter^23'25* have already demonstrated the conversion o f a 
carbonyl bond to a vinyl chloride in the bicyclic substrate 3-cyano- 
-6-azabicyclo[3.2.1]octan-3-one (Section 1.5), using triphenylphosphine and 
carbon tetrachloride and the subsequent displacement o f chloride with 
rerra-methylammonium salt o f various amino acids.






















dihydroisoxazole ring in both directions. By displacement of the chloride with the 
amino terminus of an amino acid (or peptide) generates one chain. In addition, 
coupling of the amino group at C-4 of the dihydroisoxazole ring to the carboxylic 
acid terminus of an amino acid (or peptide) would allow the peptide to be extended 
in the other direction (Scheme XIX). The dihydroisoxazole ring can mimic either 
a constrained (L)- or (D)-glycine unit, depending on the stereochemistry o f the 
heterocyclic ring at C-4. The endocyclic C=N function will then serve as a 
tra n s -amide linkage which should be more representative o f a true amide bond 
than that proposed for either BEN^243^  or the cycloheptene y-tum mimic^25  ^
described in section 1.5. The rigid dihydroisoxazole ring has y  restricted to +60° 
(for the (S)-isomer) or -60° (for the (R)-isomer) and should therefore function as a 
constraint to induce a turn in a peptide chain, similar to the situation that operates 
with proline/8) We believe that this constraint would limit the flexibility o f the 
peptide chain and induce the formation of either a y- or an inverse y-tum, by 
forming a hydrogen bond at the NH of residue i with the 0=C  of residue i+2 as 
outlined in Scheme XX.
Scheme XIX
(P ^  Protecting Group
The chemistry developed with the cycloserine ring system could be 
applied to more rigid bicycles II, III and IV (Scheme XX). These constrained 
units could then be similarly incorporated into a peptide chain (Scheme XIX). 
Bicycle (II) (a c is -fu se d  cycloserine unit) mimics a constrained (L)-glycine unit, 
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those of an inverse y-tum (Table 1).
Retrosynthetic analysis of the heterocyclic constrained bicycle (II) 
suggested 3,4-dehydroproline as a convenient starting material (Scheme XXI). We 
also envisaged the formation of the [3.2.1]bridged bicycle (III) from the 
electrophile-mediated cyclisation of N-benzylhydroxylamine derivative of
3,4-dehydroproline with phenylselenenyl chloride (27). The torsion angles of 
bridged bicycle (III) have been calculated (using CONCORD and optimised using 
the CHEMX molecular mechanics package (20 cycles per sec, dielectric 
constant=4)) to be <J>=-95.8° and y=+l 13.9°. Bicycle (III) should therefore provide 
a novel type of conformational constraint and was targeted for this reason.
Finally, the proposed (S)-57?z><9 -cycloserine unit (IV) has been 
demonstrated (from theoretical studies) to have torsion angles <j)=-60° and y=-60° 
which corresponds to a right-handed a-helix. If bicycle (VI) could be successfully 
incorporated into a peptide chain, this unit could be used not only as an a-helix 
constraint but also to induce a helical formation from the middle of the peptide 
chain and not simply from either of the C- or N-terminus of the peptide f70*77).
RESULTS AND 
DISCUSSION
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1. Synthesis and Reactivity o f 3 -Chloro-(4R)-Amino-4J5-
•Dihydroisoxazole with Amine Nucleophiles
1.1. Preparation of 3-Chloro-(4R) -A mino-4^5-Dihydroisoxazole
The initial challenge presented by this programme was to convert the 
carbonyl moiety in (R)-cycloserine (1) to an imidoyl chloride {see Introduction, 
section 2.0) which was seen as suitable handle for the incorporation of this 
molecular constraint into a peptide chain by direct displacement of this reactive 
functionality with amino acids (Scheme 1).
Two different methodologies have been reported for the conversion of a 
carbonyl to an imidoyl chloride within a dihydroisoxazole ring (Scheme 2). The 
first was developed by Baldwin and coworkers in the synthesis of AT-125 
((aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid) from tricholomic 
acid. 7^8) Here, phosphorus pentachloride was used to activate the carbonyl 
function and chlorinate it in an addition-elimination fashion. The second method 
described in the literature utilised dichlororm(dimethylamino)phosphorane (4) as 
the chlorinating agent for the conversion of tricholomic acid to AT-125/79,80^
We envisaged 3-chloro-4-amino-4,5-dihydroisoxazole (3) to be a 
suitable substrate for the investigation of the key nucleophilic displacement 
reaction. Our first attempt to prepare this substrate was by treatment of 
(4R)-[N-(Cbz)]-cycloserine (2) with PCI5 in nitromethane at reflux but this 
afforded a complex mixture of products. Repeating this reaction under milder 
conditions (stirring at room temperature) gave a mixture of the desired 




Time/h Adducts Yield /%
Xs.Methylamine 95 22 (7) 44
Xs.Piperidine 110 18 (8) 73
leq.Benzylamine 120 72 (9) 51
Xs.Benzylamine 120 7 (9) 50
Xs. Ammonia 110 48 Decomposition
Xs.Tryptamine 100 24 (10) 48
(3) 30
(6) 7
*Xs.Tryptamine 100 48 (55) 52
(54) 34
(55b) 9
Xs.(L)-Ala-7- 100 7 days (3) 45
Me-Tryptamine
(6) 25
* reaction with (S )-C bz-cyd oserine  
Xs = e x c e s s
NHCbz
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product (4R)-[N-(Cbz)]-cycloserine (5), which were difficult to separate by 
chromatography (Scheme 3). Reaction of the rm(dimethylamino)phosphorane
(4 )(8 i) to (4R)-[N-(Cbz)]-cycloserine (2) (THF at reflux) was more satisfactory and 
gave the chloro-adduct (3) in 60% yield (Scheme 4).
Triphenylphosphine and carbon tetrachloride (or bromide) have also 
been reported as useful reagents for the conversion of an acyl hydrazine to the 
corresponding acyl hydrazonyl halide/82* However, treatment of (4R)- 
-[N-(Cbz)]-cycloserine (2 ) with both of these reagent combinations resulted only in 
recovery of starting material. The only accessible route in our hands to 
3-chloro-(4R)-[N-(Cbz)amino]-4,5-dihydroisoxazole (3) from (4R)-[N-(Cbz)]- 
-cycloserine (2 ) is by the reaction of (2 ) with dichlororm(dimethylamino)- 
phosphorane (4). Although this is not the reagent of choice, since it is hydroscopic 
and on hydrolysis liberates hexamethylphosphoric triamide (HMPA), it does 
however furnish a feasible route to chloride (3) and was used with appropriate 
precautions being taken.
1.2. Reactions o f 3-Chloro-(4R)-[N-(benzyloxycarbonyl) amino]-4^-
Dihydroisoxazole with Simple Amine Nucleophiles
The reactivity of the 3-chloro-(4R)-[N-(Cbz)amino]-4,5-dihydro- 
isoxazole (3) with amine nucleophiles was examined next. Chloride (3) was 
treated with various amines (methylamine, piperidine, benzylamine, ammonia and 
tryptamine) and although successful, displacement of the halide was only observed 
under forcing conditions (sealed tube, 100°C). The yields of the corresponding 
amine adducts obtained are expressed in Table 1.
It is apparent that an equilibrium or alternative pathways are established 
on heating chloride (3) with tryptamine, as varying the reaction time from 48 to 24
Table 2
Nucleophile Base Solvent Temp/°C
Rxn
Time/h Results /%
Xs.Gly-OMe.HCI Xs .K2C 03 MeOH 115 2 (6) 26%
Xs .K2C 03 MeOH 110 2 (6b) 89%
Xs.Gly-OMe Toluene 100 6 (3) 80%
Xs.Gly-OMe.HCI Et3N THF 100-120 48 (3) 88%
(L)-Phe-OMe.HCI k2c o 3 DMF 130-160 2 (3)*+complex
mixture
(L)-Phe-OMe DMF 130 48 (3)*+complex
mixture
(L)-Phe-OMe MeOH 100 48 (3)*+complex
mixture
(S)-Leuclnol DMF 110 5 days (3)*
(S)-Leucinol MeOH 110 4 days (11)10% 
(3) 45%
* identified by Ll.c 
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hours did not alter the yield of product obtained. Encouraged by our ability to 
incorporate simple amine nucleophiles into the dihydroisoxazole ring, direct 
displacement o f chloride (3) with dipeptide (L)-alanine-7-methyltryptamine was 
examined. Heating a methanol solution o f this dipeptide and (3) in a sealed tube at 
100°C for 7 days, afforded 3-methoxy derivative (6) (25% yield) and recovered 
starting material (3) in 45% yield. Although chloride (3) did not couple with the 
dipeptide (L)-alanine-7-methyltryptamine, we did investigate the displacement of 
the chloride (3) with other amino esters.
1.1.3. Reactions of 3-Chloro-{4R)-[N-(benzyloxy carbonyl) amino]-
4y5-Dihydroisoxazole with a-Amino Esters
All attempts to achieve displacement o f chloride (3) with nucleophiles 
derived from amino esters, under the same experimental conditions used earlier for 
the simple amine nucleophiles, were unsuccessful. The results are expressed in 
Table 2 and reflect the deactivation o f nitrogen by the adjacent ester function in the 
amino ester. The methoxy adduct (6) was isolated upon treatment o f chloride (3) 
with glycine methyl ester hydrochloride in the presence o f potassium carbonate in 
methanol. It was proposed that methoxide, generated by the base present, 
competes with the glycine methyl ester to displace the chloride by an 
addition-elimination pathway (Scheme 5). To test this hypothesis, chloride (3) was 
subjected to the same experimental conditions as before but in the absence of 
glycine methyl ester hydrochloride. NMR suggested that the dimethoxy adduct 
(6b) (2x 3H singlet at 3.60 and 3.78ppm) was formed (Scheme 6). This type of 
methoxylation has been reported previously when 4-substituted-3-chloro- 







(S)-Leucinol 1.1 MeOH 110 3 days (3) 24 
(6) 62 
(11)9
(S)-Leucinol 5 MeOH 110 1 day loss (3)*
(S)-Leucinol+(6) 15 MeOH 115 2 days
complex
mixture
---------- 5 MeOH 125 1 days (3)‘
(L)-Phe-OMe 5 MeOH 125 2 days (3) 42% + complex 
mixture
(S)-Leucinol 1.1 DMF 110 8 days (3)* +
complex
mixture
(S)-Leucinol 5 DMSO 120 2 days decomp.
(S)-Leucinol 5 Acetone 120-130 3 days complexmixture
(s)-Leucinol 5 c h3n o 2 120 3 days (3) 80%





1.1.4. Reactions of 3-Chloro-(4R)-[N-(benzyloxy carbonyl) amino]-
4,5-Dihydroxisoxazole with 2-Amino Alcohols
As 2-amino alcohols are better nucleophiles than amino esters, they 
were used in an attempt to displace the chlorine from (3). We envisaged that the 
alcohol could be oxidised to give the required acid if the displacement was 
successful. In the event, heating chloride (3) with (S)-leucinol in methanol (sealed 
tube at 110°C for 4 days) gave (S)-leucinol adduct (11), but only in 10% yield. In 
addition, starting material (3) and the 3-methoxy adduct (6 ) were isolated in 24% 
and 62% yields respectively.
We anticipated that addition of sodium iodide would catalyse the above 
reaction. The corresponding iodo derivative should be more reactive than the 
chloride (3) and displacement by amino alcohol may be promoted. However, 
treatment of (S)-leucinol with (3) in the presence of sodium iodide (1.1 mol 
equivalent) gave no improvement in isolated yield of the (S)-leucinol adduct (11), 
although reaction was somewhat faster (3 rather than 4 days). Attempts to either 
detect or isolate the iodo-intermediate failed. Various solvent systems, such as 
dimethylformamide, dimethylsulphoxide, tetrahydrofuran, acetone and 
nitromethane with (S)-leucinol and chloride (3) in the presence of anhydrous 
sodium iodide were examined, but none of these gave the (S)-leucinol adduct (11). 
The results of this aspect of the study are summarised in Table 3.
High yields of the 3-methoxy adduct (6 ) were isolated from the
(S)-leucinol reaction with chloride (3). It is possible that this species may be 
an/the active intermediate. Subjecting (6 ), under the same reaction conditions as 
used with chloride (3), to (S)-leucinol and sodium iodide only gave a complex 
mixture and none of the desired adduct was observed.
Table 4
Nucleophile 1M AgN0 3 Solvent Temp/°C
Rxn
Time/days Results
(S)-Leucinol 0.5 ml MeOH 100-120 3 (3) 99%
(L)-Phe-OMe 0.5 ml MeOH 85-100 3 (3) 80%
Scheme 7
NHCbzNHCbz




Nucleophile NHiCHjCOj Solvent Temp/°C
Rxn
Time/days Results
Xs.(S)-Leucinol 3 equiv. MeOH 100 6 (3)
leq.Benzylamine 1 equiv. MeOH 100 2.5 (3) 10% 
(9) 64%
Xs = e x c e ss
-32-
Silver(I) ions are known to complex strongly to chlorides and we 
speculated that the addition of a Ag1 salt to chloride (3) might provide the required 
activation and enhance the rate of the nucleophilic displacement reaction. 
However, heating a mixture of (3) and either (S)-leucinol or (L)-phenylalanine 
methyl ester in methanol (in a sealed tube) in the presence of an excess of 1M 
aqueous silver nitrate solution gave no reaction and starting material was recovered 
(Table 4).
1.1.5. Addition o f a Weak Acid to 3-Chloro-(4R)-[N-( benzyloxycarbonyl)-
amino]-4£-Dihydroisoxazole with 2-Amino Alcohols
It would appear from our results that methanol is the only solvent in 
which displacement of the chloride (3) will occur (see Tables 2 and 3). This may 
be because methanol is a weak acid and is therefore acting as the proton source 
required for the addition-elimination mechanism (Scheme 7). The concomitant 
formation of methoxide ions would also account for the 3-methoxy adduct (6 ) 
which was observed as a by-product in a large number of simple amine 
displacement reactions of (3) (Table 1).
The addition of a weak acid, ammonium acetate, was then examined 
(Table 5). Heating (3) with (S)-leucinol in methanol in the presence of three 
equivalents of ammonium acetate (sealed tube at 100°C for six days) gave only 
starting material (3) (by TLC). Repeating the above reaction with benzylamine (1 
mol equivalent) as the nucleophilic component, gave no significant acceleration 
(the reaction went to completion in 2.5 days as compared with the original 3 days 





2.2eq.(L)-Phe~nBu4N+ MeOH 100 20 (3) 12% 
(6) 73%
2.2eq.(L)-Phe^nBu4N+ DMF 80 14 complex
mixture
-33-
1.1.6. Reactions of 3-Chloro-(4R)-[N-(benzyloxycarbonyl)amino]-
4 j5 -D ih y d ro iso x a zo le  w ith  C a rb o x y la te  S a lts  o f  a -A m in o  A c id s
Due to our lack of success in incorporating 2-amino alcohols or a-amino 
esters to the dihydroisoxazole ring in synthetically useful yields either by direct 
displacement or v ia  activation o f (3) with anhydrous sodium iodide, silver nitrate 
or ammonium acetate, we turned towards alternative and more reactive 
nucleophiles. The salts of a-amino acids should be better nucleophiles than amino 
esters because o f the negative charge on the carboxyl. The tetra-n-butylammonium 
salt of (L)-phenylalanine was then used in an attempt to displace the chloride 
moiety from (3) but under standard conditions, none of the corresponding amino 
acid adduct was detected and only starting material (3) and the 3-methoxy adduct
(6) were recovered (Table 6).
The inertness displayed by chloride (3) towards the more important 
amine nucleophiles prompted us to briefly examine sulphur-based nucleophiles. 
Cysteine is one of two primary amino acids that contain a sulphur atom /83) 
Treating chloride (3) with (L)-cysteine ethyl ester hydrochloride in methanol 
(sealed tube, 100°C for five days) afforded only recovered starting material (3) 
(Scheme 8). This reaction was not investigated further and we are unable to 















































The use of a more reactive imidoyl halide would be an alternative 
method by which to incorporate a-amino esters into the dihydroisoxazole ring of 
cycloserine (2). The general order of leaving group ability is I' > Br > Cl'/84) 
We had already tried to generate the iodide in situ but we chose to prepare the 
imidoyl bromide (12). We did not have any evidence that the iodo derivative had 
actually formed in the reactions described above. Indeed, the lack of an increase in 
reactivity when Nal had been added to reactions involving (3) suggested that either 
the corresponding iodide had not formed, or that the nature of the leaving group 
was actually unimportant.
We proposed to generate the imidoyl-bromide of (4R)-[N-(Cbz)]- 
-cycloserine (2 ), by reacting (2 ) with triphenylphosphine dibromide, a reagent that 
is commonly employed to convert alcohols to bromides/85) We speculated that the 
formation of the desired imidoyl bromide would take place by a mechanism similar 
to that employed to generate the chloro adduct (3).
The implementation of this task is shown in Schemes 9 and 9b. 
Treatment of (2) with triphenylphosphine dibromide in THF for lh at room 
temperature gave 3-bromo-(4R)-[N-(Cbz)amino]-4,5-dihydroisoxazole (12) in 16% 
yield and attempts to improve the efficiency of this reaction failed. It is possible 
that this low yield was due to the presence of hydrogen bromide generated as a 
by-product during the course of the reaction but when repeated in the presence of
1 ,2 -epoxypropane as an acid scavenger, no trace of the desired product was
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An alternative method of generating a reactive brominating agent is to 
use triphenylphosphine and carbon tetrabromide/85^  However, reacting (4R)- 
-[N-(Cbz)]-cycloserine (2) with this combination in dichloromethane for five days 
at 65°C, gave primarily the chloro adduct (3) with < 0.2% of bromine in the 
compound. This was distinguished by microanalysis and mass spectroscopy and it 
is apparent that dichloromethane was the origin of the chloride source. Changing 
the solvent to acetonitrile and heating the mixture at 80°C for five days, afforded 
only 5% of bromide (12), together with 48% of benzyl bromide. Clearly, the 
hydrogen bromide generated in this reaction caused cleavage of the 
N-benzyloxycarbonyl group.
13,2. Reactivity of3-Bromo-(4R)-[N-{benzyloxycarbonyl)amino]-
4,5-Dihydroisoxazole with (L)-Phenylalanine Methyl Ester
The reactivity of the bromide (12) towards (L)-phenylalanine methyl 
ester was then investigated. Treating a methanol solution of bromide (12) with 
(L)-phenylalanine methyl ester (sealed tube at 100°C for 10 days) afforded 
recovered starting material (12) (78%), along with 5% of the desired 
(L)-phenylalanine methyl ester adduct (13) (Scheme 10).
This was our first insight into the incorporation of an a-amino ester into 
the dihydroisoxazole ring and the bromide-based route appears to be the most 
promising. The main problem encountered was associated with the incompatibility 
of the N-protecting group for (4R)-cycloserine, which needs to be stable under 







1.2.3. Synthesis and Reactivity o f 3-Bromo-(4R)-[N-(9-
-fluorenylmethoxycarbonyl)2Lmino]4,5-Dihydroisoxazole
9-Fluorenylmethoxycarbonyl (FMOC) has been reported to be an acid 
stable amine protecting group suitable for a-amino acids and is readily removed 
under mild alkaline and nonhydrolytic conditions, such as liquid ammonia or neat 
piperidine/86,87)
(4R)-Cycloserine was selectively protected with N-(9- 
-FMOC)succinimide in 1M aqueous sodium bicarbonate, following literature 
procedure for N-FMOC protection of amino acids/86) 
(4R)-[N-(FMOC)]-cycloserine (14) was isolated in 83% yield. The corresponding 
3-bromo-(4R)-[N-(FMOC)]-4,5-dihydroisoxazole (15) was generated by treating 
(4R)-[N-(FMOC)]-cycloserine (14) with either triphenylphosphine dibromide or 
with triphenylphosphine carbon tetrabromide in yields of 19 and 23% respectively. 
The reactivity of bromide (15) was then investigated. Heating a mixture of 
tryptamine and (15) in methanol (sealed tube, 80°C, 4.5 hours) afforded 
dibenzoflulvene (16). Dibenzoflulvene was still observed (by TLC) even when the 
reaction was conducted at room temperature. Similar results were also observed 
on treating bromide (15) with dipeptide (L)-alanine-7-methyltryptamine (room 
temperature, 1 hour).
It is evident that both tryptamine and (L)-alanine-7-methyltryptamine 
are basic enough to remove the acidic proton on the p-carbon of the ethyl 
carbamate incorporated into the FMOC residue and fragmentation is driven by the 
aromaticity of the dibenzocyclopentadienyl anion (Scheme 11). There is some 
literature precedent for the removal of the FMOC protecting group by primary and 
secondary amines but these reactions usually take place at a much slower 
rate/87,88)
S chem e 12
Water Soluble
-37-




The incompatibility of FMOC as a protecting group for the amino 
function of (R)-cycloserine under our reaction conditions led us to examine the the
2,2,2-trichloroethyloxycarbonyl (TROC) group as an alternative. The TROC 
group has been reported to be stable to both acids and bases^89) but is readily 
removed reductively by, for example, zinc powder in the presence of acetic acid or 
methanol/90,91)
(4R)-[N-(TROC)]-Cycloserine (17) (61%) was prepared by treating (R)- 
-cycloserine with 2,2,2-trichloroethyloxy chloroformate. [N-(TROC)]cycloserine 
(17) was then subjected to the usual bromination conditions, however, upon 
treatment of (17) with triphenylphosphine dibromide in dibromomethane or with 
triphenylphosphine and carbon tetrabromide, none of the desired bromo adduct 
was detected. Similarly, reacting (17) with the more reactive rm(dimethylamino)- 
phosphine dibromide in THF was also unsuccessful.
Our inability to achieve the synthesis of 3-bromo-(4R)-[N-(TROC)- 
amino]-4,5-dihydroisoxazole (23) or to efficiently recover the starting material 
made us suspect that the carbamate group itself might be participating in the 
reaction as illustrated in Scheme 12. We proposed that the carbamate group is 
interacting internally with the imidoyl bromide resulting in the loss of bromide and 
eventually, the loss of the carbamate protecting group to give cycloserine which is 
water soluble. The sulphonamide group was then sought to N-protect 
(R)-cycloserine due to its reknowned stability as an amino protecting group 8^9b)
-38-
displacement reaction.
(R)-Cycloserine was N-protected to give (4R)-[N-(4-methylphenyl)- 
sulphonyl]-cycloserine (18) in 78% yield, using 4-methylphenylsulphonyl chloride 
under Schotten-Baumann conditions. The use o f pyridine as solvent for this 
reaction gave a complex mixture. Sulphonamide (18) was then subjected to the 
usual brominating agents (triphenylphosphine dibromide or triphenylphosphine 
with carbon tetrabromide) in a wide variety o f solvent systems (THF, 
dibromomethane, and dimethoxyethane) but, once again, none o f the desired 
bromo adduct was isolated nor could starting material be recovered. TLC scale 
experiments did indicate that, under the conditions used for work up (1M aqueous 
sodium bicarbonate or pH 7 buffer), material was being lost into the aqueous 
phase. Repeating the above reactions and quenching with saturated aqueous 
ammonium chloride solution (pH 6) gave only recovered starting material, 
contaminated with triphenylphosphine oxide which results from the hydrolysis of 
the brominating agent.
Returning to the synthesis of AT-125 from tricholomic acid, it was 
reported by Kelly e t  a/,(79) that exposure o f a-[N-(phthalimido)]-3-chloro-
4,5-dihydro-5-isoxazole ethyl diphenylmethyl ester (19) to hydrogen bromide in 
nitromethane for <5min at 25°C was not only insufficient to cleave the 
diphenylmethyl ester, but under these conditions halogen exchange occurred to 









We sought to apply this type of exchange process to the synthesis of our 
key intermediates. As a result, the imidoyl chlorides o f (4R)-[N-(TROC)]- 
-cycloserine and (4R)-[N-(Tos)]-cycloserine were both prepared using the same 
experimental conditions as those used for the preparation of 3-chloro- 
-(4R)-[N-(Cbz)amino]-4,5-dihydroisoxazole (3), and were obtained in yields o f 78 
and 83% respectively. Chlorides (21) and (22) were then converted to the 
corresponding imidoyl bromides (23) and (24) respectively using with 1.1 
equivalents o f hydrogen bromide in acetic acid (33% wt) (Schemes 14 and 15).
Scheme 14
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Although imidoyl bromides (23) and (24) were undistinguishable by TLC from the 
corresponding chlorides (21) and (22), these molecules were readily distingushed 
by l H  NMR (Figures 1 and 2).
The reactivity o f 3-bromo-(4R)-[N-(TROC)amino]-4,5-dihydroisoxazole 
(23) towards tryptamine was then examined. Heating bromide (23) with 





material (23) and gave a product (25) that contained both the tryptamine unit and a 
bromine atom, as verified by NMR and mass spectroscopy (Scheme 16). The 








Similarly, reaction o f bromide (23) with (L)-phenylalanine methyl ester 
as well as with glycine methyl ester (sealed tube, 100°C) gave imidazolidine- 
-dinone adducts (26) and (27), where the bromine in the dihydroisoxazole ring is 
still intact (Scheme 17 and 18).
Scheme 17  .
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It is apparent that the trichloroethyloxycarbonyl group is more 
suspectible to nucleophilic attack by amines and amino esters than the imine 
carbon at C-3 in the dihydroisoxazole ring. This may be for two possible reasons. 
Firstly, the carbamate group is the more electrophilic site than the imidoyl bromide 
and the trichloroethoxy residue is a good leaving group. Secondly, the carbamate 
itself is sterically hindering nucleophilic attack at the imidoyl bromide position on 
the ring. These must be sufficient factors to divert the course of the reaction 
towards e.g. (25)
Nucleophilic substitution o f sulphonamides should not occur so readily. 
Sulphonamide (24) was then examined and heating (24) with tryptamine in 
methanol (sealed tube at 100°C for 2.5 days) afforded the elusive tryptamine 
adduct (28) in 12% yield (Scheme 19) together with starting material (24) (19%).
The low yields o f both (24) and (28) compared with those obtained 
between 3-chloro-(4R)-[N-(Cbz)] derivative (3) and tryptamine, again suggest that 
the tosyl protecting group is hindering nucleophilic attack at the imidoyl bromide 
position. Indeed, this type of substitution was also found to be difficult in 
3-0-phenylsulphonyl-isoxazolidine.(92) It was reported that the 4,5-disubstituted
3-O-phenylsulphonyl-isoxazolidine (29) undergoes a much slower reaction with 
cyanide ions than the corresponding 4-unsubsitituted isoxazolidine (31) (Scheme 
20). It is presumed that branching at C-4 of the isoxazolidine ring slows down 
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1 .2 .5 . A tte m p t to  S y n th e s ize  3 -B r o m o -4 - [N -(p h th a lo y l)a m in o ]-4 ,5 -  
-D ih y d ro iso x a zo le  v ia  a  1 ,3  D ip o la r  C y c lisa tio n  R e a c tio n
An independent route to 3-bromo-4-[N-(phthaloyl)amino]-4,5-dihydro- 
-isoxazole (38) was also undertaken. The use o f 1,3 dipolar cycloadditions for the 
synthesis of the 3-substituted dihydroisoxazole ring sustem is well established in 
the literature/93* )^ We planned to synthesize (38) by cycloaddition of the reactive 
bromonitrile oxide (37) to vinylphthalimide (33) as illustrated in Scheme 21.
Scheme 21
(39)
Vinylphthalimide (33) was prepared in 64% yield from a reaction of 
phthalimide with vinyl acetate using sodium tetrachloropalladate as catalyst/94) 
Bromonitrile oxide (37) was generated in s itu  from dibromoformaldoxime (36) by 
reaction of (36) with potassium hydrogen carbonate. Dibromoformaldoxime (36) 
is also best generated in situ , due to its high toxicity/95) and it was derived from 
dihalogenation o f glyoxalic acid aldoxime (35) with N-bromosuccimide/93) Using 
literature procedure, glyoxalic acid aldoxime (35) was prepared, in 56% yield, 
from glyoxalic acid monohydrate (34) and hydroxylamine hydrochloride(96) and 
the overall reaction sequence is outlined in Scheme 22.
There are two possible regioisomers, 4-[N-(phthaloyl)amino]- 
-dihydroisoxazole (38) and 5-[N-(phthaloyl)amino]-dihydroisoxazole (39), that can 
arise from this cycloaddition. It has been reported that 1-substituted alkenes react
-43-
with bromonitrile oxide to give predominantly or exclusively the 5-substituted 
dihydroisoxazole/936^  There is however, one reported incident where a
4-substituted dihydroisoxazole was derived, due to the presence of the bulky 
3-(rm-butyldimethylsilyloxy) group on the dipolarophile^936) (Scheme 23), and for 
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In the event, reaction of vinylphthalimide with bromonitrile oxide gave 
exclusively the 5-[N-(phthaloyl)amino]-dihydroisoxazole (39) (28%), along with 
starting material (33) (56%). Regioselectivity in 1,3-dipolar cycloaddition can be 
explained by the frontier molecular orbital theory/138) 1-Substituted 
dipolarophiles have been reported to have the largest coefficient at the (i-carbon 
regardless whether the substituent is conjugated, electron-withdrawing or 
electron-donating or in either of the frontier orbitals (HOMO or LUMO). 
1,3-Dipolar cycloaddition are therefore dipole-HOMO or dipole-LUMO 
controlled. As there are no reported energies for the frontier orbitals or coefficient 
valves for bromonitrile oxide (the dipole), we are therefore unable to speculate 
whether the above reaction is dipole-HOMO or dipole-LUMO controlled. We are 
however, able to conclude that the largest coefficient is on the carbon atom of the 
bromonitrile oxide, since only 5-[N-(phthaloyl)amino]-dihydroisoxazole (39) was 
formed.
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1.2.6. Reactivity of 3-Bromo-5-[N-(phthaloyl)amino]-4f5-Dihydroisoxazole
To probe the lack of reactivity o f the 3-bromo-4-substituted 
dihydroisoxazoles with nucleophiles, we next examined the reaction of
3-bromo-5-[N-(phthaloyl)amino]-4,5-dihydroisoxazole (39) with a-amino esters. 
This system represents a sterically-less hindered imidoyl bromide and was of 
interest in relation to our earlier results with the 4-amino derivatives.
Treating bromide (39) with (L)-phenylalanine methyl ester in methanol 
(sealed tube, 80°C for 2 days), afforded recovered starting material (39) (23%) and 
an amino ester adduct (40) in 35% yield, w h ich  s t i l l  c o n ta in e d  b ro m in e  in the  
d ih y d ro iso x a zo le  rin g  (confirmed by mass spectroscopy and microanalysis). It is 
once again evident that the nucleophile reacted preferentially with the phthalimide 
protecting group rather than with the imidoyl bromide (Scheme 24).
Scheme 24
HN(L)-Phe-OMe,MeOH
+ (39)Sealed tube 
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1.3. Synthesis and Reactivity o f 3-Methanesulphonyloxy-
(4R)-[N-(henzyloxycarbonyl)amino]-4,5 -Dihydroisoxazole and 
2-N-Methanesulphonyl-(4R)-[N-(benzyloxycarbonyl)amino]- 
-3-Isoxazolidinone
Our inability to displace a series of dihydroisoxazole-based imidoyl 
bromides with secondary amines or amino esters, due to the participation of 
protecting groups, led us to investigate the synthesis of 3-methanesulphonyloxy- 
-(4R)-[N-(Cbz)amino]-4,5-dihydroisoxazole (42) as an alternative activated 
building block. (R)-Cycloserine is an ambident nucleophile, capable of reacting on 
the oxygen or nitrogen of the “lactam" function/97) It has been reported that 
alkylation of amides generally occurs on oxygen under neutral conditions and the 
corresponding thermodynamically more stable N-substituted products are often 
isolated as a result of rearrangement of the kinetically-formed O-substituted 
product and this type of rearrangement is generally observed at high 
temperatures/98*^
With this in mind, the O-mesylation of (4R)-[N-(Cbz)]-cycloserine (2) 
was attempted retaining the N-benzyloxycarbonyl group as it did not appear to 
participate in reactions involving amines or amino esters (see section 120 and 
1.23). Treatment of (4R)-[N-(Cbz)]-cycloserine (2) with methanesulphonyl 
chloride in pyridine afforded two products as a 1.35:1 mixture (by NMR) 
corresponding to the O-mesyl dihydroisoxazole (42) and the N-mesyl-3- 
-isoxazolidinone (43) respectively (Scheme 25a).
These two compounds were hard to distinguish spectroscopically, except 
for the fact that their proton NMR spectra were very different. One isomer 
exhibited a proton splitting pattern very similar to that of the imidoyl chloride (3) 





Based on these observations the former material was destinated as the 
O-methanesulphonyl dihydroisoxazole (42) and the latter as the 
N-methanesulphonyl-3-isoxazolidinone isomer (43). The relevant *H NMR 
spectra are shown in Figures 3 and 4.
To establish the thermodynamic stability of these two compounds and 
ascertain whether the N-methanesulphonyl (43) was the result of direct mesylation 
or arose from rearrangement of the O-methanesulphonyl isomer (42). Both 
samples were premixed with one equivalent of (4R)-[N-(Cbz)]-cycloserine (2) in 
deuterochloroform in a NMR tube. These samples were left at room temperature 
for eight days. After that time, the NMR spectra were recorded.
For the mixture of O-methanesulphonyl (42) and (2), no change was 
observed in the *H NMR spectra was observed over this time period. However, 
the mixture of N-methanesulphonyl (43) and (2), a new peak (at 2.9 ppm) was 
observed in the NMR spectrum after two days; no further change was observed 
after 8 days. We speculated that this new peak is due to methanesulphonic acid 
(assigned by comparison with the spectrum reproduced in the Aldrich *H NMR 
catalogue^")) and has arisen from slow hydrolysis of N-methanesulphonyl isomer 
(43). Addition of a small amount of water to the N-methanesulphonyl sample 
resulted in a substantial increase in intensity of this peak. Hence, we have 
established that O-methanesulphonyl (42) is relatively stable but that the 
N-methanesulphonyl isomer (43) is susceptible to hydrolysis. This experiment 
also supports that (43) is formed from direct mesylation on nitrogen, rather than by 
rearrangement of (42).
Subsequent attempts were made to improve the ratio of O- vs N- 
-sulphonylation by varying the reaction conditions (Table 7). We found that, on 

















(2 )/eq. (41)/eq. Base/eq. Solvent Rxn conditions (42) vs (43)
1 1.1 / py * (41)+(2)at 0°C, stir 0°C1h, RT 4h 1.35:1
1 10 / py * (41 )+(2) at 0°C, stir 0°C 1 h, RT 3.45h 1 .6 : 1
1 1.1 1.1 py c h 2c i2 * (41 )+(2) at 0°C, then 
add py, stirO°C 1 h, 
RT 11h
1 . 6  : 1
1 1.1 1.1 Et3N c h 2c i2 * (41 )+(2) at 0°C, then 
add Et3N, stir 0°C 0.5h
1 :2.5
1 1.1 1.1 py c h 2c i2 * (4l)+py at 0°C, then 
add (2 ), stir 0°C 1 h, 
RT 20h
2 : 1
1 1.1 1.1 py 
1.1 DMAP
c h 2c i2 * (41)+py+DMAP at 0°C, 
then add (2 ), 
stir 0°C 10 min, RT 1 h
4 :1
* refer to premixing
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[N-(Cbz)]-cycloserine (2), that a 2:1 mixture in favour of (42) was obtained. It is 
believed that, under those reaction conditions, a pyridinyl-methanesulphonyl 
species (A') is formed which is more reactive than methanesulphonyl chloride, due
We also sought to speed up the mesylation process by addition of
4-(dimethylamino)pyridine (DMAP) to a CH2C12 solution of methanesulphonyl 
chloride and pyridine. DMAP^100b,c^  is more nucleophilic than pyridine and will 
react with methanesulphonyl chloride much quicker to form species (B') which is 
stabilised by the dimethylamino residue (Scheme 25c). In this case, a 4:1 mixture 
was obtained, favouring the desired O-methanesulphonyl isomer (42).
Scheme 25c
As predicted by literature precedent,(98) under strong alkaline conditions, 
the N-alkylated product was favoured. Treatment of (4R)-[N-(Cbz)]-cycloserine 
with methanesulphonyl chloride in the presence of triethylamine (pKa 10.7)(101) 
gave a 1:2 mixture o f products favouring the N-methanesulphonyl isomer (43).
With sufficient quantity of O-methanesulphonyl (42) in hand its 
reactivity towards tryptamine and with (L)-alanine-7-methyltryptamine was
to the greater leaving group ability associated with the pyridinyl cation^100a^  
(Scheme 25b).
Scheme 25b
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examined. Heating a methanol solution of (42) and each amine in turn (50°C for 2 
hours) afforded complex mixtures that were not investigated further. Clearly, the 
O-methanesulphonyl isomer (42) is more reactive than the chloro derivative (3), 
which did not react with the dipeptide substrate even though this required heating 
at 100°C for seven days. Under milder reaction conditions, (42) was stirred with 
tryptamine in methanol at room temperature, in the presence of triethylamine. We 
envisaged that the addition of base would aid the displacement reaction as shown 
in Scheme 26. However, the only product isolated corresponded to the 
ring-opened dihydroisoxazole adduct (44), with the methanesulphonyl group now 
transferred onto the nitrogen in the dihydroisoxazole ring. The structure of (44) 
was assigned by *H and 13C NMR spectroscopy. 2-N-methanesulphonyl- 
-[3indolylethyl]amine (45) was also isolated in 8% yield from this reaction 
(Scheme 26b). This reaction probably takes place by an intermolecular rather than 
intramolecular mechanism/98,102^  which would involve a strained four-membered 
transition state. This type of 1,3 shift has indeed been reported to occur 
intermolecularly and may be illustrated by the rearrangement of
2-methoxypyridine to N-methylpyridone (Scheme 26c)/102b^  Furthermore, the 
presence of the N-sulphonyl residue would make nitrogen a better leaving group 
and thus make the ring-opening a facile process.
The same ring-opened tryptamine adduct (44) was also produced by 
reaction of the N-methanesulphonyl derivative (43) with tryptamine, under our 
standard reaction conditions. It is apparent that the use of O-methanesulphonyl 
isomer (42) as a reactive intermediate for coupling with amino esters is not a 
productive strategy due to the transfer of the mesyl group from oxygen to nitrogen 
and, eventually, to ring-opened products.
We have also examined the synthesis of the corresponding 3-trifluoro- 
-methanesulphonyloxy-4,5-dihydroisoxazole (46). (4R)-[N-(Cbz)]cycloserine (2)
-49-
was reacted with triflic anhydride in the presence of 2,6-(di-rm-butyl)- 
-4-(methyl)pyridine in dichloromethane at -78°C but upon work up, only a 
complex mixture of products was obtained. We tried to trap the putative triflate 
adduct by quenching the reaction mixture with tryptamine (Scheme 26d). 
Repeating the above reaction in the presence of tryptamine, afforded an adduct 
(46b), which contained tryptamine and two trifluoromethanesulphonyl groups 
incorporated into the dihydroisoxazole ring. The structure of this product was 







Where H2N-Trp = Tryptamine
NHCbz
NH-Trp
0 S 0 9CF.
(46b)
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1 .4 . S y n th e s is  o f  T r i a n d  T e tra p e p tid e s  o f  3 -T ry p ta m in o -(4 R )  a n d  
(4 S )- [N -(C b z )a m in o ]-4 ,5 -D ih y d ro iso x a zo le
Although amino acids could not be used to displace either chloride or
bromide from the dihydroisoxazole ring we were able to incorporate the primary 
amine tryptamine. This residue was of direct interest to Glaxo Group Research 
and our attentions were focused on the use of 3-tryptamino-4,5-dihydroisoxazole 
(10) in the construction of more complex peptides. In this context, tryptamine 
would have to act as a terminal function, since without the carboxyl moiety, we are 
unable to incorporate the dihydroisoxazole mimetic into the middle of a peptide 
sequence. A peptide chain could, however, be built up by coupling amino acids to 
the amino group at C-4 of the dihydroisoxazole ring (Scheme 27a). This would 
provide a viable means with which to construct a constrained peptide chain 
analogue that could then be studied for possible turn conformations/103^  We hoped 
that this constraint would enforce one of two turn conformations on the peptide 
chain; a y-tum for the (R)-dihydroisoxazole unit and an inverse y-tum for the 
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The first step in this sequence required that the N-benzyloxycarbonyl 
group be removed from the 3-tryptamino derivative (10). Although the N-Cbz 
group is generally removed under catalytic hydrogenation conditions/89^  in our 
hands the imine bond was also reduced to afford the 3-(tryptamino)-isoxazoline 
derivative (47). The "hard and soft acid-base" concept(104) was then applied to 
remove the N-benzyloxycarbonyl at C-4 by treating (10) (in CH2C12) with 
trifluoromethanesulfonic acid in the presence of anisole to afford amine (48) in 
85% isolated yield (Scheme 27b).
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3-Tryptamino-(4R)-amino-4,5-dihydroisoxazole (48) was then coupled 
to [N-(Cbz)]-(L)-alanine using dicyclohexylcarbodiimide and 1-hydroxyl- 
benzotriazole hydrate in dimethylformamide, to give the tripeptide (49) in 80% 
yield. This tripeptide was extended further, following removal o f the Cbz residue 
from (49) to give (50). Coupling the free N-terminus of tripeptide (50) with 
another equivalent of N-(Cbz)-(L)-alanine gave tetrapeptide (51) in 69% yield. 
The N-terminus of tripeptide (50) could similarly be reprotected, in this case with 
benzoic acid to give the corresponding N-(benzoyl) derivative (52). This reaction 
was conducted under standard peptide coupling conditions^105) rather than using 
benzoyl chloride in pyridine as this latter procedure resulted in epimerization. The
Schem e 28b
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overall synthesis of the tri- and tetrapeptides incorporating the dihydroisoxazole 
unit is shown in Scheme 28a.
As described earlier, the constrained (4R)-dihydroisoxazole unit should 
induce a y-tum and the (S)-enantiomer should induce an inverse y-turn. For 
comparison, the 3-tryptamino-(4S)-amino-4,5-dihydroisoxazole (56) was 
synthesised and converted to the corresponding diastereomeric tri-, tetrapeptide 
and the benzoyl derivatives (57), (59) and (60) respectively, using the same 
chemistiy that had been established for the (R)-series (Scheme 28b).
All the protons in the tri- and tetrapeptide of both the (R)- and (S)-series 
were well-defined in the NMR spectra and were assigned using 2D
COSY experiments. Further spectroscopic studies (ROESY and variable 
temperature NMR) on these tri and tetrapeptides, however, failed to detect an 
intramolecular hydrogen bond between the NH at C-2 with the NH at C-4 of the 
dihydroisoxazole ring (Figures 5, 6, 7 and 8). This does not rule out the possibility 
that the peptide chains does not involve a y or inverse y-tum, rather we have 
demonstrated that the peptide chains do not exist exclusively in either a y or 
inverse y-tum conformation on the NMR time scale. Although the solid state 
conformation may not necessarily be a good model as the solution conformation, 
we felt that such information would nevertheless be of interest. However, we were 
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Tetrapeptide : [3/RJ-N-[2-[2-[[3-[[2-(3-indolyI)ethyl]amino]-4,5-dihydro-4-isoxazolylamino]-
1-metnyl-2-oxoethyljamino]-1-methyl-2-oxoethyl]carbamic acid, phenylmethyl ester
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Tripeptide; [3'S]-N-[2-[[3-[[2-(3-indolyl)ethyl]amino]-4,5-dihydro-4-isoxazolylamino]-
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1.5 Summary
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In Chapter 1 we have described the synthesis and reactivity of imidoyl 
halides and mesylates derived from (R)-cycloserine. Our goal was to generate a 
novel constrained amino acid mimetic ( corresponding to L-glycine) for 
incorporation into peptides to "induce" a y-tum conformation. While we have had 
some success this chemistry and its subsequent application has been limited by a 
number of factors:-
1. The bulkiness of the protecting groups at C-4 sterically hinders
nucleophilic attack at the adjacent C-3 position.
2. The electrophilic nature of the protecting groups compared with that of
the imidoyl halides leads to reaction at this alternative site.
3. The stability of imidoyl halides towards amino esters in displacement
reactions limited the range of substrates that we were able to make 
available.
4. The mesyl group transfer from oxygen to nitrogen complicated the use
of this activating function and also activated the dihydroisoxazole 
towards ring-opening.
The incorporation of tryptamine into the dihydroisoxazole ring and our 
ability to extend a "peptide-like" chain through C-4 of the dihydroisoxazole (see 
Scheme 28a) has endorsed the possible use of the dihydroisoxazole ring as a 
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2. Synthesis o f (cis)-Hexahydro-2H-pyrrolo[2^3-d]isoxazolidine-3-one
As outlined in the Introduction (Section 2.0), bicycle (H) has torsion 
angles (j) = -65.9° and y  = 62.2°. This is in agreement with an inverse y-tum (<j> = 
-70° to -80° and \j/ = +60° to +70°) and this structure would be expected to induce 
an inverse y-tum conformation once incorporated into a peptide chain. The 
retrosynthetic analysis for the (S)-enantiomer of bicycle II is shown in Scheme 29.
We planned to activate pyirolo[2,3-d]isoxazolidine-3-one (76b) towards 
nucleophilic attack by generating the imidoyl halide function as has been already 
described in Section 1.1. We hoped that our lack of success in incorporating an 
amino acid into the dihydroisoxazole ring would not prevail upon the bicycle 
system, it being a different structure altogether. As outlined in Scheme 29, the 
starting material for the synthesis of bicycle (II) is 3,4-dehydroproline. This amino 
acid is commercially available but at a high cost (£90g_1) and for large scale 
synthetic work, we were required to prepare this material ourselves, using a 
literature procedure^106^  based on (2S,4R)-4-hydroxyproline (61). The synthesis of 
[N-(Cbz)]-3,4-dehydroproline (67) using this procedure is outlined in Scheme 30.
We sought to use N-benzylhydroxylamine (70) as a protected form of 
hydroxylamine in order to couple to dehydroproline to give the corresponding 
hydroxamic acid derivative (72). N-Benzylhydroxylamine was prepared using the 
procedure of Sneed and JonesO°7)(Scheme 31) and this proved to be a more 
reliable method in our hands than the alternative route based on the reduction of 
benzyloxime with diborane in THF/108)
The coupling of benzylhydroxylamine (70) with [N-(Cbz)]-(L)-proline
























was examined as a model for the route based on 3,4-dehydroproline. The desired 
hydroxamic acid (71) was obtained in 50% yield as shown in Scheme 32.
Scheme 32 OH
C 02H + H-N
OH
DCC, 
Ph RT, 2( 
(50%
(70) (71)
Using the same experimental protocol, [N-(Cbz)]-3,4-dehydroproline (67) 
was coupled to N-benzylhydroxylamine (70), in the presence o f dicyclohexyl- 
-carbodiimide (DCC), to give hydroxamic acid (72) in 50% yield. At the time we
peptide coupling reactions and the presence of this reagent may have led to an 
improved yield o f (72). Although some racemisation may have occurred at C-2, 
complete racemisation was not manifested, as later products, 4-phenylseleno- 
-2-(N-benzyl)-2H-pyrrolo[2,3-d]isoxazolidine-3-one (73) and the corresponding 
deselenylated derivative (75) gave optical rotations of [a]21*5!) -8.76° (c 3.4 in 
CH2 CI2 ) and [a]20D -76.9° (c 2.2 in CH2C12) respectively.
The double bond in N-benzylhydroxamic acid (72) was activated by 
addition o f phenylselenenyl chloride in dichloromethane to give 4-phenylseleno- 
-2-(N-benzyl)-bicycle (73) in 64% yield. We speculated that the initial product(s) 
were, in fact, the PhSeCl adducts (72a, 72b) and in order to effect the cyclisation 
step we found that silver tetrafluoroborate was required to remove the chloride 
(Scheme 32b). Under these conditions two products were obtained. The major 
component was the desired phenylselenenyl cis-fused [3.3.0]bicycle (73), the 
structure o f which was elucidated by extensive spectroscopic studies (Figure 9). A 
second, more minor component (74) was also isolated in 16% yield and this clearly 
contained both the phenylselenenyl group and the proline ring structure, but based 
on the NMR spectra, the benzyloxycarbonyl group at 5 5.00 + 5.12 (obtained
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from compound (72)) appeared to have been lost. The AB quartet at lower field (5 
4.60 + 4.72) suggested the presence a simple OCH?Ph residue and a molecular ion 
of 465 (M+ + H) (44 mass units less than the corresponding 4-phenylselenenyl 
bicycle (73) (509 (M+ + H)) was observed. Based on this evidence it is clear that 
the minor component is not the isomeric [3.2.1] bridged-bicycle (79) and the 
structure of this other product has not been identified.
Deseienylation of 4-(phenylseleno) bicycle (73) was achieved in 91% 
yield using tributyltin hydride in the presence of catalytic amount of azobis- 
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Complete deprotection of bicycle (75) using atmospheric hydrogenation 
in the presence of either 1 0 % palladium over charcoal catalyst or 2 0 % palladium 
hydroxide, could not be achieved. In the event, only the N-benzyloxycarbonyl 
group was removed to afford 2-[N-benzyl]pyrrolo[2,3-d]isoxazolidine-3-one (76) 
in 73 and 61% yields respectively. Other attempts to cleave both protecting groups 
simultaneously were also unsuccessful and in all cases only the 
N-benzyloxycarbonyl group was removed to give bicycle (76). These efforts 
included the use of trifluoromethanesulphonic acid and anisole/104) phase transfer 
hydrogenation with ammonium formate and 1 0 % palladium over charcoal
Schem e 33b
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catalyst/110) and the use of iodotrimethylsilane.(111) Iodotrimethysilane is known 
to cleave esters, ethers and carbamates/111^  so the removal of the 
N-benzyloxycarbonyl group was of no surprise. We had envisaged that the oxygen 
atom in the carbonyl function in bicycle (75) would be silylated and that iodide ion 
would attack the N-benzyl group as illustrated in Scheme 33b.
Subjecting the N-benzyl bicycle (76) for long periods to phase transfer 
hydrogenation conditions only led to the cleavage of N -0 bond in the bicyclic ring. 
3-Hydroxy-N-(benzyl)-2-pyrrolidinecarboxamide (77) was subsequently isolated 
in 18% yield from the above reaction after reprotection of the proline nitrogen with 
benzyl chloroformate. The overall reaction sequence is oudined in Scheme 34 and 
although a cis relationship between C-2 and C-3 would be expected, we did not 
verify this and cannot exclude the possibility that epimerisation of C-2 did not 
occur under the reaction conditions. Treating bicycle (76) with sodium-liquid 
ammonia at -78°C in THF^112^  was also unsuccessful leading to a complex mixture 
of products and with only a low (1 0 %) recovery of starting material.
It is evident that the N-benzyl protecting group cannot be removed under 
normal mild hydrogenation conditions without the cleavage of the weak N-O bond 
in bicycle (76). Bicycle (76) was nevertheless N-acylated with 4-bromobenzoyl 
chloride in the presence of 4-dimethylaminopyridine in THF (Scheme 35), in the 
hope of obtaining crystals for X-ray crystallographic analysis and to aid full 
characterisation. Unambiguous assignment of structure and stereochemistry could 
then be made as all prior intermediates had been oils. To date, we have obtained a 
satisfactory elemental analysis for the acylated bicycle (78) but, as yet, crystals for 
X-ray analysis have not been produced. Further synthetic work related to 
2H-pyrrolo[2,3-d]isoxazolidine-3-one (76) and its incorporation into a peptide 




























3 . Synthesis of2-oxa-3,6-bis-azabicyclo[33.1]octan-4-one (III)
The [3.2.1]bicycle (III) is another heterocyclic constraint unit that we 
aimed to synthesise. The torsion angles of this unit have been calculated by 
CONDOR to be <J) = -95.8° and y  = +113.9°. This molecular framework, based on 
bicycle (84), would therefore exert a very different type of constraint from that of 
the bicycle (H) described above. We had hoped that, during the electrophile- 
-mediated cyclisation of the 3,4-dehydroproline derivative (72) with phenyl- 
-selenenyl chloride and silver tetrafluoroborate, some of the bridged bicycle (79) 
may have formed i.e. path b in Scheme 36. In the event the only isomer obtained 
corresponded to (73) (path a) so we sought to synthesise the bridged bicycle (84) 
by an alternative route from (2S,4R)-4-hydroxylproline. The retrosynthetic 
analysis of bicycle (84) is shown in Scheme 37.
3.11. Synthesis and Attempted Cyclisation o f (4R)-Methanesulphonyloxy-
•N-(hydroxy)-(2S)-pyrrolidinecarboxamide
Using Schotten-Baumann conditions, the amine function of (2S,4R)- 
-4-hydroxyproline (61) was protected with benzylchloroformate. O-Benzyl- 
hydroxylamine (a latent hydroxylamine unit) was then incorporated by reacting the 
N-protected hydroxyproline (62) with O-benzylhydroxylamine in the presence of 
DCC to give (80) in 52% yield. The C-4 hydroxyl function was then mesylated 
under standard conditions and mesylate (81) was deprotected by atmospheric 
hydrogenolysis in the presence of 1 0 % palladium over charcoal as catalyst, to give 
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Attempts to cyclise hydroxamic acid (82) using methods very similar to 
those reported by Hanessian^115^  for the synthesis of tricholomic acid from 
d,l-r/*reo-2-amino-3-hydroxyglutamic acid benzyl ester (8 -N-benzyloxyamide) 
(Scheme 38) i.e. stirring at 0°C in the presence of triethylamine in water, were 
unsuccessful. Other efforts directed towards this end, such as changing the solvent 
and varying reaction conditions were also unfruitful. Hydroxamic acid (82) was a 
very polar compound and it was difficult to follow any reaction by TLC. Attempts 
to reprotect the nitrogen atom of the proline ring with either benzyl chloroformate 
or with di-rm-butyldicarbonate (BOC2 0 )  were equally unsuccessful, although 
some reprotected product (83) in only 15% yield was isolated with BOCjO. It is 
possible that hydroxamic acid (82) is polymerising in the reaction conditions 
applied to either achieve cyclisation or affect reprotection (Scheme 39).
3.12. Synthesis and Cyclisation Reactions o f 1 ~[N-(2^2^2-Trichloroethyloxy-
carbonyl)]-(4R)-Methanesulphonyloxy-N-(hydroxy)-(2S)-pyrrolidine- 
carboxamide
Given the above observations we sought an alternative protecting group 
that would be stable under hydrogenolysis conditions. 2,2,2,-Trichloroethyl- 
-oxycarbonyl (TROC) was chosen since this residue is easily removed in the 
presence of zinc in acetic acid/89a^  (2S,4R)-4-Hydroxyproline was N-protected 
with 2,2,2-trichloroethyl chloroformate in the presence of 1M aqueous sodium 
bicarbonate solution to give (85) in 97% yield which was subsequently converted 
to [N-(TROC)]-(4R)-methanesulphonyloxy-N-(hydroxy)-(2S)-pyrrolidinecarbox- 
amide (8 8 ) using the same experimental conditions established earlier for the 
synthesis of the [N-(Cbz)] derivative (82). The overall yield of (8 8 ) was 77% and 
the sequence is illustrated in Scheme 40.
Schem e 40b
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Mesylate (8 8 ) was stirred with triethylamine in methanol in an attempt to 
achieve cyclisation to generate the [3 .2 . 1 ] bridged bicycle corresponding to that 
required for (III), but instead displacement of the trichloroethyloxy group 
occurred, to give oxadiazine derivative (8 8 b) (Scheme 40b). Oxadiazine (8 8 b) 
was characterised only by spectroscopic methods; 1H, 13C NMR and IR only, an 
accurate molecular ion was not found. We envisaged an alternative mode of 
intramolecular displacement involving (89) by activating the hydroxyl at C-4 under 
Mitsunobu-type conditions/116a_c) This would give the alkoxyphosphonium salt at 
C-4, which is then susceptible to nucleophilic attack, in this case by the OH in the 
hydroxamic acid group (Scheme 41). Although, we could foresee a number of 
possible side reactions that would lead to polymerisation of the pyrrolidine ring, 
the idea was nevertheless pursued.
[N-(TROC)]-(4R)-Hydroxyl-N-(hydroxy)-(2S)-pyrrolidinecarboxamide 
(89) was prepared by debenzylation of (4R)-hydroxyl-N-(phenylmethoxy)-(2S)- 
-pyrrolidinecarboxamide (8 6 ) (Scheme 42). However, treating (89) with
triphenylphosphine and diethylazodicarboxylate, only a complex mixture was 
obtained and this route was abandoned.
3.13. Synthesis o f N-(Pivaloyl)-3 -(Hydroxyimino)-2 -oxa-5~azjabicyclo[22.1 ]-
heptane (95)
Evidently, the carbamate protecting group was interfering with the 
cyclisation of l-[N-(TROC)]-(4R)-methanesulphonyloxy-N-(hydroxy)-(2S)- 
-pyrrolidinecarboxamide (8 8 ) as described in Section 3.12. Pivaloyl chloride was 
then chosen as the N-protecting residue for (2S,4R)-4-hydroxyproline. 
[N-(Pivaloyl)]-(2S,4R)-4-hydroxyproline (91) was prepared using similar 
procedure described for FMOC N-protection of amino acids/86) N-pivaloyl (91) 
was then converted to the corresponding mesylate (93) using the same reaction
Scheme 43
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conditions employed for the synthesis o f the N-Cbz derivative (81), in 63% overall 
yield (Scheme 43). Similarly, [N-(TROC)] carboxamide (87) could be converted 
to (93) by deprotection o f the TROC group (Zn/HOAc) and then reprotection 
(pivaloyl chloride in pyridine) in 59% overall yield.
The N-pivaloyl derivative (93) was debenzylated (H2, 10% palladium 
over charcoal) to give the corresponding hydroxamic acid (94) in quantitative 
yield. We attempted to carry out the cyclisation step under basic conditions by 
treating (94) with sodium hydride in dimethylformamide. A cyclised product (95) 
was obtained in 33% yield but X-ray crystallographic analysis o f this product 
revealed its structure to be that of the 3-(hydroxyimino)-2-oxa-5-aza- 
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It is apparent that cyclisation has occurred via the carbonyl oxygen in a 
5,5 (enol-exo) exo-tet fashion rather than in a 5,6 exo-tet from the oxygen in the 
hydroxamic acid (NOH) group/117a,b) but both pathways are favoured according to 
Baldwin’s Rules of Ring Closure/114a,b) It has been reported that five-membered 
ring formation is generally much faster than the corresponding closure to give the 
six-membered ring/113) Alkylations of hydroxmates generally occur via the 
oxygen of NOH(118) and the anion of hydroxamate is known to prefer to exist in 
tautomer form (B) rather than (A) or (C)^120) with tautomer (B) stabilised by an 
intramolecular hydrogen bond(121) (Scheme 45). Hence, for a 6  exo-tet cyclisation 
to occur in (94), this hydrogen bond would have to be broken. Similarly, one can 
envisage cyclisation via the nitrogen in the hydroxamic acid (94) to give the [2.2.1] 
bicycle (97), however, this process would require a 5,5 (enol-endo) exo-tet 
cyclisation mode which is a disfavoured pathway(117) (Scheme 46).
The N-pivaloyl protecting group has been reported to be effectively 
removed under acid hydrolysis condition (reflux in TFA)/122* Subsequent 
treatment of N-(pivaloyl) bicyclo[2.2.1]heptane (95) with aqueous TFA ((4:1) at 
reflux), followed by reprotection with benzyl chloroformate afforded the 
corresponding N-(benzyloxycarbonyl)-azabicycle (99) in 37% yield (Scheme 47).
Scheme 47
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An alternative route to the [3.2.1]bridged bicycle (96) would be to 
activate the hydroxyl function at C-4 of the N-(pivaloyl) hydroxamic acid (100) by 





















amide (100) was prepared by debenzylation of N-(phenylmethoxy)-(2)-pyrrolidine- 
carboxamide (92) (H2 ,Pd/C) (Scheme 48). Treatment of (100) with 
triphenylphosphine and DEAD (THF, 0°C, lh) gave an adduct of (100) that had 
incorporated DEAD. We propose that the hydroxamic acid (NOH) function in 
(100) had reacted with the DEAD reagent before triphenylphosphine, to give the 
adduct (1 0 1 ) and this assignment is consistent with spectroscopic data obtained 
(1H, 13C NMR and IR only, no molecular ion was observed) (Scheme 49). This 
result was not a complete surprise since hydroxamic acid has a pKa of 9^ 120^  and 
repeating this reaction by first generating the PPI13/DEAD complex followed by 
addition of hydroxamic acid (100) still afforded the same adduct (101) in 46% 
yield.
The cyclisation of hydroxamic acid (100) does not offer a viable route to 
the target [3.2.1]bridged bicycle (96) as the "5,5” ring formation is favoured 
kinetically over that of the ”5,6" ring. Alternative intramolecular cyclisations 
using triphenylphosphine and DEAD to activate the 4-hydroxyl function in 
pyrrolidine (1 0 0 ) was also unfruitful and further effort on the synthesis of bicycle
(III) was thus abandoned.
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C H A P T E R  4
4. Synthesis o f 4,4-(2-pyrrolidine)-4-isoxazolidine-3‘One (IV)
The final peptide mimetic that we have examined is the spiro derivative
(IV) which has been calculated by CHEMX to have torsion angles (<j>=-60° and 
\jr=-60o) corresponding to that of a right-handed a-helix. The retrosynthetic 
analysis of this system is shown in Scheme 50, where (S)-proline is the starting 
material. We needed to be able to alkylate proline stereospecifically at C-2 with a 
"®CH2 OH" equivalent. Seebach has developed a method for the asymmetric 
a-alkylation of (S)-proline^123^  This is based on the condensation of pivaldehyde 
with (S)-proline to give a single diastereoisomer of 2-rm-butyl-l-aza-3- 
-oxabicyclo[3.3.0]octan-4-one (102). This intermediate can be deprotonated with 
lithium diispropylamine (LDA) to give a chiral, non-racemic enolate which can 
react with electrophiles with retention at the C-2 centre of the pyrrolidine ring 
(Scheme 51).
(S)-Proline was condensed with a 2.5 fold excess of pivaldehyde in the 
presence of catalytic amount of trifluoroacetic acid, with removal of water (3A 
molecular sieves). This gave bicyclo[3.3.0]octan-4-one (102) in quantitative yield 
and it should be noted that this material is very readily hydrolysed and great care 
was required in preparing and isolating this adduct {see Experimental). This point 
is not obvious from the procedures in Seebach’s papers but collaborators at Glaxo 
have encountered this problem and we are grateful for their advice on the synthesis 
of bicycle (1 0 2 ).
The alkylating agent required in our synthesis needed to function as an 
equivalent of "®CH2OH" and benzylchloromethyl ether (103) can fill this role/124) 
Benzylchloromethyl ether (103) was prepared by reacting benzyl alcohol
Schem e 52
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with formaldehyde under acidic condition (Scheme 52). In our hands, the yields of 
benzylchloromethyl ether was lower than reported in the literature <124* and 
significant amounts of dibenzylformal (104) were formed as the major by-product. 
This side reaction arises from reaction of benzyl alcohol with the desired product, 
benzylchloromethyl ether (103) (Scheme 53). Benzylchloromethyl ether is a toxic 
and hydrolytically unstable compound and upon isolation, it was often 
contaminated with benzyl alcohol. An alternative equivalent for "®CH2 ONH2" is 
reported in Section 5.1.
Oxabicyclo[3.3.0]octan-4-one (102) was deprotonated with LDA at -78°C 
in THF, as described by Seebach <123* and condensed with benzylchloromethyl 
ether (103). The pivaldehyde group was reported to be removed under strongly 
acidic or basic conditions i.e. refluxing the a-alkylated bicycle (102b) in 48% 
hydrogen bromide (in AcOH) or by treatment with lithium amide/123* Our 
collaborators (workers at Glaxo Group Research) have reported an efficient 
method of removal of the pivaldehyde group which involves simply stirring (1 0 2 b) 
with silica gel in aqueous methanol at room temperature. Given the sensitivity of 
(102) to hydrolysis, it is somewhat suiprising that Seebach was required to use 
such harsh conditions for this step. In our hands, an overall yield of 22% of the 
a-methylbenzyl ether (105) was obtained using these procedures (Scheme 54). We 
can only speculate that the low yield of a-alkylated proline obtained is due to the 
low purity of (102) and (103), but neither component could be purified without 
significant decomposition causing further complications. Another factor is that 
the C-2 centre in the pyrrolidine ring may be sterically too crowded for approach 
of benzylchloromethyl ether, we did however, repeat this alkylation reaction with 
allyl bromide which only gave a 2 1 % yield of the a-allyl product (106), this 
compares to the 87% yield reported by Seebach(123* (Scheme 55). It may then be 



























The a-alkylated proline derivative (105) was N-protected with pivaloyl 
chloride in pyridine to give (107) in 6 8 % yield (Scheme 56). N-(Pivaloyl)-(2R)- 
-methylbenzyl ether (107) was coupled to O-benzylhydroxylamine under standard 
conditions*105^  with DCC and 1-hydroxybenzotriazole in dichloromethane to give
(108) in 6 8 % yield. Hydrogenolysis (H2, Pd/C) served to remove only one benzyl 
group and we concluded that the hydroxamate O-benzyl group was the residue 
cleaved. This is based on the observation that an AB type signal at 5h 4.86 + 4.94, 
/  11.2 and 11.4 Hz from compound (108) which corresponded for the NOCH?Ph 
function was absent from the NMR spectrum of hydroxamic acid (109) (Figure 
10). Subjecting hydroxamic acid (109) to the harsher conditions of phase transfer 
hydrogenation (ammonium formate, 10% Pd/C, MeOH, 70°C, 2h) only led to the 
cleavage of the N-0 bond in the hydroxamic acid function giving amide (110) in 
36% yield. The overall reaction is outlined in Scheme 57.
The use of boron trifluoride etherate and ethanethiol as a Hard Acid - Soft 
Nucleophile system has been reported to cleave alkyl/aryl benzyl ethers.*125*’1’) 
Similarly, the use of sodium in ethanol*126) or ammonia*127) have also been 
reported to affect reductive cleavage of benzyl groups. However, treatment of 
hydroxamic acid (109) with boron trifluoride and ethanethiol gave a complex 
mixture and treatment of (109) with sodium in ethanol resulted in only recovery of 
starting material albeit in only 34% yield.
Having no success with the reductive cleavage of benzyl ether group from
(109), we decided to reverse the order of the coupling step by first removing the 
benzyl group in pyrrolidine (107) and then couple the hydroxymethyl derivative 
(111) with O-benzylhydroxylamine. Debenzylation of compound (107) was 
achieved under atmospheric hydrogenation conditions (H2, Pd/C) to afford the 
hydroxymethyl derivative (111) in 98% yield. The carboxylic acid function in 
(111) was then coupled with O-benzylhydroxylamine under standard peptide
Fig. 10





conditions^105) to give the N-(phenylmethoxy)-2-pyrrolidinecarboxamide (112) but 
this step only proceeded in low yield (10-20%) of (112) along with 8% of the 
rm-butyl ester (113), where the pivaloyl group had undergone migration to the 
methyleneoxy group at C-2 of the pyrrolidine ring (Scheme 58).
Scheme 58
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It was apparent that the hydroxymethyl group is interfering with the 
coupling step and subsequent attempts directed towards improving the yield of
(112) were unsuccessful. Efforts included using various reaction solvents such as 
THF, dimethylformamide and acetonitrile and varying reaction temperature from 
room temperature to heating at 50°C. Addition of more reactive coupling reagents, 
such as N ,N -b is  [2-oxo-3-oxazolidinyl]phosphinic chloride (BO P-C l/128) and 
benzotriazol- l-yloxyrm(dimethylamino)phosphonium hexafluorophosphate (BOP 
Reagent) 1^29) did not lead to any significant increase in the yield and the results of 
this aspect of the study are shown in Table 8.
[N-(Pivaloyl)]-2-(hydroxymethyl)-N-(phenylmethoxy)-2-pyrrolidine- 
carboxamide (112) was then debenzylated (H2, Pd/C) to give 2-hydroxymethyl- 
-N-(hydroxy)-2-pyrrolidinecarboxamide (114) in 65% yield (Scheme 59).
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Coupling of carboxylic acids and esters with hydroxylamine
derivative (111) with hydroxylamine hydrochloride in the presence of DCC and
c
triethylamine in absolute ethanol as a more direct route to hydroxamate (114). In 
our hands, only a complex mixture was obtained and we decided to follow the 
former route of coupling O-benzylhydroxylamine to carboxylic acid (111), 
followed by debenzylation to give hydroxamate (114).
We envisaged cyclisation o f hydroxamic acid (114) by activating the 
alcohol function to an alkoxyphosphonium salt by treatment of triphenylphosphine 
and D E A D /116a_c* Subjecting (114) to this reagent combination in THF at room 
temperature for 20 hours afforded the ring-opened cyclised adduct (115) in 55% 
yield along with recovered starting material (114) in 14% yield. The structure of 
(115) was elucidated from and 13C NMR spectra. It appears from the much 
simplified proton splitting pattern now observed for the protons on the pyrrolidine 
ring that the pyrrolidine ring had opened up. A molecular ion of 227 was observed 
in the C.I. spectrum which corresponded to the loss of H20  from the hydroxamic 
acid (114) which is what one would have expected if cyclisation had taken place. 
Similarly, two carbonyl peaks were observed, 1740 cm'1 and 1630 cm*1. We 
propose that cyclisation to form the spiro-compound had taken place, followed by 
fragmentation of the pyrrolidine ring (Scheme 60).
hydrochloride has also been reported/130* We sought to couple the proline
An extensive literature search on 3-hydroxyisoxazoles or 4-isoxazolidine- 

















C-5 and/or at C-5 and C-4 has been reported, there was only one literature example 
of an alkyl substituent at C-4 of this ring system/131^  We were, however, unable to 
obtain any spectroscopic data for comparison with (114), as only a dissertation 
abstract was available to us. Efforts directed towards controlling this 
fragmentation by reducing the reaction temperature i.e. stirring (114) with 
triphenylphosphine and DEAD in THF at 0°C for 7.5 hours followed by at -23°C' 
for 20 hours, afforded 7% yield of the 4-isoxazoline-3-one (115) along with 78% 
yield of recovered starting material (114). It is evident, that fragmentation of the 
putative spiro derivative is facile. Triphenylphosphine and carbon tetrabromide 
has been reported by Rapoport to effect ring closure of amino alcohols to give 
4-substituted prolines/132^  but treatment of hydroxamic acid (114) with 
triphenylphosphine, carbon tetrabromide and diisopropylethylamine in acetonitrile 
only gave a complex mixture of products.
So far, the basis of our approach to cyclise hydroxamic acid (114) lies in 
the difference in reactivity between an alcohol and the hydroxyl function in the 
hydroxamic acid (N-OH) group. We reflected on an alternative mode of 
cyclisation to spiro-adduct (IV) by converting the C-2 primary alcohol of the 
pyrrolidine ring (1 1 2 ) to a much better leaving group, such as a mesylate or a 
bromide, so that upon debenzylation, ring closure can occur in a one-pot procedure 
(Scheme 61). Efforts to mesylate the hydroxymethyl function in carboxamide 
(112) under general mesylation conditions were unsuccessful. Similar attempts to 
synthesise the corresponding bromide (116), by reacting carboxamide (1 1 2 ) with 
triphenylphosphine dibromide in THF was also unsuccessful. A new adduct was 
however isolated from this reaction, but we were unable to obtain any molecular 
ion that contained bromine. Due to the lack of starting material and available time 










5. Synthesis of N-Chloromethoxyphthalimide as a Bifunctional Equivalent
o f NH2-0-CH2®
An alternative retrosynthetic route to racemic 4-amino-3-isoxazolidinone
(1) would be to condense an electrophilic aminoxymethylene (NH2 OCH2®) (V) 
with a N-protected glycine methyl ester (Scheme 62). We felt that 
N-chloromethoxyphthalimide (118) would act as an experimentally viable 
equivalent of synthon (V) and although (118) is known in the literature, very little 
work has been done to exploit its synthetic potential.
N-Chloromethoxyphthalimide (118) was first prepared by Pratts and 
Gibbs^133) by heating the silver salt of the N-hydroxyphthalimide with an 
appropriate methyl bromide or iodide. An in situ preparation of (118) was reported 
by Forrester where the hydroxyphthalimide was heated in the presence of an 
excess of silver(I) oxide in chloroform, to give N-chloromethoxyphthalimide (118) 
in 1 2 % yield^134) and by changing the solvent to bromochloromethane, a 
quantitative yield was reported. Using the procedures supplied by Professor 
Forrester, we were able to obtain (118) in 50-64% yield as a stable crystalline 
solid (Scheme 63).
5.12. The Reactivity o f N-Chloromethoxyphthalimide
The reactivity of N-chloromethoxyphthalimide (118) towards the anions 
of diethyl malonate (119) and diethyl acetamidomalonate (120) was investigated. 
However, treating N-chloromethoxyphthalimide (118) with (119) or (120) under 
various solvent systems, bases and reactions conditions, gave none of the desired 
malonate adducts (Table 9 and 10). In most cases, starting material was recovered
O :
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eq./(118) eq./(119) eq./Base Solvent Rxn conditions
field/%crude 
(122) (123)
1 0.5 0.5 Na EtOH * (119)+Na, then 
add (118), stir 
0°C 2h
66
1 2 2.3 Na EtOH *(119)+Naat 
-15°C, add (118). 
Stir -15°C 24h
27 25
1 / 1 Na EtOH Add (118) to soln Na in EtOH, Stir 
RT3h
16 40
1 1.2 1.2 NaH THF * (H9)+NaH, add 
(118), 50°C 3h
(118)***
1 1.5 1.5 NaH THF * (H9)+NaH, add 
(118), stir RT 4h
(118)**
1 1.3 1.3 NaH THF * (119)+NaH at 
reflux 0.40h, then 
add (118), reflux 4h
(118)**
1 1.2 1.5 NaH THF * (119)+NaH at reflux 2h, then add 
(118), RT 2-5 h
(118)**
* refers to prmixing
** refers to identification by 1H NMR
*'* refers to identification by TLC.
Scheme 64
CO-Et EtOH
and identified by NMR. In the case when ethanol was used as a solvent, the 
ethoxide ions produced reacted with N-chloromethoxyphthalimide to give the 
N-ethoxymethoxy adduct (121), together with the ring-opened phthalimide (122) 
(Scheme 64).
C02Et




eq./(118) eq./(120) eq./Base Solvent Rxn conditions Results
1 1 1 LDA THF * (120)+LDA then
add (118) at -78°C 
stir 0°C 20 min
(118)**
1 1.1 1.1 NaH Benzene * (120)+NaH at reflux 1.5 h, 
then add (118), 
reflux 24 n.
(118)**
1 1.4 1 Na EtOH *(120)+Na 0°C, 







THF *(120)+base 0°C 




1 1 1.2 NaH THF *(120)+NaH, add
(118), stir RT 21 h, 
reflux 8h
(118)**
* refers to premixing
** refers to identification by 1H NMR
Table 11
(125) 'o (126) °




1 3.5 2.5 NaH THF *(124)+NaH at RT, 
then add (118), 
Stir RT 28 h
49
1 2.9 3 K2C03 CH2CI2 *(124)+K2C03 




k 2c o 3
c h 2ci2 *(124)+K2C03 
at RT 1 h, then 




MeOH *(124)+KOH at 
0°C, then add
(118), stir 0°C 




CH2CI2 *(124)+KOH at 
0°C, then add 
(118), 0°C 6 h, 
RT 60 h,
23
* refers to premixing 
** refers to recrystallised yield
Scheme 6 6
0  O
N -  O '" Cl + HSPh
(118) O
K2 C 03, MeOH 
T 2.5 days
-72-
To ensure that the anion o f diethyl malonate was being generated, diethyl 
malonate was treated with sodium hydride in THF and was quenched with methyl 
iodide to give the alkylated adduct (123) in 65% yield (Scheme 65).
Scheme 65
Displacement o f the chloride from N-chloromethoxyphthalimide (118) 
was observed on treatment o f (118) with thiophenol (124) in the presence of a base 
(Table 11) and the corresponding thiophenol adduct (125) was isolated in 76% 
yield (Scheme 66). Using methanol as the reaction solvent, the methoxide ions 
generated competed with thiophenol for the displacement of chloride in (118), 
leading to the methoxy adduct (126).
With these results in hand, N-chloromethoxyphthalimide (118) was 
treated with the enolate of imine (127) in an attempt to provide a route to the 
glycine adduct (128) which could then be cyclised to give the 
4-amino-3-isoxazolidinone, once the phthalimide protecting group had been 
removed (Scheme 67). Adding chloride (118) to a premixed solution of imine 
(127) and potassium rm-butoxide at -78°C, as described by Stork/139) followed by 
addition of sodium borohydride in ethanol at 0°C afforded only the 
N-benzylglycine ethyl ester, with no trace of the alkylated adduct. The lack of 
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the iodo-derivative (129). This was prepared in 39% yield by a halogen exchange 
reaction/135^  This involved heating N-chloromethoxyphthalimide in acetone with 
anhydrous sodium iodide (Scheme 6 8 ). Attempts to synthesise (129) by heating 
N-hydroxyphthalimide with diiodomethane in the presence of silver(I)oxide were 
unsuccessful. Subsequent reactions of iodomethoxyphthalimide with the enolate 
of diethyl malonate in THF were also unsuccessful.
An attempt to alkylate 2-rerf-butyl-l-aza-3-oxabicyclo[3.3.0]octan-4-one 
(102) with N-chloromethoxyphthalimide using LDA at -78°C in THF was 
unsuccessful. The ring-opened alkylated phthalimide adduct (130) was isolated in 
2% yield (Scheme 69).
(Some aspects of the above work was investigated by another research student 
Ajmal Hussain)
5.13 Synthesis and Reactivity o f Nfl'-(Bis-tert-Butyloxycarbonyl)-
Hydroxylamine
It is apparent that the phthalimide functionality is competing with the 
-CH2 C1 moiety in (118) for nucleophiles under "S^-type" conditions. The 
reactivity of (118) towards silyl enol ethers of cyclohexanone under Lewis 
acid-mediated conditions (TiCl4) were examined. The chloromethyl residue 
should be reactive under "SNl-type" conditions but this study was also 
unproductive. An alternative strategy would be to use ?. different protecting group 
for hydroxylamine that would not have a reactive electrophilic centre and, with this 
in mind, the rm-butyloxycarbonyl (BOC) was chosen. The bulky rm-butyl group 
would sterically hinder any nucleophilic attack at the carbamate centre and its ease 
of remova/89d) later on in the synthesis was seen as a significant advantage. We 
planned to doubly protect the nitrogen in O-benzylhydroxylamine with
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di-rm-butyloxydicarbonate by following a literature procedure^136* where double 
N-protection of formamide with this reagent has been achieved. O-Benzyl- 
-hydroxylamine was treated with 2 . 2  equivalents of BOC2 O in dichloromethane in 
the presence of catalytic amount of DMAP, to give the N,N'-6/.y(B0C)-0-benzyl- 
-hydroxylamine (132) in 6 8 % yield, together with the mono-BOC derivative (131) 
in 18% yield (Scheme 70). N,N'-My(BOC)-0-benzylhydroxylamine (132) was 
N-debenzylated (H2, 10% Pd/C) to give the corresponding N,N'-fr/s(BOC)- 
-hydroxylamine (133) in 78% yield (Scheme 71).
We planned to convert N,N'-&w(BOC)hydroxylamine (133) to the 
chloromethoxy adduct (134) (Scheme 72) by using the same experimental 
conditions established earlier for the synthesis of N-chloromethoxyphthalimide. 
Upon heating hydroxylamine (133) in bromochloromethane in the presence of 
silver(I) oxide, only a complex mixture was obtained and other efforts, such as 
deprotonation of the hydroxylamine (133) with n-butyllithium at 0°C in THF 
followed by addition of iodochloromethane, did not give the desired product. 
Further investigations are required in the above reaction if N,N'-&/s(BOC)- 




Instrumentation and Experimental Techniques
Infrared spectra were recorded in the range 4000-600 cm' 1 using a 
Perkin-Elmer 1310 grating spectrophotometer and peaks are reported ( D m a x )  in 
wavenumbers (cm'1). The abbreviation "br" is appended to a peak to indicate 
significant broadening. Spectra of liquid samples were taken as thin films on 
sodium chloride plates, or as solutions in chloroform (CHCI3 ). Spectra of 
solid samples were taken as nujol mulls.
Routine mass spectra were obtained in the electron impact (E.I.) with an 
ionizing potential of 70eV and in the chemical ionisation mode (C.I.), with 
isobutane as reagent gas. Mass spectra were also obtained in the electron 
impact mode with low ionizing potential (low eV E.I.) where appropriate 
(variable ionizing potential in the range 5-30 eV). These along with FAB and 
high resolution accurate mass determinations (in the E.I. mode) were recorded 
with a VG Analytical 7070E instrument and a VG 2000 data system. For the 
TOF mass spectra, these were recorded on Bioline-200 (Glaxo Group 
Research, Greenford). High resolution accurate mass determinations in the 
(C.I.) and (±FAB) mode were recorded using the S.E.R.C. facility at the 
University of Swansea. Where possible, the molecular ion peak is indicated 
along with all sizeable fragments.
Proton magnetic resonance (JH NMR) spectra were recorded at 270 MHz, 
unless otherwise stated, on a Joel GNM GX FT 270 spectrometer. JH NMR 
spectra were also recorded at 60 MHz on Varian Anaspect EM-360 
spectrometer, at 250 MHz on Briiker AC 250 spectrometer and at 400 MHz on 
a Varian VXR 400 spectrometer (Glaxo, Greenford). Carbon-13 magnetic
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resonance (13C NMR) spectra were recorded on a Joel GNM GX FT 270 
spectrometer operating at 6 8  MHz, unless otherwise stated, and on the Varian 
VXR 400 spectrometer at Glaxo (Greenford) operating at 100.6 MHz, using 
90 and 135 DEPT pulse sequences to aid in multiplicity determination.
Proton and 13C NMR spectra were recorded, unless otherwise stated, in 
CDC13, and are expressed in parts per million (6 ) downfield from internal 
tetramethylsilane for 1H, and deuterochloroform for 1 3 C. Multiplicities are 
given as follows: singlet (s), doublet (d), triplet (t), quartet (q), and multiplet 
(m). The abbreviation "br" is appended to a multiplicity to indicate significant 
broadening.
19F NMR spectra were recorded at 376.3 MHz on the Varian VXR 400 
spectrometer at Glaxo Group Research, Greenford.
Melting points (m.p.) were determined on commercially available apparatus 
(Gallenkamp) and are uncorrected. Elemental microanalyses were carried out 
using a Carlo Erba 1106 Elemental Analyser. Optical rotations were 
measured using a Perkin-Elmer 141 polarimeter with concentration (c) 
expressed in g/ 1 0 0  ml.
Thin layer chromatography (TLC) was used extensively as a qualitative guide 
during reactions and for assessing the purity of compounds. Merck 
DC-alufolien Kieselgel 60 F2 5 4  sheets containing fluorescent indicator were 
used for this purpose.
Visualisation of reaction components was achieved by illumination under 
short wavelength (254 nm) ultraviolet light (when possible) or using a reagent 
(typically a 7% (w/v) solution of dodeca-molyphosphoric acid in methanol, or
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aqueous KMn04, or ninhydrin in n-butanol) that would give a colour change 
with the functional groups present, as described in "Dyeing Reagents for Thin 
Layer and Paper Chromatography", E. Merck, Darmstadt, 1980.
Unless otherwise stated petrol refers to that fraction of petroleum spirit boiling 
in the range 60-80°C. Organic solvents used as eluants in chromatography 
were dried and distilled prior to use.
The Varian HPLC with a Brownlee Aquapore RP 300 column (7 pm) was 
used on an analytical scale. The Gilson HPLC with a dynamax column 
(packed with C-18 reversed phase silica (60 A)) was used on a preparative 
scale (100 mg to 5 mg). In both cases acetonitrile (0.5% TFA) - water (0.1% 
TFA) was the eluant.
Medium pressure flash column chromatography were routinely employed 
using Kieselgel 60 (Merck 9385) (flash) and 60H silica gel (Merck 7736) for 
reaction component separations. A pressure gradient was developed using 
small, commercially available hand bellows (Gallenkamp). In all cases 
columns were prepared in the least polar solvent of the eluant mixture and 
chromatography was carried out with the least polar solvent as initial eluant, 
then eluting the solvent mixtures of steadily increasing polarity. Material to 
be chromatographed was preadsorbed onto the column support and applied as 
a thin layer to the top of the column. Preparative thin layer chromatography 
was performed using Merck 60 F 254 silica gel, glass supported plates.
Tetrahydrofuran (THF) was pre-dried over sodium wire, then refluxed over 
sodium benzophenone ketyl under dry nitrogen until anhydrous. This was 
redistilled immediately prior to use. All reagents and solvents were purified 
and dried, when required, according to accepted procedures/140^
Glassware used for water-sensitive reactions was baked in an oven at 120°C 
for approximately 12h and allowed to cool in a desiccator over CaCl^ Flasks 
and stirrer bars were, however, additionally flame dried under a stream of dry 
nitrogen. In all experiments the excess solvent was removed with a Biichi 
rotary evaporator using a water aspirator at room temperature (unless 
otherwise stated) to avoid unnecessary decomposition. All yields quoted are 
of purified products and are uncorrected unless otherwise stated.
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(4RVrN-(BenzvloxvcarbonvOamino1-3-Isoxazolidinone (2)
(4R)-Cycloserinc was selectively N-protected with benzyl chloroformate using 
Schotten-Baumann’s procedures as described in the literature/137^  A 
crystalline solid was obtained in 63-79% yield, m.p. 138°C (from 
EtOAc-Petrol) (lit./137> m.p. 140-142°C) [a]19D + 29.66° (c 4.99 in acetone); 
Dmax (nujol mull) 3280 and 1680 cm'1; 5h (Acetone-d6) 4.11 (1H, dd, J  10 and 
8  Hz), 4.61-4.78 (2H, m), 5.11 (2H, s, CH2Ph), 6.82-6.90 (1H, m, 4-NH), 
7.31-7.40 (5H , m, Ph), 10.30 (1H, s(br), 2-NH); m/z (CL) 237 (M+ + H, 
78%), 193 (18), 91 (100).
NOTE: Protection of (4R)-cycloserine using higher concentrations resulted in 
reaction at both nitrogen atoms leading to (2 b).
2<4-B/5-rN-(benzvloxvcarbonyl)aminol-3-isoxazolidinone (2b)
Isolated in 13% yield as colourless solid, m.p. 123-124°C (from EtOAc-Petrol) 
(Found: C, 61.6; H, 4.83; N, 7.60. C19H1 8N2 0 6  requires C, 61.62; H, 4.90; N, 
7.56%); umax (nujol mull) 3350, 1765 and 1700 cm'1; 6 H 4.14-4.24 (1H, m), 
4.76-4.84 (2H, m), 5.16 (2H, s, CHoPh), 5.37 (2H, s, CH2 Ph), 5.65 (1H, s (br),
4-NH), 7.35-7.50 (10H, m, Phx2); m/z (+FAB) 371 (M+ + H, 4%), 327 (5), 91 
(100); (-FAB) 369 (M+- H, 8 8 %), 261 (59), 235 (30).
Dimer of (4R)-rjV-fBenzvloxvcarbonyl)amino1-4,5-dihvdroisoxazole (5)
To an ice-cooled suspension of [N-(Cbz)]-cycloserine (2) (207 mg, 0.88 
mmol) in acetonitrile (3 ml) was added phosphorus pentachloride (215 mg, 1 
mmol). The yellow solution was stirred at 0°C for 15 min and then for lh at 
room temperature. The solvent and phosphorus oxychloride were then
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removed in vacuo to give a thick yellow oil. Purification by chromatography 
on silica gel using ethyl acetate-petrol as eluant gave a colourless solid (50 
mg) which was then recrystallised from chloroform-petrol to give the dimer 
(5) (27 mg, 7%) m.p. 171-173°C (Found: C, 57.9; H, 12.3; N, 4.90. 
C2 2 H2 2 N4 0 7  requires C, 58.14; H, 12.33; N, 4.83%); omax (CHC13) 3470, 2880 
and 1690 cm'1; 5H 4.23-4.29 (1H, m), 4.40-4.48 (2H, m), 4.75-4.90 (2H, m), 
5.10-5.12 (4H, m, CH2Ph x 2), 5.37-5.47 (2H, m), 5.63-5.70 (1H, m), 
7.33-7.35 (10H, m, Ph x 2); m/z (+FAB) 455 (M+ +H, 50%), 454 (10), 91 
(100); (-FAB) 454 (M+, 19%), 453 (67), 363 (13), 237 (7).
NOTE: Changing the solvent from MeCN to THF lead to dimer (5) in 47% 
along with the 3-chloro-(4R)-[N-(benzyloxycarbonyl)amino]-4,5-dihydro- 
-isoxazole (3) in 23% yield.
Dichlororri.s(dimethvlamino)phosphorane (4)^ 81^
Hexamethylphosphorus triamide (HMPT) (3.34 ml, 0.018 mol) was added to a 
stirred solution of hexachloroethane (4.35 g, 0.018 mol) in acetonitrile (20 ml). 
The mixture was refluxed for lh under nitrogen. The solvent and 
tetrachloroethene were removed in vacuo to give a pale yellow oil/solid. 
Trituration with dried petrol (30-40°C) (20 ml) gave a pale yellow solid. The 
petrol was then quickly decanted and the solid was washed further with dried 
petrol ( 2  x 1 0  ml), dried in vacuo, flushed with nitrogen and stored in a sealed 
flask to give (4) (3.2 g, 58%). This material was not characterised further due 




To a stirred solution of dichlororris(dimethylamino)phosphorane (12.4 g, 0.04 
mol) in freshly distilled THF (50 ml) was added (2) (6.2 g, 0.026 mol). The 
mixture was heated at 100°C for 20h under nitrogen with vigorous stirring. 
After cooling, the reaction mixture was poured into water (300 ml) and 
extracted into ethyl acetate (4 x 100 ml), dried (Na2 SC>4 ), filtered and 
evaporated under reduced pressure to give a brown solid (10 g). Purification 
by chromatography on silica gel using ethyl acetate-petrol as eluant gave the 
chloro-adduct (3) (3.77 g, 60%), further elution gave starting material (2) (0.76 
g, 12%). Chloride (3) was obtained as colourless needles m.p. 138-139°C 
(EtOAc-Petrol); [a]21D +8.75° (c 4.24 in CH2 C12) (Found: C, 51.8; H, 4.32; N, 
11.0. C1 1H1 1C1N2 0 3  requires C, 51.90; H, 4.35; N, 11.00%); \)max (nujol mull) 
3320 and 1690 cm'1; 6 H 4.29 (1H, dd, J 10 and 6  Hz, 5-H), 4.28 (1H, t, J  10 
Hz, 5-H), 5.15 (2H, s, CHoPh). 5.23-5.32 (2H, m, 4-H and 4-NH), 7.36 (5H, s, 
Ph); 5C 59.9 (CH), 67.6 (CH2), 75.3 (CH2), 128.2-128.6 (PhCH), 135.6 
( P h c q u a t e m a i y ) ,  155.1 (Cquatemary), 155.3 (OC=0); m/z (70eV E.I.) 256 (M+, 
0.8%), 254 (2.5), 219 (2), 91 (100); (C.I) 257 (M+ + H, 3%), 255(10), 91(100).
3-Methoxv-(4R)-rN-(benzvloxvcarbonvl)aminol-4.5-dihydroisoxazole (6 )
To a methanol solution (2 ml) of chloride (3) (50 mg, 0.19 mmol) was added 
glycine methyl ester hydrochloride (27 mg, 0.2 mmol) and potassuim 
carbonate (34 mg, 0.25 mmol). The mixture was heated in a sealed tube at 
115°C for 2h. After that time, the solvent was removed in vacuo to give a 
solid, which was dissolved in ethyl acetate ( 6  ml) and washed with water ( 2  
ml). The organic extract was dried (Na2 S04), evaporated under reduced 
pressure and purified by chromatography, to afford a colourless solid. 
Recrystallisation from ethyl acetate-petrol afforded the 3-methoxy adduct (6 )
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(12  mg, 26% ) as colourless needles, m.p. 9 7-101°C  (Found: M+ + H, 
251 .1 0 3 2 . C 12H15N 40 4 requires 251.1032); u max (nujol mull) 3290 , 1675 and 
1625 cm'1; 5H 3 .89  (3H , s, OMe), 4 .15  (1H , dd, J  9 .5 , and 6  H z, 5-H ), 
4 .5 6 -4 .6 3  (1H , m, 5-H ), 5 .10 -5 .17  (4H , m, CH?Ph, 4 -H  and N H ), 7 .3 6  (5H , s, 
Ph); 5C 55.7  (C H ), 57 .9  (CH3), 6 7 .6  (CH2), 7 5 .4  (C H ^ , 128 .2 -128 .6  (P hcH), 
135.8 (Phcquatemary). 155.6 (Cquatemaiy), 166.8 (C = 0 ); m/z (C L ) 251 (M+ + H , 
22% ), 91 (100).
3,3-Dimethoxv-(4R)-rN-benzvloxvcarbonyl)aminolisoxazolidine (6b )
To a methanol solution (2 ml) of chloride (3) (43 mg, 0.17 mmol) was added 
potassium carbonate (34 mg, 0.25 mmol). The mixture was heated in a sealed 
tube at 110°C for 2h. After that time, the solvent was evaporated under 
reduced pressure to give a solid. Recrystallisation from ethyl acetate-petrol 
afforded the dimethoxy adduct (6b) ( 1 0  mg, 2 0 %) as a colourless solid, m.p. 
106-110°C; \>max(nujol mull) 3600, 1690, 1625cm’1; 5H 3.60 (3H, s, OMe), 
3.78 (3H, s, OMe), 4.01 (1H, dd, J 9.5 and 6.0 Hz), 4.42 (1H, t, /  9 Hz), 4.56 
(2H, s, CHoPh), 4.94-5.05 (1H, m), 5.32-5.38 (1H, s (br), NH), 7.23-7.25 (5H, 
m, Ph).
NOTE: We were unable to obtain satisfactory microanalytical data due to 
small amount of material available.
3-Methvlamino-(4R)-rN-(benzvloxvcarbonyl)amino-4,5-dihvdroisoxazole (7)
Into a dried sealed tube was placed a solution of chloride (3) (102 mg, 0.4 
mmol) in methanol (2 ml) and methylamine (40% w/w in water) (2 drops). 
The mixture was heated at 95°C for 14h, TLC, showed that reaction was 
incomplete so a further 2 drops of methylamine solution was added. After 
heating for another 7h, the solvent was removed in vacuo and the crude
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mixture was washed with 1M aqueous sodium bicarbonate ( 8  ml) and 
extracted into dichloromethane ( 4 x 5  ml), dried (Na2 S04), filtered and 
evaporated under reduced pressure to give a crude solid. Recrystallisation 
from ethyl acetate-petrol afford (7) (41 mg, 44%) as a colourless solid, m.p. 
168-170°C (Found: M+ 249.1090. C12H1 5N3 0 3  requires 249.1112) (Found: C, 
57.7; H, 6.14; N, 16.8. C12H1 5N3 0 3 requires C, 57.82; H, 6.07; N, 16.86%); 
a)max (nujol mull) 3290, 1685 and 1620 cm-1; 5H 1.92-2.18 (1H, m, NHMe), 
2.84 (3H, s, NHMe), 4.04 (1H, dd, /  9 and 5 Hz, 5-H), 4.38 (1H, t, /  9 Hz,
5-H), 5.02-5.09 (1H, m, 4-H), 5.09-5.18 (2H, m, CH?Ph), 5.45-5.50 (1H, m,
4-NH), 7.35 (5H, s, Ph); m/z (70eV E.I.) 249 (M+, 64%), 219 (27), 91 (100); 
(C.I.) 250 (M+ + H, 83%) and 91 (100).
The above experimental procedure was similarly employed for the synthesis of 
the 3-benzylamino (8 ), 3-piperidyl (9) and 3-tryptamino (10) derivatives of 
(4R)-[N-(Cbz)amino]-4,5-dihydroisoxazole.
3-Benzvlamino-(4R)-rN-(benzvloxvcarbonyl)aminol-4,5-dihvdroisoxazole (8 )
Chloride (3) (102 mg, 0.4 mmol) and benzylamine (3-4 drops (excess)) in 
methanol (2 ml) was heated in a sealed tube at 120°C for 7 h. 3-Benzylamino 
(8 ) (65 mg, 50%) was isolated as a colourless solid, m.p. 161-163°C 
(EtOAc-Petrol) (Found: C, 66.5; H, 5.97; N, 12.7. C1 8H1 9N3 0 3 requires C, 
66.52; H, 5.89; N, 12.92%); vmax (nujol mull) 3300, 1680 and 1615 cm'1’ 8 H 
2.22-2.57 (1H, s (br), NH), 4.10-4.17 (1H, m, 5-H), 4.30-4.44 (3H, m, 
NCH2Ph and 5-H), 5.10 (2H, s, OCH,Ph). 5.11-5.19 (1H, m, 4-H), 5.80 (1H, s 
(br), 4-NH), 7.29-7.36 (10H, m, Ph x 2); m/z (70eV E.I.) 325 (M+, 42%), 108 
(100), 106 (30), 91 (77); (C.I.) 326 (M+ + H, 82%), 91 (100).
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3-Piperidyl-(4R)-rN-(benzvloxvcarbonvl)aminol-4,5-dihvdroisoxazole (9)
Chloride (3) (102 mg, 0.4 mmol) and piperidine (0.08ml, 0.8 mmol) in 
methanol (2 ml) was heated in a sealed tube at 110°C for 18h. 3-Piperidyl (9) 
(94mg, 76%) was isolated as a colourless oil, which later solidified and was 
recrystallised from ethyl acetate-petrol to give (9) (22 mg, 18%) as colourless 
needles, m.p. 89-90°C (Found: M+, 303.1575. C16H2 1 N3 0 3  requires
303.1581) (Found: C, 63.7; H, 7.07; N, 13.8. C1 6H2 1 N3 0 3 requires C, 63.35; 
H, 6.98; N, 13.85%); v max (nujol mull) 3300 and 1700 cm 1; 8 H 1.41 (6 H, s 
(br)), 3.08 (4H, s (br)), 4.10-4.13 (2H, m, 5-CH2), 4.95-5.06 (3H, m, CHjPh 
and 4-H), 5.36-5.42 (1H, m, 4-NH), 7.20 (5H, s, Ph); Sc 23.9 (CH2), 25.0 (CH2  
x 2), 47.9 (CH2  x 2), 56.2 (CH), 67.0 (CHj), 74.7 (CH2), 127.9-128.4 (PhCH), 
136.0 (Phcuatemay), 55.2 (Cquatemary), 161.3 (OC=0); m/z (E.I.) 303 (M+, 
100%), 108 (75).
N- r3-[T3-meth yl-1 -(hydroxymethvO-1 -butvll aminol -4.5-dihydroisoxazole (11)
Into a dried sealed tube were placed chloride (3) (67 mg, 0.26 mmol), 
(S)-leucinol (0.034 ml, 0.29 mmol) and anhydrous sodium iodide (20 mg, 0.14 
mmol) in methanol (2 ml). The mixture was heated at 120°C for 24h, TLC 
showed that reaction was slow, so a further 0.5 equivalents of anhydrous 
sodium iodide (19 mg, 0.13 mmol) was added. The mixture was then heated 
at 120°C for another 48h. After that time, the solvent was evaporated under 
reduced pressure to give an oil, which was dissolved in dichloromethane ( 1 0  
ml) and washed with water (3 ml). The organic extract was dried (Na2 S04) 
and evaporated under reduced pressure to give a solid. Purification by 
chromatography on silica gel using ethyl acetate-petrol as eluant gave starting 
material (3) (16 mg, 24%) followed by 3-methoxy derivative (6 ) (40 mg, 62%) 
(see above) and further elution afforded the diastereoisomeric leucinol-adduct
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(11) (12 mg, 13%) as a yellow oil. This fraction was separated by 
chromatography as the major ( 8  mg, 9%) and the minor diastereoisomer (lib )  
(4 mg, 4%).
Major isomer (11): (Found: M+, 335.1892. requires 335.1845);
Umax (CHC13) 3420, 2930, 1705 and 1630 cm'1; 6 H (400 MHz) 0.91 (6 H, t, J 
6.4 Hz, CHMeA 1.28-1.42 (2H, m,), 1.60-1.70 (2H, m,), 3.45 (1H, dd, J  11 
and 5 Hz), 3.56-3.63 (1H, m,), 3.73 (1H, dd, /  11 and 2.2 Hz), 4.05 (1H, dd, J 
9 and 5 Hz), 4.31-4.40 (2H, m), 5.02-5.08 (1H, m), 5.13 (2H, s, ClfcPh), 5.73 
(1H, d, J 7.5 Hz,), 7.37 (5H, s, Ph); 5C 22.2 (CH3), 22.9 (CH3), 24.8 (CH), 
39.9 (CH), 40.4 (CH2), 53.7 (CH), 6.46 (CH^, 67.5 (CH2), 72.5 (CH2),
128.2-128.6 (PhCH), 138.4 (Phcquatemary), 142.7(Cquatemary), 156.4 (OC=0); 
m/z (low 70eV E.I.) 335 (M+, 1%), 91 (100). (C.I.) 336 (M+ + H, 1.6%), 91 
(100).
The minor diastereoisomer (lib ) was impure and it was only characterised by 
!H NMR.: 5h (400 MHz) 0.9 (6 H, t, /  7 Hz, CHMe^, 1.30-1.44 (2H, m), 
1.59-1.66 (2H, m), 3.56-3.62 (2H, m), 3.70-3.78 (lH,m), 4.01 (1H, dd, J 9.5 
and 4 Hz, 5-H), 4.36 (1H, t, J 9.5 Hz, 5-H), 4.43-4.50 (1H, m), 5.02-5.08 (1H, 
m,), 5.13 (2H, s, CH2 Ph), 5.26-5.30 (1H, m,), 7.32-7.39 (5H, m, Ph).
Attempted preparation of 3-bromo-(4R)-rN-(benzvloxvcarbonyl)amino1- 
-4,5-dihvdroisoxazole (12) from triphenylphosphine and carbon tetrabromide 
in dichloromethane
To an ice-cooled suspension of (4R)-[N-(Cbz)]-cycloserine (2) (10 g, 0.042 
mol) and carbon tetrabromide (15.4 g, 0.046 mol) in dichloromethane (100 ml) 
was added triphenylphosphine (12.2 g, 0.046 mol) and the yellow solution was 
heated at 65°C for five days. After that time the mixture was poured into 
water (200 ml) and extracted into dichloromethane (4 x 80 ml). The combined 
organic extracts were dried (Na2 SQ4), filtered and evaporated under reduced
-86-
pressure to give an orange oil (36.1 g). Purification by chromatography on 
silica gel using ethyl acetate-petrol as eluant gave a colourless solid. 
Recrystallisation from ethyl acetate-petrol (40-60 v/v) gave primarily chloride 
(3) as colourless needles, m.p. 137.5-138.5°C. Halogen microanalysis 
revealed that there was <0.2% of bromine present in the compound. We were 
unable to obtain satisfactory microanalysis for the above chloride (3) (Found: 
C, 50.35; H, 4.26; N, 10.68; Br, <0.20; Cl, 13.72. Cn Un ClN20 3 requires C, 
51.87; H, 4.32; N, 11.00: Cl, 13.93%); (nujol mull) 3300, 1690 cm 1; 8 H
4.24-4.30 (1H, m), 4.62 (1H, t, J  9.7 Hz), 5.10-5.20 (2H, m, CB>Ph). 5.25-5.37 
(2H, m), 7.35 (5H, s, Ph); m/z (+ FAB) 301/299 (M+ + H, 45%), 257 (M+ + H, 
35%), 255 (M+ + H, 100%), 91 (100); (- FAB) 299/297 (M+ - H, 52%), 255 
(M+- H, 45%), 253 (M+ -H, 100%).
3-Bromo-(4R)-rN-(benzvloxvcarbonyl)amino]-4,5-dihvdroisoxazole (12)
To an ice-cooled solution of triphenylphosphine (237 mg, 0.9 mmol) in 
dichloromethane ( 6  ml) was added dropwise bromine (0.047 ml, 0.9 mmol) 
and a white precipitate was formed within 5 min. The suspension was stirred 
at 0°C for lh, followed by addition of [N-(Cbz)]-cycloserine (2) (207 mg, 0.8 
mmol). The mixture was stirred at room temperature for 1.5h and then poured 
into 1M aqueous sodium bicarbonate (25 ml) and the product was extracted 
with dichloromethane (3 x 10 ml). The extracts were dried (Na2 S04), filtered 
and evaporated under reduced pressure to give a solid. Purification by 
chromatography on silica gel using ethyl acetate-petrol as eluant gave bromide
(12) (44 mg, 16%). Recrystallisation from ethyl acetate-petrol gave (12) as 
colourless needles, m.p. 141-143°C (Found: C, 44.1; H, 3.62; N, 9.28. 
C11H1 1BrN20 3  requires C, 44.17; H, 3.71; N, 9.36%); vmax (nujol mull) 3330 
and 1685 cm'1; 8 H 4.22 (1H, dd, J  10 and 6  Hz, 5-H), 4.58 (1H, t, J 10 Hz,
5-H), 5.17-5.20 (3H, m, CHjPh and NH or 4-H), 5.29-5.38 (1H, m, NH or
-87-
4-H), 7.37 (5H, s, Ph); m/z (CL) 301/299 (M+ + H, 7%), 91 (100).
3-Phcnylalanyl methyl ester-(4R)-rN-(benzvloxycarbonvl)aminol- 
-4,5-dihydroisoxazole (13)
To a solution of bromide (12) (38 mg, 0.13 mmol) in methanol (2 ml) in a 
sealed tube was added (L)-phenylalanine methyl ester (57 mg, 0.26 mmol). 
The mixture was heated at 100°C for 10 days. After that time, the solvent was 
evaporated under reduced pressure to give a solid, which was redissolved in 
dichloromethane (5 ml) and washed with water (10 ml). The aqueous layer 
was then extracted with dichloromethane ( 3 x 8  ml) and the combined organic 
extracts dried (Na2 S04) and concentrated in vacuo to give an oil (67 mg). 
Purification by chromatography using ethyl acetate-petrol as eluant gave 
recovered starting material (12) (30 mg, 78%) followed by the 
(L)-phenylalanyl adduct (13) (7 mg, 5%) as a yellow oil (further purification 
by preparative TLC led to decomposition of the product): Umax (CHC13) 3420, 
2940 and 1720 cm'1; 5H 2.86 (1H, dd, J  13.5 and 7.8 Hz, CHoPh). 3.09 (1H, 
dd, J 13.5 and 5.1 Hz, CHoPh), 3.70-3.85 (6 H, m, OMe, CHC02 Me, 5-CH2), 
3.91 (1H, dd, J 11.5 and 3.7 Hz, 4-H), 4.67-4.76 (1H, m, 4-NH), 5.15 (2H, s, 
COoCHoPh), 7.18-7.39 (10H, m, Ph x 2), (1 x NH not seen); m/z (+ FAB) 398 
(M+ + H, 2%), 337 (4), 221 (20), 180 (48), 91 (100).
(4R)-rN-(9-Fluorenvlmethoxvcarbonyl)aminol-3-isoxazolidinone (14)
To an ice-cooled solution of (4R)-cycloserine (9g, 0.088 mol) in 1M aqueous 
sodium bicarbonate (176 ml) was added a solution of N-(9-FMOC)- 
-succinimide (29.7 g, 0.088 mol) in dioxane (170 ml). On completion of 
addition, a white precipitate occurred and this mixture was stirred at room 
temperature for 2.5h. After that time, the mixture was cooled to 0°C and
-88-
acidified with concentrated hydrochloric acid to pHl. The precipitate was 
filtered and the solid washed with ether (5 x 120 ml). The crude solid (23.6 g) 
was then washed with cyclohexane (800 ml) in a Soxhlet apparatus, to give the 
N-protected cycloserine (14) (23 g, 80%) as a colourless crystalline solid, m.p. 
143-145°C. Due to the solubility properties of (14), attempts to recrystallised
(14) from either hot ethanol or methanol were unsuccessful; ‘umax(nujol mull) 
3313 and 1670 cm 1; 5h (DMSO-d6) 3.94-3.97 (1H, m), 4.21-4.27 (1H, m), 
4.29-4.40 (2H, m, CO-,CH-,). 4.47-4.63 (2H, m), 7.30-7.47 (4H, m), 7.71 (2H. 
d, J  7.5 Hz), 7.85-7.96 (3H, m), 11.38-11.53 (1H, s(br), NH); m/z (Tof) 325 
(M+ + H, 9%).
3-Bromo-(4R)-rN-(9-fluorenvlmethoxvcarbonvl)amino1-4,5-dihydroisoxazole
(15)
To an ice-cooled suspension of (4R)-[N-(FMOC)]-cycloserine (14) (2.2 g, 6 . 8  
mmol) and carbon tetrabromide (2.5 g, 7.6 mmol) in dibromomethane (3 ml) 
was added triphenylphosphine (1.97 g, 7.5 mmol). The yellow solution was 
stirred at 0°C for 10 min and then heated between 55-60°C for 2.5h. After that 
time, the solvent was removed in vacuo to give a crude oil which was 
dissolved in dichloromethane (70 ml) and washed with 0.1M aqueous sodium 
bicarbonate solution (50 ml) and water (30 ml). The organic extract was dried 
(Na2 S04) and evaporated under reduced pressure to give an oil (4.39 g). 
Purification by chromatography using ethyl acetate-petrol as eluant afforded 
(15) (572 mg, 22%) as a solid. Recrystallisation from ethyl acetate-petrol 
gave the bromo-derivative (15) as a colourless needles, m.p. 198-199°C 
(Found: C, 56.11; H, 3.89; N, 7.29. C18H1 5BrN2 0 3  requires C, 55.83; H, 3.90; 
N, 7.23%); \)max (CHBr3) 3410, 3120-2920 (br), 1720 cm'1; 5H (250 MHz), 
4.26-4.36 (2H, m, COoCHo), 4.43-4.60 (3H, m), 5.09-5.13 (1H, m, NH),
5.25-5.37 (1H, m, 4-CH), 7.33 (2H, t, J 7.5 Hz), 7.42 (2H, t, J 7.5 Hz), 7.58
-89-
(2H, d, J  7.5 Hz), 7.78 (2H, d, J 7.5 Hz); 5C (100.6 MHz), 46.3 (CH), 61.0 
(4-CH), 67.5 (5-CH2), 72.0 (CH^, 120.0-128.0 (PhCH), 131.8 (PhCquatemaiy), 
132.0 ( P ^ C q u a t e m a r y ) *  139.5 ( P h c q u a t e m a r y ) *  141.5 ( ^ q u a t e r n a r y ) ’ 143.7 
( ^ q u a t e r n a r y ) ’ ( 1  x  C q u a te m a iy  not Seen); mjz ( E . I . )  389 /  389 (M+, 10%).
Reaction of 3-Bromo-(4R)-rN-(9-fluorenvlmethoxvcarbonyl)amino1-4,5- 
-dihydroisoxazole (15) with tryptamine
To a solution of bromide (15) ( 6 8  mg, 0.17 mmol) in methanol (1.5 ml) was 
added tryptamine (40 mg, 0.19 mmol). The mixture was heated in a sealed 
tube at 50°C for 22h. After that time, the solvent was evaporated under 
reduced pressure to give an oil which was purified by chromatography using 
ethyl acetate-petrol to afford starting material (15) (23 mg, 34%) and 
dibenzofulvene (16) (18 mg, 60%), whose *H NMR was identical to that 
reported in the literature/86)
(4R)-rN-(2,2,2-Trichloroethvloxvcarbonyl)aminol-3-isoxazolidinone (17)
(4R)-Cycloserine (2.02 g, 0.02 mol) was selectively N-protected with
2,2,2-trichloroethyl chloroformate (2.72 ml, 0.02 mol) in 1M aqueous sodium 
bicarbonate (39 ml) as described for the synthesis of (4R)-[N-(FMOC)]- 
-cycloserine (14). Recrystallisation from ethyl acetate afforded [N-(TROC)]- 
-cycloserine (17) (2.8 g, 51%) as colourless needles, m.p. 170-171°C (Found: 
C, 25.7; H, 2.49; N, 10.9. C6H7 C13 N2 0 4  requires C, 25.97; H, 2.54; N, 
10.09%); umax (nujol mull) 3300, 1725 and 1670 cm'1; SH (DMSO-d6) 0.42 
(1H, s (br), NH), 3.99 (1H, dd, J 10 and 8  Hz), 4.50 and 4.69 (2H, m), 4.82 
(2H, s, CH2CC13), 8.34 (1H, d, J 8.4 Hz, NH); m/z (70eV E.I.) 280 (M+, 1%), 
278 (M+, 2.3%), 277 (M+, 0.5%), 276 (M+, 2.3%), 101 (10); (C.I.) 281 (M+ + 
H, 5%), 279 (M+ + H, 15%), 278 (M+ + H, 2.5%), 277 (M+ + H, 15%), 206(5),
-90-
204 (6), 251 (3), 249 (3), 236 (11), 234 (12).
Reaction of (4R)-rN-(2.2,2-trichloroethvoxvcarbonyl)aminol-3- 
-isoxazolidinone (17) with triphenylphoshphine dibromide
To an ice-cooled solution of triphenylphosphine (229 mg, 0.87 mmol) in 
dibromomethane (4 ml) was added bromine (0.04 ml, 0.87 mmol) drop wise. 
The mixture was stirred at 0°C for lh followed by addition of [N-(TROC)]- 
-cycloserine (17) (212 mg, 0.76 mmol). The mixture was stirred at 0°C for 
0.5h and then at room temperature for 1.5h. TLC revealed that starting 
material was still present, so the mixture was heated at 50-60°C for 20h. On 
returning, the solvent was evaporated under reduced pressure to give an oil. 
The oil was redissolved in ethyl acetate (10 ml) and washed with water (5 ml). 
The aqueous layer was then extracted with ethyl acetate (10 ml). The 
combined ethereal layers were dried (Na2 SC>4 ), filtered and evaporated under 
reduced pressure to give an oil (500 mg). Purification by chromatography 
using ethyl acetate-petrol was eluant, afforded recovered starting material (17) 
(36 mg, 17%) as the only characterisable component.
3-Chloro-(4RHN-(2.2.2 -trichloreth yloxycarbon vPaminol -4,5- 
-dihvdroisoxazole (2 1 )
Isoxazolidinone (17) was converted to chloride (21) by heating a solution of 
(17) (986 mg, 3.5 mmol) and dichlorofns(dimethylamino)phosphorane (4) (5 
equiv.) in THF (40 ml) at reflux for 20h, using the same procedure employed 
for 3-chloro-4-[N-(Cbz)-4,5-dihydroisoxazole (3). Purification by 
chromatography on silica gel, using ethyl acetate-petrol as eluant, gave (2 1 ) 
(81 mg, 78%) as a solid. Recrystallisation from ethyl acetate-petrol afforded 
(21) as fine colourless needles, m.p. 124-125°C (Found: C, 24.3; H, 1.90; N,
-91-
9.49. C6H6 C14 N2 0 3  requires C, 24.35; H, 2.04; N, 9.46%); \)max (nujol mull) 
3300 and 1700 cm 1; 5H 4.37 (1H, dd, J 10 and 5.7 Hz, 5-H), 4.70 (1H, t, J 9.9 
Hz, 5-H), 4.78 (2H, s, CH2 CC13), 5.32 (1H, td, J 9.7 and 5.9 Hz, 4-H), 
5.46-5.54 (1H, m, 4-NH); 8 C 60.1 (CH), 75.2 (CH2), 75.3 (CHJ, 149.7 
(^ quaternary)* 153.7 (0C=0), (1 x CC13  not seen); m/z (70eV E.I.) 298 (M+, 
0.5%), 296 (M+, 1%), 294 (M+, 1%), 261 (4.2), 259 (4.6), 163 (19), 135 (23); 
(C.I.) 299 (M+ + H, 46%), 297 (M+ + H, 100%), 295 (M+ + H, 76%), 263 (8 ), 
261 (15), 259 (12).
3-Bromo-(4R)-rN-(2,2,2-trichloroethvloxycarbonvl)amino1-4,5- 
-dihydroisoxazole (23)
To a solution of chloride (21) ( 8 6  mg, 0.29 mmol) in dibromomethane (0.5 ml) 
was added hydrogen bromide in acetic acid (33% w/w, 0.06 ml, 0.32 mmol). 
The green solution was heated at 80°C for 6 h and then stirred at room 
temperature for 20h. On returning, the solvent was removed under reduced 
pressure to give an oil which was dissolved in ethyl acetate ( 1 0  ml), washed 
with pH7 buffer (3 ml) and saturated aqueous ammonium chloride solution (3 
ml). The organic extracts was dried (Na2 S04) and concentrated in vacuo to 
give a solid. Recrystallisation from ethyl acetate-petrol gave the bromide (23) 
(60 mg, 61%) as colourless needles, m.p. 116-117°C (Found: C, 21.3; H, 1.68; 
N, 8.24. C6H6 BrCl3 N2 0 3  requires C, 21.16; H, 1.78; N, 8.22%); umax (nujol 
mull) 3300 and 1695 cm'1; 8 H 4.29 (1H, dd, J 9.9 and 5.9 Hz, 5-H), 4.62 (1H, 
t, J 9.5 Hz, 5-H), 4.79 (2H, s, CHCC13), 5.34 (1H, td, J 9.9, and 5.9 Hz, 4-H), 
5.42-5.49 (1H, m, 4-NH); 8 C 62.4 (CH), 74.3 (CH2), 74.9 (CH2), 138.9 
(^ quaternary)* 153.7 (OC=0), (1 x CC13 not seen); rn/z (C.I.) 345 (M+ + H, 
16%), 343 (55), 341 (8 6 ), 339 (48), 307 (5), 305 (10), 303 (4), 265 (5), 261 (9), 
259 (4), 193 (20), 191 (21).
-92-
l-(3-Bromo-4,5-dihvdro-4-isoxazolyl)-3-r2-lH-indol-3-vl)ethvllurea (25)
To a solution of bromide (23) (13 mg, 0.038 mmol) in methanol (0.5 ml) in a 
sealed tube, was added tryptamine (10 mg, 0.065 mmol) and the mixture was 
heated at 100°C for 1.5h. The solvent was removed in vacuo to give a solid 
which was purified by chromatography on silica gel, using ethyl acetate-petrol 
as eluant, to give indolylethylamino adduct which was recrystallised from 
ethanol to give (25) (6 . 8  mg, 51%) as colourless needles, m.p. 184-188°C 
(dec.) (Found: C, 47.6; H, 4.26; N, 15.9. C14H15BrN4 0 2  requires C, 47.86; H, 
4.30; N, 15.94%); t>max (nujol mull) 3430, 3390, 3290 and 1625 cm'1; SH 
(DMSO-d6) 2.81 (2H, t, /  7 Hz, CH2 CH2 NH), 3.26-3.33 (2H, m, 
CH2 CH2 NH), 4.03 (1H, dd, /  9.2 and 6.7 Hz, 5-H), 4.48 (1H, dd, J 10.3 and
9.2 Hz, 5-H), 5.30-5.40 (1H, m, 4-H), 6.07 (1H, t, /  6  Hz, CH2 CH2 NH), 6.83 
(1H, d, /  9.1 Hz, 4-NH), 6.98 (1H, td, J  7.5 and 1.5 Hz), 7.07 (1H, td, J 7.5 and
1.5 Hz), 7.13 (1H, d, J 2 Hz), 7.33 (1H, d, J 7.5 Hz), 7.55 (1H, d, J  7.5 Hz),
10.81 (1H, s (br), NH on indole); 5C (DMSO-dg) 25.9 (CH2), 40.3 (CH2), 60.9 
(CH), 73.9 (CH2 ), 111.4-122.8 (PhCH), 127.3 ( P h C q u a te r n a r y ) .  136.4
( P ^ q u a t e r n a r y ) » 142.5 ( C q U a t e r n a r y ) ,  156.7 (C—O), (1 X  C q U a j e r n a r y  not Seen), 




To a solution of bromide (23) ( 8 8  mg, 0.26 mmol) in methanol (1 ml) in a 
sealed tube was added (L)-phenylalanine methyl ester (91 mg,0.51 mmol) and 
this mixture was heated at 100°C for 5.5 days. The solvent was removed in 
vacuo to give an orange oil which was washed with 1M aqueous sodium 
bicarbonate (5 ml), extracted into dichloromethane ( 3 x 5  ml), dried (Na2 S04)
-93-
and evaporated under reduced pressure. Purification of the residue by 
chromatography followed by preparative TLC, using ethyl acetate-petrol (1:1 
v/v) as eluant, gave the imidazolidinedinone (26) (25 mg, 28%) as a yellow oil 
(Found: M+ + H, 388.0140. C13H1 3BrN3 0 3  (Br = 79) requires 338.0140); 5H 
2.90-3.06 (1H, m, CHoPh), 3.23-3.32 (1H, m, CHoPh), 4.19-4.34 (1H, m, 5-H), 
4.35-4.41 (1H, m, CHCH2 Ph), 4.47-4.55 (1H, m, 5-H), 5.46-5.57 (1H, m,
4-H), 5.91-6.01 (1H, m, NH), 7.18-7.24 (2H, m), 7.32-7.38 (3H, m); 5C 37.4 /
37.7 (CH2), 57.9 /  58.1 (CH), 60.0 (CH), 70.9 (CH2), 127.9-129.6 (PhcH),
134.2 (Phcquatemary). 135.1 (Cquatemary), 154.8 (C=0), 171.4 (C=0); m/z (C.I.) 
340 /  338 (M+ + H, 7%), 260 (54), 91 (100).
r3R/l-3-r3-Bromo-4,5-dihvdro-4-isoxazolyll-2,4-imidazolidinedinone (27)
To a solution of bromide (23) ( 6 6  mg, 0.19 mmol) in methanol (1.5 ml) in a 
sealed tube was added glycine methyl ester (50 mg, 0.58 mmol). The mixture 
was heated at 100°C for 4 days after which time the solvent was evaporated 
under reduced pressure and the crude solid washed with 1M aqueous sodium 
bicarbonate (5 ml), extracted into dichloromethane ( 3 x 8  ml), dried (Na2 S04) 
and concentrated in vacuo to give an oil. Purification by chromatography, 
using ethyl acetate-petrol (7:3 v/v) as eluant, gave starting material (23) (15 
mg, 23%) and further elution afforded the imidazolidinedione adduct (27) (12 
mg, 26%) as a colourless solid, m.p. 177-179°C (sublimed) (ethyl 
acetate-petrol)(Found: M+ + H, 248.9671. C6 H7 BrN3 0 3 (Br = 79) requires 
248.9671); vmax (CHC13) 3440 (br), 1725 cm'1; 6 H (Acetone-d6) 4.07 (2H, s), 
4.55 (1H, dd, /  9 and 7.7 Hz, 5-H), 4.68 (1H, dd, J  11.5 and 9 Hz, 5-H), 5.79 
(1H, dd, J  11.5 and 7.9 Hz, 4-H). (1 x NH not seen); m/z (C.I.) 250 /  248 (M+ 
+ H, 100%), 168 (20), 170 (74), 143 (34).
(4R)-rN-(4-Methvlphenyl)sulphonamidol-3-Isoxazolidinone (18)
(4R)-Cycloserine (1 g, 0.01 mol) was selectively N-protected with 
(4-methylphenyl)sulphonyl chloride (1.9 g, 0.01 mol) in 1M aqueous sodium 
bicarbonate (20 ml) as described for the preparation of [N-(FMOC)]- 
-cycloserine (14). The reaction was completed after stirring at 0°C for lh and 
then at room temperature for 0.45h. [N-(Tos)]-(18) (2 g, 79%) was isolated as 
a solid after recrystallisation from methanol, m.p. 201-202°C (Found: C, 46.4; 
H, 4.72; N, 10.5. C1 0H12N2 O4S requires C, 46.88; H, 4.72; N, 10.93%); omax 
(nujol mull) 3280 and 1675 (br) cm’1; 6 H (DMSO-d6) 2.39 (3H, s, PhMe), 
3.67-3.73 (1H, m), 4.21-4.33 (2H, m), 7.39 (2H, d, J  8  Hz), 7.73 (2H, d, J 8  
Hz), 8.41 (1H, d (br), /  7.5 Hz, 4-NH), (1 x NH not seen); m/z (70eV E.I.) 256 
(M+, 0.7%), 155 (47); (C.I.) 257 (M+ + H, 7%), 155 (54).
Attempts to generate 3-bromo-(4R)-[N-(Tos)amino]-4,5-dihydroisoxazole (24) 
by reaction of (4R)-[N-(Tos)amino]-3-isoxazolidinone (18) with either 
Ph3 PBr2  or Ph3P/CBr4  employing similar reaction conditions to those applied 
to (4R)-[N-(TROC)]-cycloserine (17), were unsuccessful.
3-Chloro-(4R)-fN-(4-methvlphenyl)sulphonamido1-4,5-dihvdroisoxazole (22)
(4R)-[N-(Tos)]-cycloserine (18) (189 mg, 0.7 mmol) and dichlororm- 
-(dimethylamino)phosphorane (4) (5 equiv.) in THF (10 ml) was heated at 
reflux for 20h. Following a similar workup procedure employed to isolate 
chloride (3), chloride (22) (160 mg, 83%) was isolated as a colourless solid 
after reciystallisation from ethyl acetate-petrol m.p. 129-130°C (Found: C, 
43.8; H, 4.05; N, 10.25. C10Hn ClN2 O3S requires C, 43.73; H, 4.04; N, 
10.19%); wmax (nujol mull) 3250 cm'1; 5H 2.46 (3H, s, PhMe), 4.22 (1H, dd, J
-95-
10.3 and 5.3 Hz, 5-H), 4.50 (1H, dd, /  10.3 and 9.3 Hz, 5-H), 4.85 (1H, td, J
9.4, and 5.3 Hz, 4-H), 5.04 (1H, d(br), J  9.3 Hz, 4-NH), 7.36 (2H, d, /  8  Hz), 
7.78 (2H, d, J 8  Hz); m/z (70eV E.I) 274 (M+, 1.5%), 276 (0.7), 155 (42), 119 
(10); (Cl.) 277 (M+ + H, 39%), 275 (100), 155 (74), 119 (16), 91 (94).
3-Bromo-(4R)-fN-(4-methvlphenyl)sulphonamidol-4.5-dihvdroisoxazole (24)
To a solution of chloride (22) (22 mg, 0.08 mmol) in dibromomethane (0.5 ml) 
was added hydrogen bromide in acetic acid (33% w/w, 0.016 ml, 0.08 mmol). 
The yellow solution was heated at 80°C for 6 h and then stirred at room 
temperature overnight. On returning, another one equivalent of hydrogen 
bromide in acetic acid was added and the mixture was heated for a further 
hour. The solvent was evaporated under reduced pressure to give an oil which 
was dissolved in dichloromethane (5 ml) and washed with water (1 ml). The 
organic extract was dried (Na2 S04) and concentrated in vacuo and the residue 
recrystallised from ethyl acetate-petrol to give (24) (18 mg, 6 8 %) as colourless 
needles m.p. 125-127°C (Found: C, 37.9; H, 3.53; N, 8.75. C10H11BrN2 O3S 
requires C, 37.63; H, 3.47; N, 8.77%); \)max (nujol mull) 3260 cm'1; SH 2.45 
(3H, s, PhCHj), 4.16 (1H, dd, J 10.3 and 5.3 Hz, 5-H), 4.41 (1H, t, J 10 Hz, 
5-H), 4.86 (1H, td, J 9.3, and 5.3 Hz, 4-H), 5.27 (1H, d, J  9.5 Hz, 4-NH), 7.35 
(2H, d, J 8  Hz), 7.78 (2H, d, /  8  Hz); m/z (CL) 321 /  319 (M+ + H, 8 .6 %), 155 




A solution of bromide (24) (51 mg, 0.16 mmol) and tryptamine (55 mg, 0.34 
mmol) in methanol (1.5 ml) was heated at 100°C for 2.5 days in a sealed tube. 
The solvent was then evaporated under reduced pressure to give a solid. 
Purification by chromatography using ethyl acetate-petrol as eluant to give 
starting material (24) (10 mg, 19%) followed by the indolylethylamino adduct 
(28) (8.2 mg, 12%) as a colourless solid. 5H(Acetone-d6) 2.45 (3H, s, PhMe),
3.03 (2H, t, /  7 Hz, CH?CB>NH), 3.35-3.45 (2H, m, CH?CH?NH), 3.53-3.59 
(1H, s, 5-H), 3.90-3.97 (1H, m, 5-H), 4.70-4.78 (1H, m, 4-H), 5.02-5.08 (1H, 
m, NH), 7.02 (1H, t, J 7.3 Hz), 7.10 (1H, t, J  7.3 Hz), 7.20 (1H, s), 7.36-7.46 
(3H, m), 7.62 (1H, d, J 7.7 Hz), 7.79 (2H, d, J 8.4 Hz), 10.1 (1H, s, NH on 
indole), (1 x NH not seen).
NOTE: A molecular ion was not found for adduct (28).
Glyoxalic acid aldoximine (35)^96^
To a cooled solution of glyoxalic acid monohydrate (6.17 g, 0.67 mol) in 
water (45 ml) was added hydroxylamine hydrochloride (4.69 g, 0.067 mol), 
followed by careful addition of sodium carbonate (7.15 g, 0.067 mol) until the 
solution was weakly basic. The yellow solution was left to stir at room 
temperature for 12h. On returning, the mixture was acidified with 
concentrated sulphuric acid to pH4 and then extracted into ether (500 ml) with 
a liquid-liquid extraction apparatus for 7h. The ether solution was evaporated 
under reduced pressure to give a colourless solid (5.12 g). Recrystallisation 
from ethyl acetate, afforded aldoxime (35) (3.36 g, 56%), m.p. 138.5-140°C 




Vinylphthalimide (33) (2.23 g, 64%) was synthesised from phthalimide (3 g, 
0.02 mol) and vinyl acetate (50 ml) in the presence of sodium 
tetrachloropalladate (92 mg) as described in the literature/94) The product was 
recrystallised from ethyl acetate-petrol to give pale yellow needles, m.p.
83.5-84.5°C (lit./94) 84°C), umax (nujol mull) 1715 cm'1; 6 H 3.46 (1H, d, J 10 
Hz, vinyl H), 4.50 (1H, d, J 16 Hz, vinyl H), 5.29 (1H, dd, /  16 and 9 Hz, 
vinyl H), 6.16 (2H, dd, J 5.5 and 3 Hz), 6.28 (2H, dd, J 5.5 and 3 Hz); m/z 
(70eV E.I.) 173 (M+, 100%), 46 (12), 104 (45), 76 (54).
3-Bromo-5-rN-(phthalovl)aminol-4,5-dihydroisoxazole (39)
The dibromoaldoxime was generated in situ by the addition of N-bromo- 
-succimide (1.78 g, 0.01 mol) to a cooled solution of glyoxalic acid aldoxime 
(4.50 mg, 5.5 mmol) in dimethoxyethane (5 ml) and water (1.5 ml) as 
described in the literature/93®) The dibromoaldoxime formed was added 
dropwise to a suspension of vinylphthalimide (1.73 g, 0.01 mol) in 
dimethoxyethane (5 ml) and potassium hydrogen carbonate (2 g, 0.02 mol) at 
room temperature. On addition, the orange solution went paler in colour and 
then darkened with gas (carbon dioxide) given off. After stirring for 20 min, a 
solid (potassium bromide) precipitated out. The mixture was left to stir at 
room temperature for 48h and, on returning, was filtered and washed with 
ethyl acetate (15 ml). The filtrate was then washed with brine (2 x 25 ml), 
dried (MgS04), filtered and evaporated under reduced pressure to give a light 
brown solid which was purified by chromatography using ethyl acetate-petrol 
as eluant (15:85 v/v) to give vinylphthalimide (33) (970 mg, 56%) and further 
elution (25:75 v/v) gave bromide adduct (39) (450 mg, 28%) as a colourless 
solid. Recrystallisation of bromide (39) from ethyl acetate-petrol afforded
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colourless needles, m.p. 170-171°C (Found: C, 44.8; H, 2.32; N, 9.51. 
Cn H7 BrN2 0 3  requires C, 44.76; H, 2.39; N, 9.49%); \)max (nujol mull) 3180, 
1775 and 1715 cm'1; SH 3.62 (2H, d, J 7.5 Hz, 4-CH2), 6.55 (1H, t, J  7.5 Hz, 
5-H), 7.79 (2H, dd, 7 6  and 3 Hz), 7.90 (2H, dd, J  6  and 3 Hz); m/z (70eV E.I.) 
296/294 (M+, 4%), 215 (44). (C.I.) 297 /  295 (M+ + H, 6 %), 215 (10).
2-r2-(3-Bromo-4t5-dihvdro-isoxazol-ylcarbamovl)-benzovlaminol-3- 
-phenylpropionic acid, methyl ester (40)
Into a dried sealed tube were placed a solution of bromide (39) (93 mg, 0.3 
mmol) and (L)-phenylalanine methyl ester (102 mg, 0.56 mmol) in methanol 
(1.5 ml). The mixture was heated at 80°C for 48h and after that time the 
solvent was removed in vacuo to give an orange oil which was purified by 
chromatography using ethyl acetate-petrol as eluant to give starting material 
(39) (21 mg, 27%) followed by the ring-opened phthaloyl adduct (40) (50 mg, 
35%) which was recrystallised from ethyl acetate-petrol as colourless solid, 
m.p. 154-155°C (Found: C, 52.9; H, 4.16; N, 8.73. C2 1 H2oBrN3 0 5  requires C, 
53.16; H, 4.25; N, 8.85%); Pmax (nujol mull) 3280, 1750 and 1640 cm'1; 5h 
(DMSO-d6) 3.02-3.11 (3H, m, CH2ph and 4-H), 3.60-3.72 (4H, m, OMe and
4-H), 4.52-4.64 (1H, m, QHC02 Me), 6.13-6.26 (1H, m, 5-H), 7.19-7.32 (5H, 
m, Ph), 7.40-7.54 (4H, m, Ph), 8.82 (1H, t, J 7.7 Hz, NH), 9.41-9.43 (1H, m,
5-NH); m/z (+FAB) 476/474 (M+ + H, 14%), 310 (100), 250 (75); (-FAB) 474 
I A ll  (M+ - H, 83%).
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3-Methanesulphonvloxv-(4R)-rN-(benzvloxvcarbonvl)aminol-4,5-dihydro- 
-isoxazolc (42) and 2-N-methanesulphonvl-(4R)-rN-(benzvloxvcarbonyl)- 
amino-3-Isoxazolidinone (43)
To an ice-cooled solution of methanesulphonyl chloride (0.04 ml, 0.52 mmol) 
in dichloromethane (2 ml) was added pyridine (0.042 ml, 0.52 mmol) and
4-(dimethylamino)pyridine (65 mg, 0.53 mmol). The mixture was stirred at 
0°C for 10 min before additon of [N-(Cbz)]-cycloserine (2) (111 g, 0.47 
mmol). The mixture was then stirred at room temperature for lh, after which 
time the mixture was diluted with dichloromethane ( 2 0  ml) and washed with 
0.1M aqueous hydrochloric acid (3 x 10 ml). The organic extract was dried 
(Na2 S04) and evaporated under reduced pressure to give a solid which was 
purified by chromatography, using ethyl acetate-petrol as eluant, to give the
O-mesylated dihydroisoxazole (42) (91 mg, 62%) as colourless solid followed 
by the 2-N-mesylated-3-isoxazolidinone (43) (18 mg, 12%) as an oil.
O-Mesylate (42): m.p. 105-107°C (EtOAc-Petrol) (Found: C, 45.98; H, 4.48; 
N, 8 .8 6 ; S, 9.98. C12H1 4N2 0 6S requires C, 45.86; H, 4.49; N, 8.89; S, 
10.18%); omax (CHBr3) 3409, 3027, 2925 and 1720 cm'1; 5H (250 MHz) 3.38 
(3H, s, S 0 2 Me), 4.37 (1H, dd, J 10 and 5 Hz, 5-H), 4.72 (1H, t, /  10 Hz, 5-H), 
5.09-5.20 (2H, m, Cl^Ph), 5.22-5.38 (2H, m, 4-H and NH), 7.30-7.38 (5H, m, 
Ph); 5C (100.6 MHz), 39.7 (CH3), 35.1 (4-CH), 67.8 (5-CHz), 76.9 (CHzPh), 
128.3-128.7 (PhcH), 135.7 (Phcquatemary), 155.3 (Cquatemaiy), 169.8 (OC=0); 
m/z (+FAB), 315 (M+ + H, 58%), 219 (64), 91 (100). 
N-Mesyl-3-isoxazolidinone (43): 0)max (CHBr3) 3410,2925,2850 and 1765 
cm’1; 5h (250 MHz), 3.28 (3H, s, S 0 2 Me), 4.40-4.48 (1H, m), 4.68-4.87 (2H, 
m), 5.13 (2H, s, CHzPh), 5.40-5.46 (1H, s (br), NH), 7.35 (5H, s, Ph); 6 C 
(100.6 MHz), 40.0 (CH3), 54.0 (4-CH), 67.8 (5-CH2), 74.4 (CHjPh), 
128.0-131.0 (PhCH), 135.8 (Phcquaternary), 169.8 (OC=Q), ( 1  x C=C not seen).
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l-r2-r-2-(l H-indol-3-yl)-ethylaminol -1 - ff( methylsulphon vDaminol ox vl - 
methvll-2-oxoethyllcarbamic acid, benzyl ester (44) and 2-N-methane- 
-sulphonvl-r3-Indolvlethyllamine (45)
To a suspension of O-mesylate (42) (106 mg. 0.3 mmol) in methanol (2 ml) 
was added tryptamine (60 mg, 0.37 mmol) and triethylamine (0.052 ml, 0.37 
mmol). The mixture was stirred at room temperature for lh, after which time 
the solvent was removed in vacuo to give an oil. The oil was dissolved in 
ethyl acetate (15 ml), washed with water (2 x 10 ml) and the organic extract 
was dried (Na2 S0 4 ) and evaporated under reduced pressure. The residue was 
purified by preparative reverse HPLC using a gradient elution of acetonitrile- 
-water as eluant (3:7 v/v to 7:3 v/v, over a period of 30 min) gave 
N-methanesulphonyltryptamine (45) (6.2 mg, 8 %) as a pink solid, followed by 
the ring-opened dihydroisoxazole (44) (11 mg, 8 %) as a colourless solid. 
Recrystallisation of (44) from ethyl acetate-petrol gave a colourless solid, m.p. 
134-135°C.
(44): (Found: C, 55.4; H, 5.49; N. 11.61; S, 6.44. C2 2 H2 6 N4 0 6S requires C, 
55.74; H, 5.53; N, 11.81; S, 6.75%); umax (CHBr3) 3460, 3410, 2940,1710 and 
1670 cm’1; 5H (250 MHz, DMSO-d6), 2.81 (2H, t, J  7.5 Hz, OfcO^NH), 2.99 
(3H, s, S 0 2 Me, 3.28-3.37 (2H, m, CHjO^NH), 3.95-4.12 (2H, m), 4.30-4.40 
(1H, m), 5.02 (1H, d, J 12.5 Hz, part of AB system), 5.09 (1H, d, /  12.5 Hz, 
part of AB system), 6.94-7.16 (3H, m), 7.30-7.40 (6 H, m, Ph and NH), 7.53 
(2H, t, J  7.5 Hz), 8.12-8.17 (1H, m, CH?CHoNH). 9.95 (1H, s, NHS02 Me),
10.81 (1H, s, NH on indole); 8 C (100.6 MHz, DMSO-d6) 24.9 (CH^, 36.1 
(CH3), 39.8 (CH2), 53.6 (CH), 65.5 (CH2), 75.7 (O^Ph), 111.1-128.1 (PhCH),
111.5 ( P h c q u a te m a r y ) .  1 2 6 -9  ( P h C q u a te m a ry ) >  136.1 ( ^ q u a t e r n a r y ) ’ 136.7
(Phcquatemaiy)»155.6 (C=0), 168.5 (OC=0); m/z (+ FAB), 475 (M+ + H, 51%), 
315 (3), 288 (7), 143 (85), 91 (60).
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(45): (Found; M+, 238.0776. Cn H1 4N2 0 2S requires 238.0776); \)max (CHBr3) 
3460, 2970, 2820 cm*1; 6 H (250 MHz, DMSO-d6), 2.84-2.93 (5H, m, SOiMe, 
CH2 CH2 NH), 3.22 (2H, m, O^Cl^NH), 6.96-7.11 (3H, m), 7.20 (1H, s), 7.34 
(1H, d, J 7.5 Hz), 7.53 (1H, d, J  7.5 Hz), 10.84 (1H, s, NH on indole); 5C 
(Methanol-d4), 24.8 (CH2), 40.2 (S0 2 Me), 42.3 (CH2), 112.58 (PhCH), 113.1 
( p h C q u a te m a iy )>  119.5-124.1 (PhCH), (2 x Phcquatemaiy not seen); m/z (Tof) 238 
(M+, 20%).
NOTE: Repeating the above reaction in dimethylformamide solution afforded 
(45) in 35% and (44) in 10% yield.
Reaction of 2-N-methanesulphonvl-(4R)-rN-(benzyloxvcarbonvl)amino1- 
-3-isoxazolidinone (43) with Tryptamine
Compound (44) was similarly isolated as a colourless solid ( 6 6  mg, 53%) from 
the reaction of the 2-N-mesylate (43) (82 mg, 0.26mmol) with tryptamine (48 
mg, 0.29 mmol) in triethylamine (0.04 ml, 0.29 mmol) and methanol (2 ml) at 
room temperature for 2 h.
l-r3-r-2-(lH-indol-3-vl)-ethvlaminol-2-r(trifluoromethvl)sulphonvn-3- 
-rr(trifluoromethyl)sulphonvloxvl-4-isoxazolvncarbamic acid, phenyl ester 
(46b)
To a solution of (4R)-[N-(Cbz)]-cycloserine (100 mg, 0.42 mmol) and 2,6-di- 
-rm-butyl-4-methylpyridine (101 mg, 0.49 mmol) in dichloromethane (5 ml) 
at -78°C was added dropwise triflic anhydride (0.08 ml, 0.47 mmol). After 
stirring at -78°C for 10 min, TLC showed loss of starting material. 
Tryptamine (160 mg, 1.0 mmol) was then added and the mixture was further 
stirred at -78°C for another 45 min and then at 0°C for lh. On returning, the 
mixture was poured into water (10 ml), extracted with dichloromethane (3 x
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10 ml) and the extracts were dried (Na2 S04) and evaporated under reduced 
pressure to give an orange oil/solid. Purification by chromatography using 
ethyl acetate-petrol as eluant afforded the Ws-trifluoromethanesulphonyl 
derivative (46b) (124 mg, 44%); (CHBr3) 3464, 3360, 2923, 1725, 1509, 
1231, 1200 cm 1; 6 H (250 MHz, DMSO-d6), 2.95 (2H, t, /  7.5 Hz, 
CH2 CH2 NH), 3.41 (2H, t, J  7.5 Hz, C^OfcNH), 4.43 (1H, dd, J  10 and 6.25 
Hz, 5-H), 4.82 (1H, t, /  10 Hz, 5-H), 5.08 (2H, s, OkPh), 5.35-5.46 (1H, m,
4-H), 6.96-7.11 (2H, m), 7.21 (1H, d, /  2.5 Hz), 7.30-7.40 (6 H, m), 7.50 (1H, 
d, J 7.5 Hz), 8.40 (1H, d, J  7.5 Hz, NH), 9.33 (1H, s,), 10.90 (1H, s, NH on 
indole); 8 C (100.6 MHz), 26.4 (CH2), 44.4 (CH2), 54.4 (CH), 68.0 (CH^, 77.4 
(CH2), 1 1 1 . 2  ( P h C q u a te m a r y ) ,  111.8-129.0 ( P h C H ) ,  127.0 ( P h C q u a t e m a x y ) ,  135.5 
(^ hcquatemary), 136.5 (Ph(^ quateniaiy), 159.0 (^ - 'q u a t e r n a r y ) , ^  £ ^ 3  < U ld  1 X
Quaternary not seen); 6 F (376.3 MHz, DMSO-dg) -97.2 and -92.3; (+FAB) 661 
(M+ + H, 0.75%), 660 (8 ), 369 (10), 292 (58) 219 (10); (-FAB) 659 (M+ - H, 
1.6%), 367 (17), 291 (28), 149 (100).
NOTE: An accurate molecular ion was not found for this compound.
r3/Rl-r3-rr2-(3-indolvl)ethvnamino1-4,5-dihvdroisoxazolylcarbamic acid, 
phenylmethyl ester (1 0 )
To a solution of chloride (3) (5.12 g, 0.02 ml) in methanol (30 ml) in a sealed 
tube was added tryptamine (6.33 g, 0.04 mmol). The orange solution was 
heated at 100°C for 48h, after which time the solvent was removed in vacuo to 
give a solid. Purification by chromatography using ethyl acetate-petrol as 
eluant afforded starting material (3) (1.52 g, 30%) followed by the 3-methoxy 
adduct (6 ) (0.34 g, 6 .8 %) and then finally the indolylethylamino adduct (10) 
(3.62 g, 48%). Recrystallisation from ethyl acetate-petrol gave (10) as a pale 
yellow solid, m.p. 171-173°C; [a]19D + 44.7° (c 4.0 in acetone) (Found: C, 
66.4; H, 5.86; N, 14.8. C2 1 H2 2 N4 0 3  requires C,66.65; H,5.86; N,14.80%);
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Vmax (nujol mull) 3425, 3310, 3220, 1700 and 1640 cm 1; 8 h (250 MHz, 
DMSO-dg) 2.91 (2H, t, J 7.5 Hz, CH2 CH2 NH, 3.28 (2H, m, CH2 CH2 NH), 3.7 
8 (1H, t, /  8 Hz, 5-H), 4.21 (1H, t, J 8.7 Hz, 5-H), 4.91-5.11 (3H, m, 4-H and 
CH-iPh). 6.03 (1H, t, 7  5 Hz, CHoCHuNH). 6.98 (1H, td, J  8  and 1.1 Hz), 7.07 
(1H, td, /  8  and 1.1 Hz), 7.13 (1H, d, J 2.2 Hz), 7.32-7.40 (6 H, m), 7.54 (1H, 
d, J  7.8 Hz), 7.99 (1H, d, J 8.4 Hz, 4-NH), 10.81 (1H, s, NH on indole),; 8 c  
(Acetone-dfi) 25.5 (CH2), 48.9 (CH2), 59.8 (CH), 67.1 (CHj), 72.7 (CH2),
112.2-129.3 (Phc„), 113.4 (PhCquatemary), 137.7 (PhCquatemaly), 159.7 
( ( - q u a l e m a i y ) *  (?  ^ P h C q u a t e m a r y  and 1 X  C q y y y , m a j y  not Seen), Itl/z (+FAB) 379 
(M+ + H, 89%), 91 (78); (-FAB) 377 (M+ - H, 21%), 269 (100).
3-N-r3-rf2-(3-indolvl')ethvllamino1-(4)-amino-3-isoxazolidine (471
To a solution of indolylethylamino derivative (10) (1.74 g, 0.004 mmol) in 
methanol (50 ml) was added 10% palladium over charcoal catalyst (0.35 g) 
and the mixture was then subjected to atmospheric hydrogenation for 2 0 h. 
After that time, the catalyst was removed by filtration through celite and the 
filtrate was evaporated under reduced pressure to give the isoxazolidine (47) 
(1.10g, 97%) as a yellow foam; (CHC13) 3470, 3400, 2890 and 1610 
cm'1; 8 h (methanol-dl,) 3.03 (2H, t, J  7.5 Hz, CH2 CH2 NH), 3.27-3.32 (2H, m, 
CH2CH2 NH), 3.41-3.61 (4H, m), 5.85 (1H, m, CH2 CH2NH), 6.95-7.15 (3H, 
m), 7.32 (1H, d, J  7.5 Hz), 7.56 (1H, d, J  7.5 Hz), 11.85 (1H, s (br), NH on the 
indole), (3 x NH not seen); m/z (+FAB) 247 (M+ + H, 100%), 231 (3), 161 (2).
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r3'Rl-r3-rr2-(3-indolvl)ethvnaminol-4,5-dihvdro-4-isoxazolvlamine (48)
To a solution of indolylethylamino derivative (10) (520 mg, 1.4 mmol) in 
dichloromethane (4 ml) was added anisole (0.3 ml, 2.7 mmol), followed by 
dropwise addition of trifluoromethanesulphonic acid (0.86 ml, 9.6 mmol) with 
vigorous stirring. The mixture was diluted with dichloromethane (5 ml) and 
washed with 1M aqueous hydrochloric acid (15 ml). The acidified extract was 
cooled to 0°C and made alkaline with 5M aqueous sodium hydroxide to pH 
8-9. The mixture was extracted with dichloromethane (2 x 50 ml), dried 
(Na2 S04) and evaporated under reduced pressure to give a yellow oil. 
Purification by chromatography, using dichloromethane-methanol (9:1 v/v) as 
eluant, gave the corresponding free amine (48) (211 mg, 62%) as an oil, [a]20D 
- 10.9° (c 10.75 in CH2 Cl2); vmax (CHC13) 3480, 3300, 2920 and 1610 cm'1; 
5h (DMSO-d6) 1.98 (2H, s (br), NH2), 2.94 (2H, t, J  7.5 Hz, CH2 CH2 NH),
3.25-3.29 (2H, m, OE^CTfcNH), 3.52 (1H, t, /  9 Hz), 4.07-4.22 (2H, m), 5.84 
(1H, t, /  6  Hz, CHoCHoNH). 6.98 (1H, td, /  7.5 and 1.5 Hz), 7.07 (1H, td, /
7.5 and 1.5 Hz), 7.17 (1H, d, J 2.2 Hz), 7.34 (1H, d, /  8  Hz), 7.55 (1H, d, J  7.7 
Hz), 10.82 (1H, s, NH on indole); 8 C 24.3 (CH2), 43.5 (CH), 59.5 (CH2), 73.8 
(CH2), 1 1 1 .2 -1 2 2 . 6  (PhCH), 136.1 ( P h C q u a t e m a r y ) ,  165.4 (Cquaternary), ( 2  x
Phcquatemary n 0 t StQVi)' (70eV  E *L > 24 4  (M ’ 9 % )’ 128 (8 )’ 77 (3 1 )* (CL) 
245 ((M+ + H, 100%).
f3/Rl-r2-rf3-rr2-(3-indolvl)ethvnaminol-4,5-dihydro-4-isoxazolvlaminol- 
- 1  -methvl-2-oxoethyllcarbamic acid, phenylmethyl ester (49)
To an ice-cooled solution of N-(Cbz)-(L)-alanine (74 mg, 0.33 mmol) in 
dimethylformamide (1 ml) was added 1-hydroxybenzotriazole hydrate (69 mg, 
0.5 mmol) and dicyclohexylcarbodiimide (73 mg, 0.35 mmol). After stirring 
for 5 min, a white precipitate formed, and to this was added a solution of
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3-tryptamino-(4R)-amino-4,5-dihydroisoxazole (48) (50 mg, 0.2 mmol) in 
dimethylformamide (0.5 ml). The mixture was stirred at room temperature for 
2 0 h after which time the dicyclohexylurea was filtered off and washed with 
ethyl acetate (10 ml). The filtrate was evaporated under reduced pressure to 
give a yellow oil which was purified by chromatography, using ethyl 
acetate-petrol (8:2 v/v) as eluant, to give the tripeptide (49) (69 mg, 80%) as a 
pale yellow solid, m.p. 155,5-157°C (EtOAc); [a]21p + 65.0° (c 0.52 in 
ethanol) (Found: C, 64.1; H, 5.94; N, 15.2. C2 4 H2 6 N5O4  requires C, 64.13; H, 
6.06; N, 15.57%); \>max (CHC13) 3420 (br), 2920, 1715, 1670 and 1620 cm'1: 
5h (DMSO-d6) 1.20 (3H, d, J 7.5 Hz, CHMe), 2.89-2.96 (2H, m, CH2 CH2 NH), 
3.21-3.30 (2H, m, O ^QfcNH), 3.79 (1H, dd, J 9 and 6.7 Hz, 5-H), 4.04-4.09 
(1H, m), 4.19 (1H, t, /  9 Hz, 5-H), 5.00 (1H, d, J  13.1 Hz, part of AB system),
5.05 (1H, d, J 12.5 Hz, part of AB system), 5.11-5.20 (1H, m), 5.83 (1H, t, /
5.2 Hz, CH0 CH0 NH). 6.96 (1H, td, /  8  and 1.1 Hz), 7.06 (1H, td, J  8.2 Hz and
1.1 Hz), 7.31-7.37 (6 H, m,), 7.47 (1H, d ,/7 .1  Hz), 7.53 (1H, d, /7 .8  Hz), 8 . 6 6  
(1H, d, J 7.9 Hz), 10.30 (1H, s, NH on indole); m/z (+FAB) 450 (M+ + H, 
80%), 289 (4), 91 (89), 77 (23); (-FAB) 448 (M+ - H, 19%), 342 (17), 242 (8 ).
r3'R1-N-r2-rr3-IT2-(3-indolyl)ethvllamino1-4,5-dihvdro-4-isoxazolvlarninol- 
-l-methyl-oxoethyll amine (50)
To a dichloromethane solution (3 ml) of tripeptide (49) (248 mg, 0.55 mmol) 
was added anisole (0 . 1 2  ml, 1 mmol), followed by dropwise addition of 
trifluoromethanesulphonic acid (0.29 ml, 3 mmol). The mixture was stirred at 
room temperature for 5 min and then cooled to 0°C and neutralised with 5M 
aqueous NaOH solution. The product was then extracted into 
dichloromethane ( 6  x 10 ml) and dried (Na2 S04) and concentrated in vacuo to 
give the tripeptide (50) (150 g, 8 6 %) as a yellow solid. Recrystallisation from 
ethanol afforded (50) as a colourless solid, m.p. 158-159°C [a]21D +116.7° (c
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0.45 in ethanol) (Found: C, 60.9; H, 6.79; N, 21.6. C16H2 iN5 0 2  requires C, 
60.94; H, 6.71; N, 22.20%); i>max (CHC13) 3480, 3340, 2920, 2850, 1650 and 
1620 cm*1; 6 H (DMSO-d6) 1.10 (3H, d, /  7.0 Hz, CHMe), 1.60-2.00 (1H, s 
(br), NH), 2.93 (2H, t, J 7.5 Hz, OfcCHjNH), 3.22-3.30 (3H, m, O ^O fcNH  
and CHMe), 3.80 (1H, dd, J 8 . 8  and 6.4 Hz, 5-H), 4.18 (1H, t, J 8 . 6  Hz, 5-H), 
5.10 (1H, dd, J 8 . 6  and 6.4 Hz, 4-H), 5.96 (1H, t, J  5.6 Hz, CH?CH?NH), 6.97 
(1H, td, J  7.9 Hz and 1.3 Hz), 7.06 (1H, td, /  8.2 Hz and 1.2 Hz), 7.12 (1H, d, 
J 2.4 Hz), 7.34 (1H, d, J  7.9 Hz), 7.55 (1H, d, /  7.7 Hz), 10.30 (1H, s, NH on 
indole), (2 x NH not seen); m/z (C.I.) 316 (M+ + H, 1.6%), 129 (16), 91 (41).
r3^Rl-N-r2-r2-rr3-rf2-(3-indolvl)amino1-4.5-dihvdro-4-isoxazolylamino1- 
- 1  -methyl-2 -oxoethyll aminol - 1  -methyl-2 -oxoethyll carbamic acid, 
phenylmethyl ester (51)
The coupling of tripeptide (50) (55 mg, 0.16 mmol) with N-(Cbz)-(L)-alanine 
(59 mg, 0.26 mmol) was performed using the same procedures as described 
for the synthesis of tripeptide compound (49). The crude solid was purified by 
chromatography using ethyl acetate-petrol as eluant to give tetrapeptide (51) 
(57 mg, 69%) as a pale yellow solid, m.p. 208-210°C (dec.)(ethanol-ether); 
[<x]21D +30.25° (c 4.0 in ethanol) (Found: C, 62.3; H, 6.28; N, 15.7. 
Q27H3 2 N5O5  requires C, 62.29; H, 6.20; N, 16.14%); i)max (nujol mull) 3270, 
1680 and 1620 cm'1; 8 H (DMSO-d6) 1.18-1.23 (6 H, m, CHMe x 2), 2.89-2.96 
(2H, m, CHjCHjNH), 3.22-3.30 (2H, m, CH2 CH2NH), 3.77 (1H, dd, J  8 . 6  and
6 . 6  Hz, 5-H), 4.07 (1H, t, J  7.1 Hz), 4.16-4.24 (1H, m, 5-H), 4.26 (1H, t, J 7.3 
Hz), 4.97 (lH,d, J  12.6 Hz, part of AB system), 5.04 (1H, d, J 12.6 Hz, part of 
AB system), 5.10-5.19 (1H, m, 4-H), 5.90 (1H, t, J  5.3 Hz, CHjCHjNH), 6.96 
(1H, td, J 7.5 and 1.1 Hz), 7.06 (1H, td, J 8.2 and 1.3 Hz), 7.14 (1H, d, J 2.2 
Hz), 7.30-7.37 (6 H, m,), 7.53 (2H, t, J  8.4 Hz), 8.00 (1H, d, /  7 Hz, NH), 8.59 
(1H, d, J 7 Hz, NH), 10.3 (1H, s, NH on indole); m/z (+FAB) 521 (M+ + H,
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Tripeptide (50) (39 mg, 0.12 mmol) was coupled to benzoic acid (26 mg, 0.21 
mmol) in the presence of 1-hydroxybenzotriazole hydrate (39 mg, 0.29 mmol) 
and dicyclohexylcarbodiimide (47 mg, 0.22 mmol) in dimethylformamide (1 
ml) as described for the synthesis of tripeptide (49). The crude oil was 
purified by chromatography on silica gel using ethyl acetate-petrol as eluant to 
afford the N-benzoyl-tripeptide (52) (43 mg, 85%) as a pale yellow solid, m.p.
196-197°C (ethanol-ether), [ct]19D +91.95° (c 0.27 in CH2 C12) (Found: C, 6 6 .0 ; 
H, 6.09; N, 16.6. requires C, 65.86; H, 6.00; N, 16.69%); »max
(CHC13) 3490, 3250, 2990, 1720,1630 and 1620 cm 1; 5 (DMSO-d6) 1.34 (3H, 
d, /  7 Hz, CHMe). 2.94-2.99 (2H, m, Q&O^NH), 3.25-3.30 (2H, m, 
CH2 CH2 NH), 3.77 (1H, dd, J  8.4 and 7.3 Hz, 5-H), 4.24 (1H, t, J  8 . 8  Hz, 5-H), 
4.40-4.45 (1H, m, 4-H), 5.22 (1H, q, J 1 3  Hz, CHMe), 5.90 (1H, t, J  5.5 Hz, 
CH0 CH0 NH). 6.95 (1H, td, /  7 and 1.4 Hz), 7.08 (1H, td, /  7 Hz and 1.4 Hz), 
7.17 (1H, d, /  2.2 Hz), 7.33 (1H, d, /  8.1 Hz), 7.42-7.58 (4H, m), 7.90 (2H, d, J 
7 Hz), 8.58 (1H, d, J 6 . 6  Hz, NH), 8.75 (1H, d, J  8.1 Hz, 5-NH), 10.8 (1H, s, 
NH on indole); m/z (70eV E.I.) 419 (M+, 0.6%), 105 (100), 77 (56).
(2S)-rN-(Benzvloxvcarbonyl)aminol-3-Isoxazolidinone (53)
(4S)-Cycloserine (1.98 g, 0.19 mol) was N-protected with benzyl 
chloroformate (3.05 ml, 0.021 mol) as described in the literature^137) for the 
R-isomer. The N-protected product (53) (5.15 g, 74%) was isolated as a 
crystalline solid, m.p. 134-5-135.5°C (from EtOAc-petrol) [a]19D -29.74° (c
-108-
5.08 in acetone); omax (nujol mull) 3280 and 1670 cm-1; 8 H 4.10 (1H, dd, /  11 
and 7 Hz), 4.63-4.72 (1H, m), 4.80 (1H, t, J 8  Hz), 5.12 (2H, s, CH,Ph). 5.27 
(1H, s(br), NH), 7.36 (5H, s, Ph), (1 x NH not seen).
NOTE: The 2 ,4 -£/5 -[N-(Cbz)amino]-3 -isoxazolidinone (1.03 g, 14%) was also 
isolated and it was only identified by TLC by co-running the compound with 
the corresponding R-isomer.
3-Chloro-(4S)-rN-(benzvloxvcarbonvl)aminol-4.5-dihydroisoxazole (54)
(4S)-[N-(Cbz)]-cycloserine (53) (5.09 g, 0.021 mol) was heated with five 
equivalents of dichlorofm(dimethylamino)phosphorane (4) in THF (60 ml), as 
described for the (R)-isomer (2). The reaction was completed after heating for 
2.5h and the chloro adduct (54) (4.58 g, 8 6 %) was isolated as colourless 
needles, m.p. 136.5-137.5°C (ethyl acetate-petrol), [a]18D -8.96° (c 4.85 in 
CH2CI2) (Found: C, 51.6; H, 4.27; N, 11.0. C ^H nO ^C ^ requires C, 51.88; 
H, 4.35; N, 10.99%); omax (nujol mull) 3400 and 1680 cm'1; 5H 4.29 (1H, dd, J 
10 and 6  Hz, 5-H), 4.69 (1H, t, /  10 and 5 Hz, 5-H), 5.10-5.20 (2H, m, 
CH2Ph), 5.25-5.35 (2H, m, 4-H and NH), 7.36 (5H, s, Ph); m/z (70eV E.I.) 
254 (M+, 2.5%), 91 (100). (C.I.) 255 (M+ + H, 10%), 257 (3), 219 (2.5), 108 
(10), 91 (100).
r3/S1-r3-fr2-(3-indolvl)ethvnamino1-4,5-dihvdroisoxazolylcarbamic acid, 
phenylmethyl ester (55) and 3-methoxv-(4S)-rN-(benzvloxvcarbonyl)amino1- 
-4,5-dihydroisoxazole (55b)
Chloride (54) (4.10 g, 0.16 mmol) in methanol (15 ml) was heated with 
tryptamine (5.18 g, 0.032 mol) in a sealed tube, at 100°C for 20h. The solvent 
was removed under reduced pressure to give a solid which was purified by 
chromatography using ethyl acetate-petrol as eluant to give starting material
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54) (1.4 g, 34%), followed by the 3-methoxy (55b) (0.35 g, 9%) and finally the 
indolylethylamino adduct (55) (3.15g, 52%) as a straw coloured solid, m.p. 
168-170°C (EtOH), [a]19D -42.5° (c 3.87 in acetone) (Found: C, 66.7; H, 5.88; 
N, 15.0. C2 1 H2 2 N4 O3  requires C, 6 6 .6 8 ; H, 5.86; N, 14.80%); u^ax (nujol 
mull) 3380, 3260, 3200,1675 and 1615 cm*1; 5H (DMSO-d6) 2.92 (2H, t, J  7.5 
Hz, CH2 CH2 NH), 3.22-3.31 (2H, m, CH2 CH2 NH), 3.79 (1H, dd, 7 9 and 7.5 
Hz, 5-H), 4.20 (1H, t, J 9 Hz, 5-H), 4.92-5.01 (1H, m, 4-H), 5.02 (1H, d, J  12 
Hz, part of AB ystem), 5.09 (1H, d, J 12 Hz, part of AB system), 6.05 (1H, t, J 
6 Hz, CH2 CH2 NH), 6.98 (1H, t, /  7.5 Hz), 7.07 (1H, t, /  7.5 Hz), 7.17 (1H, d, 
J  2.2 Hz), 7.30-7.43 (5H, m, Ph), 7.55 (1H, d, J 7.7 Hz), 8.02 (1H, d, J 8.4 
Hz), 10.8 (1H, s, NH on indole), (1 x NH not seen); m/z (C.I.) 379 (M+ + H, 
0.9%) and 245 (1).
3-Methoxy adduct (55b) was isolated as a colourless solid: m.p. 117.9-118°C 
(EtOAc-Petrol) (Found: M+ + H, 251.1032. C12 H1 5N2 0 4  requires 251.1032); 
Umax (nujol mull) 3260, 1670 and 1615 cm*1; 5H 3.89 (3H, s, OMe), 4.16 (1H, 
dd, J 9.8 and 6  Hz, 5-H), 4.56-4.63 (1H, m, 5-H), 5.10-5.21 (4H, m, CH^h,
4-H and NH), 7.36 (5H, s, Ph); 8 C 55.7 (CH), 57.9 (CH3), 67.4 (CH2), 75.4 
(CH2), 128.2-128.5 (PhCH), 135.4 (PhCquatemary), 155.5 (Cquatemary), 167.3 
(C=0); m/z (70eV E.I.) 250 (M+, 0.8%), 106 (20), 91 (100. (C.I.) 251 (M+ + 
H, 28%), 219 (0.8), 106 (18), 91 (100).
f3'SH3-IT2-(3-indolvl)ethvllaminol-4,5-dihvdro-4-isoxazolvlamine (56)
Dihydroisoxazole (55) (1.02 g, 0.027 mol) was debenzylated to the 
corresponding amino derivative (56) using the same procedure employed for 
the conversion of (4R)-(10) to (48). The product was purified by 
chromatography on silica gel using dichloromethane-methanol (9:1 v/v) as 
eluant to give (56) (464 mg, 70%) as a colourless oil, [<x]20d +12.51° (c 8.4 in 
CH2 Cl2); 5h (DMSO-d6) 2.94 (2H, t, J 7.3 Hz, ClfcCT^NH), 3.24-3.37 (2H,
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rn, CH2 CH2 NH), 3.55 (2H, m), 4.10-4.23 (2H, m), 5.87 (1H, m, CHoCHoNH).
6.80 (1H, td, J  7.7 and 1.1 Hz), 7.07 (1H, td, J  7.0 and 1.1 Hz), 7.18 (1H, d, /
2.2 Hz), 7.35 (1H, d, J  8.1 Hz), 7.55 (1H, d, J 7.9 Hz), 10.2 (1H, s, NH on 
indole), (1 x NH not seen).
r3/Sl-N-r2-rr3-rr2-(3-indoIvl)ethvllamino1-4.5-dihydro-4-isoxazolvlaminol- 
-l-methyl-2-oxoethvncarbamic acid, phenylmethyl ester (57)
Indolylethylamino derivative (56) (0.8 g, 3.3 mmol) was coupled to 
N-(Cbz)-L-alanine (1.13 g, 5 mmol) as described for the conversion of 
(4R)-(48) to (49). Purification by chromatography, using ethyl acetate-petrol 
as eluant, afforded tripeptide (57) (1.14 g, 77%) as a pale yellow solid. m.p.
197-199°C (dec.), [a]19D -5.0° (c 0.52 in DMF) (Found: C, 64.1; H, 6.02; N,
15.4. C2 4 H2 6 N5 O4  requires C, 64.13; H, 6.06; N, 15.40%); \)max (nujol mull) 
3350, 3270, 1680, 1645 and 1620 cm’1; 5H (DMSO-d6) 1.19 (3H, d, /  7 Hz, 
CHMe). 2.88-2.96 (2H, m, CH,CH?NH). 3.23-3.32 (2H, m, CH2 CH2 NH), 
3.78-3.84 (1H, m), 4.04 (1H, t, J 7.5 Hz), 4.16 (1H, t, J 9 Hz), 4.96-5.12 (3H, 
m, CH2Ph and 4-H), 5.94 (1H, t, J  5.3 Hz, CH0 CH0 NH). 6.97 (1H, td, J 8.1 
and 1.1 Hz), 7.07 (1H, td, /  8.2 and 1.2 Hz), 7.16 (1H, d, J  2.2 Hz), 7.30-7.38 
(5H, m, Ph), 7.46 (1H, d, J 7.3 Hz), 7.54 (1H, d, /  7.5 Hz), 8.46 (1H, d, J 7.7 
Hz, NH), 10.3 (1H, s, NH on indole); m/z (+FAB) 450 (M+ + H, 74%), 91 
(63). (-FAB) 448 (M+ - H, 10%), 314 (7), 151 (33), 135 (27).
r3/,S1-N-r2-rr3-rr2-(3-indolyl)amino1-4,5-dihvdro-4-isoxazolylamino1- 
-l-methyl-2-oxoethvriamine (58)
Tripeptide (57) (282 mg, 0.62 mmol) was N-debenzylated to (58) using the 
same procedure employed for the conversion of the (4R)-(49) to (50). The 
product was purified by chromatography using dichloromethane-methanol (9:1
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v/v) as eluant, to afford amine (58) (124 mg, 63%) as a colourless oil, [a]20D 
-61.8° (c 0.5 in ethanol); \)max 3470, 3380-3320 (br), 2920, 1665 and 1635 
cm’1; 6 h (DMSO-d6) 1.80 (3H, d, /  7 Hz, CHMe), 2.95 (2H, t, J  7.3 Hz, 
OfcCHjNH), 3.22-3.30 (2H, m, CH^I^NH), 3.40-3.48 (2H, m), 3.82 (1H, 
dd, J  8 . 8  and 5.5 Hz), 4.19 (2H, t, J 8 . 8  Hz)„ 5.09 (1H, dd, /  9 and 6  Hz), 6.10 
(1H, t, J  5.5 Hz, CH?CHoNH). 6.97 (1H, td, J  7.7 and 1.1 Hz), 7.08 (1H, td, J 
7 and 1.1 Hz), 7.15 (1H, d, /  2.2 Hz), 7.32 (1H, d, /  8  Hz), 7.53 (1H, d, J 7.7 
Hz), 8.04-8.08 (1H, s (br), NH), 10.82 (1H, s, NH on indole); m/z (+FAB) 316 
(M+ + H, 100%), 228 (14); (-FAB) 314 (M+ - H, 77%), 299 (6 ), 272 (13).
[3/Sl-N-r2-r2-fr3-rr2-(3-indolvl)ethvllamino1-4,5-dihvdro-4-isoxazolylaminol- 
- 1 -methyl-2 -oxoethvnamino!- l-methyl-2 -oxoethvllcarbamic acid, 
phenylmethyl ester (59)
Tripeptide (58) (51 mg, 0.16 mmol) was coupled to N-(Cbz)-L-alanine (59 
mg, 0.27 mmol) using the procedure employed for the conversion of (4R)-(48) 
to (49). Care was required to wash the product thoroughly with methanol 
from the dicyclohexylurea precipitate. Purification by chromatography using 
ethyl acetate-petrol (7:3 v/v) followed by dichloromethane-methanol (9:1 v/v) 
as eluant gave the tetrapeptide (59) (41 mg, 48%). m.p. 248-249°C 
(dec.),[<x]19D -29.39° (c 0.33 in DMF) (Found: M+ + H, 521.2512. ( ^ 3 3 ^ 0 5  
requires 521.2512); \)max (nujol mull) 3390, 3320, 3260, 1690 and 1640 (br) 
cm 1; 8 h (DMSO-d6), 1.19 (3H, d, J 7.1 Hz, CHMe), 1.20 (3H, d, J 7.0 Hz, 
CHMe). 2.88-2.97 (2H, m, Cf^O^NH), 3.22-3.33 (2H, m, O^CI^NH),
3.80 (1H, dd, /  8 . 8  and 5.5 Hz, 5-H), 4.05 (1H, t, J 7.3 Hz), 4.16 (1H, t, /  8 . 8  
Hz, 5-H), 4.24 (1H, t, /  7.1 Hz), 4.97-5.12 (3H, m, CT^Ph and 4-H), 5.94 (1H, 
t, J  5.3 Hz, CH?CHoNH), 6.97 (1H, td, J 7.9 and 1.1 Hz), 7.06 (1H, td, J 8  and
1.2 Hz), 7.16 (1H, d, J 2.4 Hz), 7.30-7.37 (6 H, m, Ph and NH), 7.48 (1H, d, J 
7 A  Hz), 7.55 (1H, d, J 7.5 Hz), 7.98 (1H, d, J 1 3  Hz, NH), 8.55 (1H, d, /  8
-112-
Hz, NH), 10.3 (1H, s (br) NH on indole), (1 x NH not seen); §c (100.6 MHz, 
DMSO-d6) 18.6 and 18.7 (CH3  x 2), 24.9 (CH2), 44.4 (CH2), 47.8 (CH), 50.6 
(CH), 56.9 (CH), 65.9 (CH2), 72.7 (CH2), 111.9-128.9 (PhCH), 136.8 
(Phcquatemaiy). 137.5 (PhCquattrmiy). 156.3 (Cquatemary), 159.2 (0 C=0 ), 172.7 
(NC=0), 173.0 (NC=0), (2 x PhCquatemary not seen ); m/z (+FAB) 521 (M+ +
H, 35%), 314 (0.7), 206 (1.4), 149 (100), 91 (48); (-FAB) 519 (M+ - H, 20%), 
385 (8 ), 227 (7).
f3/S]-N-r2-IT3-IT2-(3-indolyl)ethvllaminol-4.5-dihvdro-4-isoxazolvlaminol- 
- l-methyl-2 -oxoethvllbenzamide (60)
Tripeptide (58) (112 mg, 0.36 mmol) was coupled with benzoic acid (76 
mg,0.61 mmol) following the procedure described for the conversion of 
(4R)-(50) to (52). The mixture was purified by chromatography, using ethyl 
acetate-petrol as the eluant, to afford the product N-benzoyl-tripeptide (60) (91 
mg, 61%) as a pale yellow solid which we were unable to recrystallise. m.p.
246.5-248°C (dec.), [a]20D -42.86° (c 0.14 in CH3 CN) (Found: M+ + H, 
420.2036. C2 3 H2 5 N5 O3  requires 420.2035); umM (nujol mull) 3390, 3350, 
3280 and 1645 cm'1; SH (DMSO-d6) 1.37 (3H, d, 7 7.3 Hz, CHMe). 2.83-2.89 
(2H, m, CHjCHjNH), 3.21-3.32 (2H, m, CHjCHiNH), 3.85 (1H, dd, 7 8.4 and
6 . 6  Hz), 4.18 (1H, t, 7 8.4 Hz), 4.40-4.52 (1H, m), 5.15 (1H, m) 5.84 (1H, t, 7 6  
Hz, CHjCHjNH). 6.98 (1H, t, 7 7.7 Hz), 7.07 (1H, t, 7  7.3 Hz), 7.16 (1H, d, 7
I.5 Hz), 7.33 (1H, d, 7 8  Hz), 7.45-7.58 (4H, m), 7.91 (2H, d, 7 7 Hz), 8.52 
(1H, d, 7 6 . 6  Hz), 8.67 (1H, d, 7 8.1 Hz), 10.82 (1H, d, NH on indole); 8 c 
(100.6 MHz, DMSO-d6) 18.3 (CH3), 25.0 (CH^, 44.5 (CH2), 49.8 (CH), 57.0 
(CH), 72.4 (CH2), 111.9-128.7, ( P h c H ) ,  131.8 ( P h C q u a t e m a ly ) ,  134.6 
( P h C q u a t e m a r y ) ,  136.8 (Phcquatemary)’ 1 5 9 3  (Cquatemary). 166.8 (OC=0 ), 173.4 
(NC=0), (1 x Plicquatemaiy not seen); m/z (+FAB) 420 (M+ + H, 100%), 105 
(57). (-FAB) 418 (M+ - H, 100%), 258 (8 ), 227 (8 ), 135 (35), 92 (28).
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3,4-Dehydroproline was synthesised according to a literature procedure from 
(2S,4R)-[N-(Cbz)]-4-hydroxyproline methyl ester (63), which was in turn 
prepared from (2S,4R)-4-hydroxyproline/106)
(2S)-rN-(Benzvloxycarbonvl)1-3,4-dehvdroproline (67)
To an ice-cooled solution of methyl ester (6 6 ) (13.6 g, 0.052 mol) in methanol 
(150 ml) was added 1M aqueous solution of lithium hydroxide (55 ml). The 
mixture was stirred at room temperature for 6 h. After that time, most of the 
solvent (120 ml) was evaporated under reduced pressure. The mixture was 
than cooled to 0°C and acidified to pHl with 5M aqueous hydrochloric acid. 
On acidification a yellow oil crashed out of solution. The mixture was then 
extracted into dichloromethane (5 x 100ml), dried (Na2 S04), filtered and 
evaporated in vacuo to give N-protected dehydroproline (67) (12.6 g, 98%) as 
an orange oil. \)max (thin film) 3200-2851 (br), 1750-1660 (br) cm"1; 5H 
42.8-4.36 (2H, m), 5.08-5.27 (3H, m), 5.76-5.90 (1H, m, vinyl H), 5.98-6.09 
(1H, m, vinyl H), 6.60-6.90 (1H, s (br), OH), 7.30-7.40 (5H, m, Ph); m/z (C.I.) 
248 (M+ + H, 15%), 202 (28), 91 (100).
The overall yield from (2S,4R)-4-hydroxylproline to N-Cbz-dehydroproline 
was 8 6 %. The NMR spectrum of (67) was checked against a commercially 
available sample of N-Cbz-dehydroproline.
N-Benzylhydroxylamine (7Q)(107)
N-Benzylhydroxylamine (70) was prepared according to literature procedure 
as colourless needles (ethyl acetate-petrol) m.p. 54-56°C (lit./107) 56-57°C); 
W  (nuJo 1  mull> 3 2 6 0  and 3 1 5 0  cm_1; 5h 3-99 (2H, s, CH2Ph), 5.60-5.75 (2H,
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s(br), NH and OH), 7.33-7.35 (5H, m, Ph); mjz (E.I.) 123 (M+, 80%) and 91 
(100).
N-Benzyl-1 -(benzvloxvcarbonyl)-2,5-dihvdro-N-hydroxy-1 -pyrrole- 
carboxamide (72)
To an ice-cooled solution of [N-(Cbz)]-3,4-dehydroproline (67) (12.6 g, 0,05 
mol) in dichloromethane (150 ml) was added N-benzylhydroxylamine (6.85 g, 
0.055 mol), followed by addition of dicyclohexylcarbodiimide (11.8 g, 0.055 
mol). After 5-10 min, a precipitate occurred. The mixture was stirred at room 
temperature for 20h. After that time, the dicyclohexylurea was filtered and 
washed with dichloromethane (5 x 30 ml). The filtrate was then washed with 
1M aqueous hydrochloric acid (100 ml), followed by 1M aqueous potassium 
hydrogen carbonate solution (100 ml) and water (100 ml). The organic extract 
was dried (Na2 S04) and evaporated under reduced pressure to give an oil 
which was purified by chromatography using ethyl acetate-petrol (3:7 v/v) as 
eluant, to give pyrrolecarboxamide (72) (8.74 g, 49%) as a colourless oil 
(Found: M+ + H, 353.1501. C2oH21N20 4 requires 353.1501); omax (CHC13) 
3150 (br), 2900, 1680-1640 (br) cm'1; SH 4.17-4.37 (2H, m, NCHjPh), 4.67 
(1H, dd, J 15 and 5 Hz, vinyl H), 4.87-4.98 (1H, m, vinyl H), 5.00-5.12 (2H, 
m, COjCHjPh), 5.65-5.69 ( 1 H, m, 5-H), 5.80-5.85 (1 H, m, 5-H), 5.95-6.00 
(1H, m, 2-H), 7.29-7.34 (10H, m, Ph), 9.40-9.50 (1H, s (br), OH); 8c 28.9 
(CH), 33.8 (CH), 52.0 (CH2), 53.7 (CH2), 63.5 (CH), 67.6 (CH2), 125.3-128.5 
(PhCH). 135.9 (Phcquatemary)» 155.2 (PhcqUatemary)» 168.2 ( C q U.i [ e m .!ry ) , (  1 X  0 = 0  
not seen); m/z (CL) 353 (M+ + H, 4%) and 91 (100).
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(4R)-Phenvlseleno-2-fN-(bcnzvl)1-2H-pyrrolor2t3-d1isoxazolidine-3-onc (73)
To an ice-cooled solution of (72) (8.75 g, 0.025 mol) in dichloromethane (50 
ml) was added phenylselenenyl chloride (4.55 g, 0.024 mol). As the reaction 
proceeded the solution changed from red to a yellow colour and the mixture 
was stirred at room temperature until all the starting material had disappeared 
(2h) as judged by TLC. Silver tetrafluoroborate (4.78 g, 0.024 mol) was then 
added to the ice-cooled solution and was further stirred in the dark for 1.5h at 
room temperature. The silver salts were removed by filtration through celite 
and the solids washed with dichloromethane (2 x 30 ml). The combined 
filtrate was poured into water (100 ml) and extracted into dichloromethane (3 
x 100 ml). The extracts were dried (Na2 S04) and evaporated under reduced 
pressure to give an oil which was purified by chromatography using ethyl 
acetate-petrol (3:7 v/v) as eluant, to give the minor phenylselenenyl product 
(74) (1.94 g, 16%) followed by the isoxazolidinone (73) (8.1 g, 64%) as a 
yellow oil.
Isoxazolidinone (73): (Found: M+ + H, 509.0980. C^H^h^C^Se requires 
509.0985); omax (thin film), 3050, 3020, 2970 (br), and 1690 cm’1; 5H (400 
MHz, DMSO-d6, 75°C) 3.65 (1H, dd, /  12.5 and 6  Hz, 5-H), 3.78 (1H, dd, J
12.5 and 2.5 Hz, 5-H), 3.91 (1H, dt, /  6  and 2 Hz, 4-H), 4.62 (1H, d, J 15.9 Hz, 
part of AB system), 4.69 (1H, d, J 15.9 Hz, part of AB system), 5.02 (1H, 
d(br), /  7 Hz, 2-H), 5.09 (1H, d, J  13.6 Hz, part of A'B' system), 5.10 (1H, dd, 
J 6 . 8  and 2.3 Hz, 3-H), 5.15 (1H, d, J  12.5 Hz, part of A'B' system), 7.25-7.39 
(13H, m), 7.51-7.54 (2H, m); 6 C 41.6 (CH), 48.8 (CH^, 51.0 (CH2), 61.7 
(CH), 67.6 (CH2), 85.2 (CH), 127.6-129.5 ( P h C H ) ,  135.3 ( P h C q u a t e m a x y ) .  135.5 
( P h C q u a te m a iy )>  148-2 ( P h C q Ua te m a r y )»  I 6 0 -8  (C=0), (1 X  C=0 not Seen); m/z 
(CL) 509 (M+ + H, 5%), 507 (3), 506 (2), 91 (60).
Compound (74): (Found M+ + H, 465.1109. C^H^h^C^Se requires
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465.1076); omax (thin film) 3050, 3020, 2910, 2790 and 1680 cm 1; 5H (400 
MHz, DMSO-d6, 60°C) 2.80 (1H, dd, J 10.5 and 4.9 Hz, 5-H), 3.14 (1H, dd, /
10.5 and 5.9 Hz, 5-H), 3.72 (1H, ddd, J  6 , 4.9 and 2.5 Hz, 4-H), 3.98 (lH,d, J
13.2 Hz, part of AB system), 4.05 (1H, d, J 13.2 Hz, part of AB system), 4.13 
(1H, d, /  7 Hz, 2-H), 4.60 (1H, d, /  16 Hz, part of A'B' system), 4.72 (1H, d, /  
16 Hz, part of A'B' system), 5.07 (1H, dd, /  7 and 2.3 Hz, 3-H), 7.28-7.35 
(13H, m), 7.47-7.50 (2H, m); 5C 44.7 (CH), 48.5 (CHj), 54.8 (CH2), 56.3 
(CH2), 6 6 . 2  (CH), 86.4 (CH), 128.0-133.8 ( P h c H ) ,  135.0 ( P h C q u a t e m a r y ) ,  138.2 
(Pl^ Cquatemaiy)» 163.5 (CqUa^erna]y), (1 x CqUa[emary not seen), m/z (C.I.) 465 (M 
+ H, 30%), 91 (100).
rN-(Benzvloxvcarbonvl)-(a^)-hexahvdro-2-rN-(benzvl)l-2H-pyrrolor2.3-dl- 
isoxazolidine-3-one (75)
To a solution of (73) (8.1 g, 0 .0 1 6  mol) in toluene (100  ml) in a sealed tube 
was added tributyltin hydride (11 ml, 0 .047  mol), followed by a catalytic 
amount of azobisisobutyronitrile. The mixture was heated at 100°C  for 5h. 
Removal of solvent followed by purification by chromatography, using ethyl 
acetate-petrol (1:1 v/v) as eluant, gave the deselenated cis-fused bicycle (75) 
(5.1 g, 91% ) as a colourless oil; (Found: M+ 352 .1436 . C2oH20N 20 4 requires 
352.1423); umax (thin film) 3060 , 3 020 , 2 9 5 0  and 1690 cm"1; 5H 1 .99-2 .30  
(2H , m, 5-C H 2), 3 .16 -3 .3  (1H , m), 3 .7 4 -3 .9 4  (1H , m (br)), 3 .68  (2H , s, 
N C H 2Ph), 4 .8 5 -5 .0 6  (2H , m ), 5 .1 7 -5 .2 5  (2H , m , C 0 2CH2Ph), 7 .2 8 -7 .5 2  (10H , 
m , Ph x 2); 6C 30 .6  (C H ^ , 44 .8  (CH 2), 48 .7  (CH 2), 6 2 .6  (C H ), 67 .5  (CH2), 
8 1 .0  (CH ), 128 .0 -128 .6  (PhCH), 134.7 (PhCqUatemary). 136.4 (PhCqUatemaiy),
164.5 (C=0), (1 x C=0 not seen); m/z (E.I.) 352 (M+, 100%) and 91 (63).
Using the above procedure, the minor adduct (74) (1.28 g, 2.7 mmol) was 
deselenylated to afford a compound (75b) (604 mg, 73%) as a yellow oil;
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(Found M+ + H, 309.1603. C19H2iN202 requires 309.1603); \)max (CHC13) 
2920, 2840 and 1675 cm'1; 5H 1.90-1.99 (1H, m, 5-H), 2.02-2.12 (1H, m, 5-H),
2.64-2.89 (2H, m, 4 -CH2), 3.93 (1H, d, J  7.5 Hz, 2-H), 4.05 (1H, d, J 12 Hz, 
part of AB system), 4.15 (1H, d, J  13.5 Hz, part of AB system), 4.65 (1H, d, J 
15 Hz, part of A'B' system), 4.75 (1H, d, /  16 Hz, part of A'B' system), 4.93 
(1H, td, J  6.8 and 2.2 Hz, 3-H), 7.26-7.40 (10H, m, Ph x  2); 5C 32.3 (CH2),
48.3 (CHj), 50.7 (CH2), 55.6 (CH2), 67.0 (CH), 81.0 (CH), 126.9-128.8 
(PhCH), 135.1 (P hcquatemary), 138.5 (PhCqualemary)> 166.1 ( O O ) ;  m/z (C L ) 309 
(M+ + H, 100%), 216 (11), 91 (74). (+FAB) 309 (M+ + H, 100%), 217 (8), 202 
(5), 91 (98).
fris)-Hexahvdro-2-rN-(benzvl)l-2H-pvnolor2,3-dlisoxazolidine-3-one (76)
To a solution of isoxazolidine-3-one (75) (125 mg, 3.5 mmol) in methanol (5 
ml) was added 20% palladium hydroxide over charcoal catalyst (20 mg). The 
mixture was then subjected to atmospheric hydrogenation for 34h. The 
catalyst was removed by filtration through celite and the solids washed with 
methanol (15 ml). The filtrate was evaporated under reduced pressure to give 
an oil which was purified by chromatography, using dichloromethane- 
-methanol (9:1 v/v) as eluant, to give bicycle (76) (47 mg, 61%) as a 
colourless oil. (Found: M+ 218.1052. C12H14N202 requires 218.1055); \)max 
(thin film) 3300, 2920 and 1675 cm'1; 5H 1.90-2.07 (2H, m, 5-CH2), 2.70-2.91 
(2H, m, NH and 4-H), 3.15 (1H, ddd, J 9.8, 6.7 and 2.2 Hz, 4-H), 4.47 (1H, d, 
J 1 Hz, 2-H), 4.63 (1H, d, J 15.6 Hz, part of AB system), 4.74 (1H, d, J 15.4 
Hz, part of AB system), 4.98-5.05 (1H, m, 3-H), 7.30-7.36 (5H, m, Ph); 5C 
(Methanol-d4) 28.9 /  29.0 (CH2), 44.3 /  44.5 (CH2), 57.4 /  57.5 (CH2), 65.7 /
66.5 (CH), 81.9 /  82.4 (CH), 128.7-130.9 (PhCH), 139.5 (PhCquatemaxy), 164.9 /
165.7 (C=0); m/z (70eVE.I.) 218 (M+, 11%), 128 (8), 85 (100).
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Attempt to N-dcbenzylatc rN-(Benzyloxvcarbonvl)l-(ci.s)-hexahvdro- 
-2-fN-(benzyl)l-2H-pvrrolor2.3-d1isoxazolidine-3-one (75) with 
Iodotrimethylsilane
Iodotrimethylsilane was generated according to literature procedure^111) from 
trimethylsilylchloride (0.23 ml, 1.8 mmol) and anhydrous sodium iodide (4.10 
mg, 2.7 mmol) in acetonitrile (5 ml). To this mixture was added bicycle (75) 
(144mg, 0.4 mmol) in acetonitrile (1.5 ml). The mixture was stirred at room 
temperature for lh and then heated at reflux for 45 min, by which time 
compound (76) was observed by TLC along with the disappearance of starting 
material. The mixture was then further heated at reflux for 72h. On returning 
the solvent was removed in vacuo and the mixture suspended in 
dichloromethane and the solids were removed by filtration and the filtrate was 
evaporated under reduced pressure to afford an oil. The oil was purified by 
chromatography, using ethyl acetate-petrol ( 1 : 1  v/v) and dichloromethane- 
-methanol (9:1 v/v) as eluant, to give isoxazolidine-3-one (76) (36 mg, 40%).
Other methods attempted to remove the N-benzyl residue from compound (75) 
and (76) included the Hard acid-Soft nucleophile approach (CF3 SO3 H and 
anisole)(104) and dissolving metal reduction (Na /  NH3 )^ 112\  In both cases 
N-debenzylation was unsuccessful and in the former reaction the 
isoxazolidine-3-one (76) was isolated in 80% yield.
l-rN-(Benzvloxvcarbonvl)-3-hvdroxvl-N-(phenvlmethvl)-2-pyrrolidine- 
carboxamide (77)
To a solution of isoxazolidine-3-one (75) (108 mg, 0.3 mmol) in methanol (5 
ml) was added ammonium formate (81 mg, 1.3 mmol) and 10% palladium 
over charcoal (109 mg). The mixture was left to stir at room temperature.
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After 3.5h, starting material (75) had disappeared and [N-(benzyl)]- 
-pyrrolo[2,3-d]isoxazolidinone (76) was be seen by TLC. The mixture was 
then left to stir at room temperature for 20h. On returning, more ammonium 
formate (216 mg, 3.4 mmol) and catalyst (179 mg) were added and the 
reaction was left to stir at room temperature for another 24h. After that time, 
the catalyst was removed by filtration through celite and the solids washed 
with methanol (15 ml). The filtrate was evaporated under reduced pressure to 
give a colourless solid which was dissolved in 1M aqueous sodium 
bicarbonate (1 ml), cooled to 0°C and a solution of benzyl chloroformate 
(0.044 ml, 0.3 mmol) in dioxane (1 ml) was added. The mixture was stirred at 
0°C for 0.5h and then at room temperature for 2h. After that time, the mixture 
was extracted with ether (2 x 10 ml), dried (Na2S04) and concentrated in 
vacuo to afford an oil. The aqueous layer was cooled to 0°C and acidified to 
pHl with 5M aqueous hydrochloric acid. The mixture was then extracted with 
dichloromethane (3 x 10 ml), dried (Na2S04), filtered and evaporated under 
reduced pressure to give an oil. The two oils were combined and purified by 
chromatography using ethyl acetate-petrol as eluant, to give the
3-hydroxypyrrolidine (77) (30 mg, 28%) as a colourless solid, m.p. 131-133°C 
(ethyl acetate-petrol) (Found: C, 67.5; H, 6.17; N, 7.99. C20H22N2O4 requires 
C, 67.78; H, 6.25; N, 7.90%): umax (nujol mull) 3280, 1705, 1690 and 1645 
cm’1; 8h 2.05-2.16 (2H, m, 4 -CH2 ), 2.28-2.45 (2H, m, 5-CH2), 3.53-3.79 (2H, 
m, 2-H and NH or OH), 4.37-4.62 (4H, m, NCH2OPh, 3-H, NH or OH), 5.14 
(2H, s, C 02CH2Ph), 7.27-7.37 (10H, m, Ph x 2); m/z (C.I.) 355 (M+ + H, 




To an ice-cooled solution of isoxazolidine-3-one (76) (256 mg, 1.1 mmol) in 
THF ( 8  ml) was added 4-bromobenzoyl chloride (286 mg, 1.3 mmol) and
4-dimethylaminopyridine (162 mg, 1.3 mmol). The mixture was stirred at 0°C 
for 15 min and then at room temperature for 20h. After that time, the solvent 
was evaporated under reduced pressure and the crude solid was purified by 
chromatography using ethyl acetate- petrol as eluant, to afford the 
N-(4-bromobenzoyl) derivative (78) as a solid. Recrystallisation from ethyl 
acetate afforded (78) (153 mg, 38%) as a colourless needles, m.p. 143-145°C 
(Found: C, 56.8; H, 4.23; N, 6.98. C^H^Brh^C^ requires C, 56.85; H, 4.27; 
N, 6.98%); \)max (nujol mull) 1680 and 1620 cm'1; 5H 2.0-2.10 (2H, m, (br),
4-CH2), 4.62-4.82 (4H, m, 5-CH2  and CH2 Ph), 5.02-5.10 (2H, m), 7.36 (5H, s, 
Ph), 7.58 (4H, d, /  6  Hz, COPh-Br); m/z (70eV E.I.) 402 (M+, 100%), 400 




(2S,4R)-[N-(Cbz)]-4-hydroxyproline (62) (1.5 g, 5.7 mmol) was coupled with
O-benzylhydroxylamine (707 mg, 5.7 mmol) in the presence of 
dicyclohexylcarbodiimide (1.34 g, 6.4 mmol) in dichloromethane (30 ml) 
under standard peptide coupling procedure/105^  The pyrrolidinecarboxamide 
derivative (80) (1.1 g, 52%) was isolated as a colourless solid, m.p. 130-131°C 
(EtOAc-Petrol) (Found: C, 64.88; H, 6.02; N, 7.58. C2 oH2 2 N2 0 5  requires C, 
64.85; H, 5.99; N, 7.56%); umax (nujol mull) 3470, 3260, 1690 and 1675 cm'1; 
5h 2.13-2.25 (1H, m, 3-H), 2.50-2.60 (1H, m, 3-H), 3.49-3.57 (2H, m, 5-CH2),
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4.26-4.34 (1H, m), 4.50-4.58 (1H, m), 4.86-4.93 (2H, m, NCIfcPh), 5.05 (1H, 
d, J 12.5 Hz, part of AB system), 5.10 (1H, d, J 12.6 Hz, part of AB system), 
7.32-740 (10H, m, Ph x 2), 9.57 (1H, s, NH /  OH), (1 x NH /  OH not seen); 
m/z (+FAB) 371 (M+ + H, 40%), 91 (100); (-FAB) 369 (M+ - H, 100%), 352 
(20), 272 (5), 256 (5), 93 (6 ).
l-rN-(Benzvloxvcarbonvl)1-(4R)-Hvdroxvl-N-(phenylmethoxv)-(2S)- 
-pyrrolidinecarboxamide (81)
To an ice-cooled solution of pyrrolidinecarboxamide (80) (500 mg, 1.3 mmol) 
in pyridine (3 ml) was added methanesulphonyl chloride (0.1 ml, 1.3 mmol). 
The mixture was stirred at 0°C for 4h and then left in a freezer (-23°C) for 
20h. On returning, the mixture was diluted with dichloromethane (30 ml) and 
washed with 1M aqueous hydrochloric acid (20 ml) and water (2 x 20 ml). 
The dichloromethane extract was dried (Na2 S04) and evaporated under 
reduced pressure to give a solid which was recrystallised from ethyl acetate to 
afford the mesylated product (81) (408 mg, 65%) as a colourless solid, m.p. 
130-132°C (Found: C, 56.2; H, 5.33; N, 6.2. C ^ H ^ N ^ S  requires C, 56.25; 
H, 5.40; N, 6.24%); omax (nujol mull) 3400,1705 and 1670 cm'1; 5H 2.27-2.38 
(1H, m, 3-H), 2.76-2.87 (1H, m, 3-H), 2.98 (3H, s, S 0 2 Me), 3.60-3.68 (1H, m, 
5-H), 3.92 (1H, d, J  12 Hz, 5-H), 4.34 (1H, t, J  7.5 Hz, 2-H), 4.86 (1H, d, J
11.5 Hz, part of AB system), 4.93 (1H, d, J 11.2 Hz, part of AB system), 5.06 
(1H, d, J 12.5 Hz, part of A'B' system), 5.14 (1H, d, /  12.3 Hz, part of A'B' 
system), 5.24-5.33 (1H, m, 4-H), 7.31-7.42 (10H, m, Ph x 2), 9.46 (1H, s, NH); 
m/z (+FAB) 449 (M+ + H, 9%), 207 (4), 91 (51).
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(4R)-Methanesulphonvloxv-N-(hydroxv)-(2S)-pyrrolidinecarboxamide (82)
To a solution of pyrrolidinecarboxamide (81) (12.26 g, 0.027 mmol) in 
methanol (700 ml) was added 10% palladium over charcoal catalyst (2.48 g). 
The mixture was then subjected to atmospheric hydrogenation for 3h and, after 
which time, the solution was filtered through celite and the solids were washed 
with methanol (200 ml). The filtrate was evaporated under reduced pressure 
to give a brown oil/solid which was then suspended in dichloromethane (50 
ml) and filtered. The filtered solid was found to be the doubly deprotected 
material (82) (5.2 g, 8 6 %) m.p. 118-119°C (MeOH) (Found: C, 32.13; H, 5.40; 
N, 12.1. C6H12N2 0 5S requires C, 32.15; H, 5.39; H, 12.49%); omax (nujol 
mull) 3260, 3200 and 1650 cm'1; 6 H (DMSO-d6) 1.95-2.05 (1H, m, 3-H),
2.12-2.21 (1H, m, 3-H), 2.94-3.02 (1H, m, 5-H), 3.10-3.21 (4H, m, S 02Me and
5-H), 3.61 (1H, t, /  8  Hz, 2-H), 5.18-5.21 (1H, m, 4-H), (2 x NH and 1 x OH 
not seen); m/z (E.I.) 224 (M+, 100%), 164 (42).
NOTE: The filtrate was evaporated under reduced pressure and *H NMR 
showed that it was a mixture.
An attempt to cvclise (4R)-Methanesulphonyloxv-N-(hvdroxv)-(2S)- 
-pyrrolidinecarboxamide (82) with Triethylamine
To an ice-cooled solution of hydroxamic acid (82) (238 mg, 1.0 mmol) in 
methanol (4 ml) was added dropwise triethylamine (2 ml). The mixture was 
then left in a freezer (-23°C) for 48h. After that time, TLC (reverse phase) 
showed that only starting material was present. The mixture was then left to 
stir at room temperature for 2  days, but again, only starting material was 
observed and isolated, as proven by *H NMR.
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1 - IN-( rerr-B utyloxvcarbonvDl -(4R)-Methanesulphon ylox v-N - (hydroxy)- (2S )- 
-pyiTolidinecarboxamidc (83)
To an ice-cooled suspension of hydroxamic acid (82) (101 mg, 0.45 mmol) in 
THF/water (2:1) (5 ml) was added di-rm-butyldicarbonate (109 mg, 0.5 
mmol). The mixture was stirred at room temperature for 20h. After that time, 
the solvent was removed in vacuo to give a solid which was suspended in 
dichloromethane (3 ml) and filtered to give the N-BOC material (83) (56 mg) 
m.p. 161-166°C (EtOH) (Found: C, 40.9; H, 6.29; N, 8.65. Cn H2 oN2 0 7S 
requires C, 40.74; H, 6.22; N, 8.63%); \)max (nujol mull) 3360, 3200 and 1655 
cm*1; 8 h (Methanol-d4) 1.45 (9H, s, COMe3), 2.21-2.34 (1H, m, 3-H), 
2.46-2.58 (1H, m, 3-H), 3.12 (3H, s, S 0 2 Me), 3.66-3.86 (2H, m, 5-CH2),
4.13-4.27 (1H, m, 2-H), 5.29-5.34 (1H, m, 4-H), (1 x NH and 1 x OH not 
seen); m/z (+FAB) 325 (M+ + H, 38%), 308 (14), 269 (100), 225 (61), 165 
(23).
l-rN-(2,2,2-Trichloroethvloxvcarbonvl)l-(2S,4R)-Hvdroxylproline (85)
(2S,4R)-4-Hydroxyproline (1.73 g, 0.013 mol) was selectively N-protected 
with 2,2,2,-trichloroethyl chloroformate in the presence of 1M aqueous 
sodium bicarbonate solution (26 ml) at 0°C for 1.5h and then at room 
temperature for another 1.5h, as described in the synthesis of (4R)- 
-[N-(FMOC)amino]-3-isoxazolidinone (14). [N-(TROC)]-4-Hydroxy-proline 
(85) was isolated as an oil (3.89 g, 97%); pmax (nujol mull) 3300 (br), 1725 
and 1670 cm'1; 6 H (DMSO-d6) 1.90-2.23 (1H, m, 3-H), 2.12-2.28 (1H, m,
3-H), 3.35-3.58 (2H, m, 5 -CH2), 4.20-4.36 (2H, m, 2-H and 4-H), 4.77 (1H, d, 
J 12.3 Hz, part of AB system), 4.88 (1H, d, J  12.8 Hz, part of AB system), 
5.17-5.30 (1H, s (br), OH), (1 x OH not seen); m/z (CL) 310 (M+ + H, 20%), 
308 (M+ + H, 50%), 306 (M+ + H, 56%), 276 (8 ), 274 (40), 277 (6 8 ), 272 (6 8 ).
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l-rN-(2,2,2-Trichloroethvloxvcarbonvl)l-(4R)-Hvdroxyl-N-(phenvlmethoxv)- 
-(2S)-pyrrolidinecarboxamide (8 6 )
[N-(TROC)]-(2S,4R)-4-Hydroxyproline (85) (281 mg, 0.9 mmol) was coupled 
with O-benzylhydroxylamine (124 mg, 1 mmol) as described for the 
conversion of [N-(Cbz)]-hydroxyproline (62) to the O-benzylhydroxamic acid 
(80). Pyrrolidine (8 6 ) (203 mg, 55%) was isolated as a colourless solid, m.p, 
161-162°C (ethyl acetate-petrol) (Found: C, 43.6; H, 4.05; N, 6.65. 
Ci5 H1 7 Cl3 N2 0 5  requires C, 43.76; H, 4.16; N, 6.80%); umax (nujol mull) 3370, 
3250, 1700 and 1670 cm 1; SH (DMSO-d6) 2.05-2.15 (2H, m, 3-CH2), 
3.42-3.60 (2H, m, 5 -CH2), 4.18-4.36 (2H, m), 4.63-4.95 (4H, m, O C^Ph  and 
CH2 CC13), 5.10-5.21 (1H, s (br), OH), 7.37-7.39 (5H, s (br), Ph), 11.34-11.36 
(1H, m, NH); m/z (CL) 415 (M+ + H, 1.7%), 413 (M+ + H, 5%), 411 (M+ + H, 
6 %), 379 (0.9), 377 (1.4), 262 (14), 107 (46), 91 (100).
l-rN-(2,2.2-Trichloroethvloxvcarbonyl)l-(4R)-Methanesulphonvloxv-N- 
-(phenylmethoxv)-(2S)-pyrrolidinecarboxamide (87)
O-Benzylhydroxamic acid (8 6 ) (1.35 g, 3 mmol) was O-mesylated with 
methanesulphonyl chloride (0.28 ml, 36 mmol) in pyridine (3.5 ml) at -23°C, 
for 20h. Pyrrolidinecarboxamide (87) (1.4g, 96%) was isolated as a colourless 
oil, following the procedures employed for the conversion of the [N-(Cbz)] 
derivative (80) to (81); *umax (CHC13) 3350 (br), 2920 (br) and 1710 cm'1; 8 H 
2.36-2.48 (1H, m, 3-H), 2.79-2.89 (1H, m, 3-H). 3.06 (3H, s, S 0 2Me), 3.74 
(1H, dd, J 12.7 and 4.5 Hz, 5-H), 4.00-4.57 (1H, m, 5-H), 4.34 (1H, t, J 7.5 
Hz, 2-H), 4.62 (1H, d, J 11.9 Hz, part of AB system), 4.80 (1H, d, J 12.1 Hz, 
part of AB system), 4.90-4.99 (2H, m), 5.31-5.37 (1H, m), 7.39 (5H, s, Ph),




-N-(hvdroxv)-(2S)-pyrrolidinecarboxamide (8 8 )
To a solution of pyrrolidine (87) (217 mg, 0.44 mmol) in methanol (5 ml) was 
added 10% palladium over charcoal catalyst (47 mg). The mixture was then 
subjected to atmospheric hydrogenation for 20h. After that time, the catalyst 
was removed by filtration through celite and the solids washed with methanol 
(20 ml). The filtrate was evaporated under reduced pressure to give the 
hydroxamic acid (8 8 ) (122 mg, 69%) as an oil which later solidified and was 
recrystallised from ethyl acetate as a colourless solid, m.p. 168.6-169.1°C 
(Found: C, 27.6; H, 3.38; N, 6.84. requires C, 27.05; H, 3.28;
N, 7.00%); pmax (nujol mull) 3340, 3250 and 1675 cm’1; 8 H (DMSO-d6) 
2.14.2.28 (1H, m, 3-H), 2.38-2.46 (1H, m, 3-H), 3.25 (3H, s, S 0 2 Me),
3.65-3.85 (2H, m), 4.13-4.20 (1H, m), 4.77-4.93 (2H, m, C l^C C y, 5.27-5.38 
(1H, m), 9.19 (1H, s, NH), 10.14 (1H, s, OH); m/z (+FAB) 399 (M+ + H, 
91%), 338 (20), 244 (36).
NOTE: Subsequent runs afforded (8 8 ) in the range of 69-96% yield.
Octahvdro-7-r(methanesulphonv)oxvl-pyrrolor 1 ,2-dl \ 1,2,51oxadiazine (8 8 b) 
from cvclisation of l-[N-(2,2,2-trichloroethvloxvcarbonyl)l- 
-(4R)-methanesulphonvloxyN-(hvdroxv)-(2S)-pvrrolidinecarboxamide (8 8 ) 
with Triethylamine
To a solution of hydroxamic acid (8 8 ) (85 mg, 0.21 mmol) in methanol (1.5 
ml) was added triethylamine (0.03 ml, 0.23 mmol. TLC of the mixture after 
1.5h at room temperature showed mostly starting material. The mixture was 
then heated at 60°C for 2h. After that time, the solvent was removed under 
reduced pressure to give an oil. The oil was dissolved in dichloromethane (10
-126-
ml) and washed with saturated aqueous ammonium chloride solution ( 2  ml). 
The dichloromethane extract was dried (Na2 S0 4 ) and concentrated in vacuo to 
give an oil which was purified by chromatography, using dichloromethane- 
-methanol (9:1 v/v) as eluant, to give oxadiazine (8 8 b) (14 mg, 27%) as an oil; 
0)max (CHC13) 3260 (br), 2910, 1785 and 1725 cm’1; 5H (DMSO-d6) 2.01 (1H, 
ddd, J 13.9, 11.4 and 5.5 Hz, 3-H), 2.47 (1H, dd, J  13.9 and 6 . 6  Hz, 3-H), 3.06 
(3H, s, S 0 2 Me), 3.41 (1H, d, /  13.2 Hz, 5-H), 3.90 (1H, dd, J 13.1 and 5.5 Hz,
5-H), 4.34 (1H, dd, J 11 and 6 . 6  Hz, 2-H), 5.39 (1H, t, /  5.1 Hz, 4-H), (1 x NH 
not seen); 5C (DMSO-d6) 34.0 (CH2), 37.9 (CH3), 52.3 (CH^, 59.1 (CH), 82.5 
(CH), 157.7 (Cquaternary), (1 x C=0 not seen); m/z (+FAB) 251 (M+ + H, 
1.4%), 149 (100); (-FAB) 249 (M+ - H, 26%), 95 (100).
An accurate molecular ion was not found for oxadiazine (8 8 b).
NOTE: Heating a solution of (8 8 ) ( 8 6  mg, 0.21 mmol) in dimethylformamide 
(1 ml) in the presence of sodium hydride (60% dispersed in oil, 10 mg, 0.25 




To a solution of pyrrolidine (8 6 ) (238 mg, 0.57 mmol) in methanol (5 ml) was 
added 10% palladium over charcoal catalyst (49 mg). The mixture was then 
subjected to atmospheric hydrogenation for 2h. After that time, the catalyst 
was removed by filtration through celite and the solids washed with methanol 
(20 ml). The filtrate was evaporated under reduced pressure to give 
hydroxamic acid (89) as an oil (178 mg, 97%); omax (CHC13) 3400 (br), 2930, 
1700 (br) cm’1; SH (Methanol-d4) 2.05-2.28 (2H, m (br), 3-CH2), 3.56-3.68 
(2H, m (br), 5-CH2), 4.38-4.48 (2H, m, 2-H and 4-H), 4.69-4.85 (2H, m,
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CH2 CC13), ( 1  x  NH and 1 x  OH not seen); m/z (C.I.) 322/320 (M+, 0.8%), 290 
(0.7), 288 (1), 287 (0.8), 286 (0.7).
(2S.4R)-rN-(l-oxo-2.2-Dimethvloxopropyl)1hvdroxvproline (91)
To an ice-cooled solution of (2S,4R)-4-Hydroxyproline (580 mg, 4.4 mmol) in 
1M aqueous sodium bicarbonate (8 . 8  ml, 8 . 8  mmol) was added a solution of 
trimethylacetyl chloride (0.6 ml, 4.8 mmol) in dioxane (5 ml) over a period of 
2h. The mixture was further stirred at 0°C for 4h and then at room 
temperature for 20h. After that time, the mixture was extracted with ether (2 x 
10 ml) and the aqueous layer cooled to 0°C and acidified with 5M aqueous 
hydrochloride acid to pHl. The product was extracted into ethyl acetate ( 6  x 
20 ml), dried (Na2 S04) and concentrated in vacuo to give the [N-(l-oxo-2,2- 
-dimethylpropyl)]hydroxyproline (91) as a colourless solid. Recrystallisation 
from ethanol-ether afforded (91) (548 mg, 54%) m.p. 169-170°C (Found: C, 
56.1; H, 8.1; N, 6.57. C1oH1 7N 0 4  requires C, 55.8; H, 7.96; N, 6.50%); omax 
(nujol mull) 3250, 1735 cm'1; 8 H (Methanol-d4) 1.25 (9H, s, COCMe3 ), 1.95 
(1H, ddd, /  13.5, 9.0 and 4.5 Hz, 3-H), 2.15-2.26 (1H, m, 3-H), 3.73-3.89 (2H, 
m, 5-CH^, 4.46-4.55 (2H, m, 2-H and 4-H), (2 x OH not seen); m/z (C.I.) 216 
(M+ + H, 100%), 200 (15), 154 (20), 8 6  (24).
Large scale preparation of l-rN-(l-oxo-2,2-dimethvlpropvlYl-(4R)-Hvdroxyl- 
-N-(phenvlmethoxv)(2S)-pyrrolidinecarboxamide (92)
To an ice-cooled solution of (91) (40.8 g, 0.19 mmol) in dichloromethane (11) 
and dimethylformamide (15 ml) was added portionwise 1-hydroxybenzo- 
-triazole hydrate (33.4 g, 0.24 mol) followed by dicyclohexylcarbodiimide 
(47.0 g, 0.23 mol). The suspension was stirred at 0°C for 1.25h, followed by 
dropwise addition of a solution of O-benzylhydroxylamine (28.6 g, 0.23 mol)
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in dichloromethane (100ml). A further 400 ml of dichloromethane was added 
to the mixture and the mixture was stirred at 0°C for another lh and then at 
room temperature for 20h. After that time, the dicyclohexylurea was removed 
by filtration and the solids washed with dichloromethane (800 ml). The 
filtrate was then washed with 2M aqueous hydrochloric acid (500 ml), 1M 
aqueous sodium bicarbonate (600 ml) and brine (600 ml). The 
dichloromethane extract was dried (Na2 S0 4 ), filtered and evaporated under 
reduced pressure to give, after recrystallisation from ethyl acetate, 
N-(phenylmethoxy)pyrrolidinecarboxamide (92) (40.89 g, 67%) as a 
colourless solid, m.p. 176-177°C (Found: C, 63.60; H, 7.61; N, 8.72. 
CnH^NjC^ requires C, 63.73; H, 7.55; N, 8.74%); *umax (nujol mull) 3240, 
3250 (br), 3140, 1670 and 1620 cm 1; 8 H 1.21 (9H, s, COCMes), 2.04-2.22 
(2H, m, 3-CH2), 3.70 (1H, dd, /  11 and 4 Hz, 5-H), 3.90 (1H, d, /  11 Hz, 5-H), 
4.44-4.57 (2H, m, 2-H and OH), 4.90 (2H, s, CH2 Ph), 5.57 (1H, d, J 10.6 Hz,
4-H), 7.34-7.41 (5H, m, Ph), 10.02 (1H, s, NH); m/z (CL) 321 (M+ + H, 
0.5%), 198 (48), 170 (60), 152 (31), 91 (100).
l-rN-(l-oxo-2,2-dimethvlpropyl)l-(4R)-Methanesulphonvloxv-N- 
-(phenvlmethoxv)-(2S)-pyrrolidinecarboxamide (93)
4-Hydroxyl-2-pyrrolidinecarboxamide (92) (56.3 g, 0.17 mmol) was
O-mesylated with methanesulphonyl chloride (0.015 ml, 0.19 mmol) using 
procedure described earlier for the synthesis of (81). Mesylate (93) (46 mg, 
67%) was isolated as a colourless oil (Found: M+ + H, 399.1590. 
Ci8H2 7 N20 6S requires 399.1590); Pmax (thin film) 3420 (br), 3200, 2960, 
2220, 1680 and 1610 cm'1; 6 H 1.22 (9H, s, COCMe3), 2.17-2.29 (1H, m, 3-H), 
2.76-2.83 (1H, m, 3-H), 3.04 (3H, s, S0 2 Me), 3.69-3.77 (1H, m, 5-H), 4.24 
(1H, d, J 12.5 Hz, 5-H), 4.61-4.68 (1H, m), 4.86-4.94 (2H, m, CT^Ph),
5.34-5.40 (1H, m), 7.35-7.43 (5H, m, Ph), 10.45 (1H, s, NH); 6 C 27.2 (CMeQ,
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32.2 (CH2), 38.3 (S0 2 Me), 53.8 (CH2), 56.9 (CH), 73.0 (CH2), 79.3 (CH), 
128.5-129.0 (PhCH), 135.1 (PhCquatemary)> 168.7 (C=0 ), 178.2 (C=0 ), ( 1  x 
CMe3  not seen); m/z (+FAB) 399 (M+ + H, 13%), 276 (100), 91 (41); (-FAB) 
397 (M+ - H, 2.4%), 95 (100).
Synthesis of l-rN-(l-oxo-2,2-dimethylpropyl)l-(4R)-Methanesulphonvloxv- 
-N-(phenylmethoxv)-(2S)-pyrrolidinecarboxamide (93) from l-fN-CTROOI- 
-(4R)-methanesulphonvIoxv-N-(phenvlmethoxv)-(2S)-pyiTolidinecarboxamide
m
To a solution of [N-(TROC)]-pyrrolidinecarboxamide derivative (87) (221 mg, 
0.45 mmol) in acetic acid (3 ml) was added zinc powder (218 mg) and the 
mixture was stirred at room temperature for 20h. After that time the solids 
were removed by filtration through celite and the solids washed with methanol 
(15 ml). The filtrate was evaporated under reduced pressure to give an oil. 
The oil was dissolved in dichloromethane (15 ml) and washed with 1M 
aqueous sodium bicarbonate (2 ml), dried (Na2 S04) and concentrated in vacuo 
to give an oil. The oil was redissolved in dichloromethane (4 ml), cooled to 
0°C and trimethylacetyl chloride (0.06 ml, 0.45 mmol) and pyridine (0.036 ml, 
0.45 mmol) was added. The mixture was stirred at 0°C for 3.5h. After that 
time, another 7 ml of dichloromethane was added to the mixture and the 
mixture was washed with 1M aqueous hydrochloric acid ( 2 x 4  ml). The 
organic layer was separated, dried (Na2 S04) and evaporated under reduced 
pressure to give an oil (340 mg). Purification by chromatography using ethyl 
acetate-petrol as eluant, gave the [N-(l-oxo-2,2-dimethylpropyl)J adduct (93) 





0-Benzylhydroxamic acid (93) (53 mg, 1.3 mmol) was O-debenzylated under 
an atmosphere of hydrogen in the presence of palladium over charcoal catalyst 
( 1 2 2  mg), using the same procedure described earlier for the debenzylation of 
[N-(TROC)]-(4R)-methanesulphonyloxy-N-(phenylmethoxy)-(2S)- 
-pyrrolidinecarboxamide (87). Hydroxamic acid (94) (41 mg, 100%) was 
isolated as an oil, which later solidified and was recrystallised from ethanol to 
give (94) as a colourless solid, m.p. 156.5-157.5°C (Found: C, 42.7; H, 6.57; 
N, 9.08. Cn H2 oN2 0 6S requires C, 42.85; H, 6.54; N, 9.08%); \)max (CHC13) 
3320 (br), 2930 (br), 1673 and 1610 cm’1; 6 H (DMSO-d6) 1.15 (9H, s, 
COCMe3), 1.80-2.10 (1H, m, 3-CH), 2.23-2.34 (1H, m, 3-CH), 3.25 (3H, s, 
S 0 2 Me), 3.78-3.85 (1H, m, 5-H), 4.04-4.11 (1H, m, 5-H), 4.22-4.32 (1H, m),
5.34-5.40 (1H, m), 10.14 (1H, s, NH /  OH), (1 x NH /  OH not seen); m/z 
(+FAB) 309 (M+ + H, 26%), 276 (100), 248 (29).
1-rN-(l-oxo-2,2-Dimethvlpropyl)l-3-(hvdroxvimino)-2-oxa-5-azabicvclo- 
r2.2.11heptane (95)
To an ice-cooled solution of pyrrolidine (94) (2.92 g, 9.5 mmol) in 
dimethylformamide (13 ml) was added sodium hydride (60% dispersion in oil, 
424 mg, 10 mmol). After stirring at 0°C for 15 min, a thick suspension formed 
and the mixture was then warmed to 60°C and then allowed to stir at room 
temperature for 20h. After that time, the dimethylformamide was evaporated 
under reduced pressure and the mixture was dissolved in dichloromethane (30 
ml) and washed with saturated ammonium chloride solution (20 ml). The 
aqueous layer was further extracted with dichloromethane ( 2 0  ml) and the 
combined organic extracts were dried (Na2 S04) and concentrated in vacuo to
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give an oil. Purification by chromatography using ethyl acetate-petrol (4:6 
v/v) to (7:3 v/v) as eluant, gave azabicycle (95) (670 mg, 33%) as colourless 
needles, m.p. 208-209°C (ethanol-ether), [a]22-^  -48.23° (c 0.51 in MeOH) 
(Found: C, 56.9; H, 7.77; N, 13.2. C10H16N2 O3  requires C, 56.59; H, 7.60; N, 
13.19%); vmax (nujol mull) 3360 (br), 1680 cm*1; 8 h (DMSO-dg) 1.17 (9H, s, 
COCMeO, 1.95-2.10 (2H, m, 3-CH2), 3.40-3.65 (2H, m, 5-CH2), 5.10-5.20 
(2H, m, 2-H and 4-H), 9.62 (1H, s, NH); 8 C (DMSO-dg) 27.4 (CM*,), 52.9 
(CH2), 57.6 (CH), 79.1 (CH), 155.7 (COCMeA 174.8 (NC=0), (1 x CMe3  
and 1 x CH2  not seem); m/z (70eV E.I.). 212 (M+, 4.6%), 8 6  (6 ); (C.I.) 213 
(M+ + H, 13%), 197 (100), 170 (76), 85 (30).
NOTE: Azabicycle (95) was similarly obtained by heating hydroxamic acid 
(94) (61 mg, 0.19 mmol) with triethylamine (0.05 ml, 0.35 mmol) in THF (4 
ml) at 80-100°C for 6  days. Purification by chromatography afforded (95) (3.4 
mg, 7%) followed by starting material (94) (14 mg, 22%). Azabicycle (95) 
obtained from this method was verified by comparison of JH NMR spectra 
will that obtained from the above reaction.
l-rN-BenzvloxvcarbonvlYl-2-(hvdroxyimino)-2-oxa-5-azabicvclor2.2.n- 
heptane (99)
Azabicycle (95) (53 mg, 0.25 mmol) was dissolved in trifluoroacetic acid and 
water (4:1) (2 ml) and heated at 70-90°C for 1.5h. After this time, the solvent 
was evaporated under reduced pressure to give an oil which was then 
dissolved in 1M aqueous sodium bicarbonate solution (0.5 ml), cooled to 0°C 
and a solution of benzyl chloroformate (0.04 ml, 0.28 mmol) in dioxane (1 ml) 
was added dropwise, over a period of 10 min. The mixture was stirred at 0°C 
for 4h and at room temperature for 20h. After that time, the mixture was 
washed with ether ( 2 x 5  ml) and the aqueous layer was cooled to 0°C and
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acidified to pHl with 5M aqueous hydrochloric acid. The aqueous mixture 
was then extracted with ethyl acetate ( 5 x 5  ml) and separated. The organic 
extracts were dried (Na2 S04) and concentrated in vacuo to give an oil. 
Purification by chromatography, using ethyl acetate-petrol as eluant, afforded 
the N-benzyloxycarbonyl derivative of azabicycle (99) (24 mg, 37%) as an oil 
(Found: M+ + H, 263.1032. requires 263.1032); Dmax (CHCI3 )
3350 (br), 2920, 1780 and 1670 cm*1; 5H (Methanol-d4) 1.94-2.08 (1H, m,
3-H), 2.26-2.40 (1H, m, 3-H), 3.27-3.36 (1H, m, 5-H), 3.52-3.60 (1H, m, 5-H), 
4.22-4.32 (2H, m, 2-H and 4-H), 4.97-5.14 (2H, m, CB,Ph). 7.23-7.28 (5H, m, 
Ph), (1 x OH not seen); m/z (C.I) 263 (M+ + H, 5%), 202 (15), 108 (14), 91 
(100).
l-[N-(l-oxo-2.2-dimethvlpropyl)1-(4R)-hvdroxvl-N-(hvdroxv)-(2S)- 
-pyrrolidinecarboxamide (1 0 0 )
O-Benzylhydroxamic acid (92) (5.26 g, 16 mmol) in methanol (100 ml) was
O-debenzylated under atmospheric hydrogenation conditions in the presence 
of 10% palladium over charcoal catalyst (1.03 g) for 20h. After that time, the 
catalyst was removed by filtration through celite and the solids washed with 
methanol (50 ml). The filtrate was evaporated under reduced pressure to give 
hydroxamic acid (100) (2.79 g, 74%) as colourless needles, m.p. 188-190°C 
(ethanol-ether) (Found: C, 52.5; H, 8.02; N, 12.0. C1oH18N2 0 4  requires C, 
52.16; H, 7.88; N, 12.16%) omax (nujol mull) 3460, 3250 (br), 1655 and 1625 
cm'1; 5h (DMSO-d6) 1.14 (9H, s, CMe-0 , 1.68-1.81 (1H, m, 3-CH), 1.82-194 
(1H, m, 3-CH), 3.54-3.68 (2H, m, 5 -CH2 ), 4.23 (1H, t, J  8  Hz,2-H), 4.28-4.37 
(1H, m 4-H), 5.02 (1H, d, J, 3 Hz, 4-OH), 8.75 (1H, s, NH), 11.24 (1H, s, 
NOH); m/z (+FAB) 231 (M+ + H, 72%), 198 (100), 170 (33), 8 6  (25). (-FAB) 
229(M+ -H , 100%).
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1 - f T1 -(t-Butvlcarbonvl)-pvrrolidin-2-yllcarbonvlamino-oxv) -1 -
-(ethoxvcarbonyamino)carbamic acid, ethyl ester (1 0 1 )
To a cooled suspension of hydroxamic acid (100) (123 mg, 0.53 mmol) in 
THF (5 ml) was added triphenylphosphine (284 mg, 1 mmol) followed by 
dropwise addition of diethylazodicarboxylate (0.17 ml, 1 mmol) which gave a 
yellow solution. The mixture was stirred at 0°C for lh. After that time, the 
solvent was removed in vacuo and the mixture was purified by 
chromatography using ethyl acetate-petrol as eluant, to afford triphenyl- 
-phosphine oxide, followed by ester (101) (125 mg, 58%) as a colourless oil; 
\)max (thin film) 3440 (br), 2980, 1790, 1740 and 1620 cm'1; 8 H 1.24 (9H, s, 
COCMe3), 1.40 (3H, t, J 7 Hz, CHjCHJ, 1.46 (3H, t, /  7 Hz, CH3 CH2 ),
2.26-2.47 (2H, m, 3-CH2), 2.80-2.87 (1H, m, OH), 3.91 (1H, d, J 10.8 Hz,
5-H), 4.06-4.16 (2H, m, 5-H and NH), 4.18-4.28 (1H, m), 4.39-4.59 (4H, m, 
CH3 CH2  x2), 4.66-4.73 (1H, s (br), 4-H), 6.11 (1H, t, J 7.5 Hz, 2-H); 5C 24.2 
(CMeQ, 27.2 and 27.3 (CH3  x2), 36.9 (CH2), 38.9 (CMe3), 56.9 (CH2), 63.7 
(CH2), 65.5 (CH2), 65.9 (CH), 70.4 (CH), 148.1 (Cquatemary), 148.9 
( ^ • q u a t e r n a r y ) ’ 151.4 ( C q U a t e r n a r y ) ,  177.5 ( C q U a t e m a r y ) .
NOTE: No molecular ion was found for this compound.
2-rm-Butvl- l-aza-3-oxabicyclor3.3.01octan-4-one (102)
(102) was prepared following the procedure given by Glaxo Group Research 
(Greenford) rather than literature procedure/123^  were difficulties were 
encountered upon isolation of this material.
Into a 250 ml round bottom flask was placed a suspension of (L)-proline 
( 1 0 . 1 2  g, 0.088 mol), trifluoroacetic acid (0 . 2  ml) and trimethylacetaldehyde 
(23 ml, 0.019 mol) in dichloromethane (150 ml). The mixture was heated at
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reflux under nitrogen in a Soxhlet apparatus, with dried 3A molecular sieves 
in the Soxhlet thimble. After heating for 48h with four changes of fresh 
molecular sieves and with all the proline in solution. The solvent was then 
removed under reduced pressure to give a red/brown oil, which was 
immediately suspended in dry hexane (10 ml) and stoppered. The orange 
solution was then transferred via cannular under nitrogen into a dry 1 0 0  ml 
round bottom flask containing 20 ml of dry hexane. The mixture was then 
allowed to stand at room temperature for 2 0  min, so that any unreacted 
(L)-proline precipitated. The liquid was then transferred into a dry 100 ml 
round bottom flask again via cannular under nitrogen and evaporated under 
reduced pressure to give the bicycle (102) (15.23 mg, 95%) as a red/orange 
oil, which was immediately sealed and stored under nitrogen. 
NOTErSpectroscopic data was not collected due to the high susceptibility of 
the compound (1 0 2 ) to moisture.
(2R)-Methylbenzyl ether-(2S)-pyrrolidinecarboxvlic acid (105)
To a solution of diisopropylamine (1.57 ml, 0.01 mol) in THF (15 ml) at -78°C 
was added dropwise n-butyllithium (1.26M in hexane, 8.9 ml, 0.01 mol). The 
resulting solution was stirred at -78°C for 15 min and then at 0°C for 5 min. 
The solution was then recooled to -78°C and a solution of bicycle (102) (1.37 
g, 7.4 mmol) in THF (2 ml) was added dropwise and the resulting orange 
solution was then stirred at -78°C for lh. After that time, a solution of benzyl 
chloromethyl ether*124) (103) (1.2 g, 7.6 mmol) in THF (2 ml) was added 
dropwise. The mixture was then further stirred at -78°C to -30°C for 2h and at 
room temperature for 20h. On returning, the mixture was diluted with ether 
(20 ml) and acidified to pH6  with 2M aqueous hydrochloric acid ( 6  ml). The 
ether layer was separated and then washed with water (3 x 10 ml), dried 
(MgS04) and concentrated in vacuo to give a brown oil which was redissolved
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in methanol ( 6  ml) and water (1.5 ml). To this mixture was added silica gel 
(Merck 9385 1.9 g). The mixture was then stirred at room temperature for 7h. 
On returning, the silica gel was removed by filtration and washed with 
methanol (50 ml). The filtrate was evaporated under reduced pressure to give 
an orange oil which was purified by chromatography using 
dichloromethane-methanol (9:1 v/v) and then with methanol as eluant, to give 
the a-alkylated adduct (105) (380 mg, 22%) which recrystallised from ethanol 
as a colourless solid, m.p. 238-249°C (dec.) (Found: C, 66.2; H, 7.35; N, 5.93. 
Ci3 H1 7N0 3  requires C, 66.36; H, 7.28; N, 5.95%); \>max (nujol mull) 3075, 
2480 and 1610 cm'1; 8 H (DMSO-d6) 1.62-1.88 (3H, m), 2.00-2.08 (1H, m), 
2.98-3.09 (1H, m), 3.23-3.40 (1H, m), 3.56 (1H, d, J 9.9 Hz, part of AB 
system), 5.89 (1H, d, J  9.9 Hz, part of AB system), 4.50 (2H, s, PhCH?Q), 
7.36 (5H, s, Ph), 8.30-8.80 (2H, s (br), NH and OH); m/z (+FAB) 236 (M+ + 
H, 100%), 190 (15), 91 (38); (-FAB) 234 (M+ - H, 100%).
l-rN-(l-oxo-2,2-dimethvlpropylYl-(2R)-Methvlbenzvl ether-(2S)-pyrrolidine- 
carboxylic acid (107)
To an ice-cooled solution of a-benzylmethylether adduct (105) (830 mg, 3.5 
mmol) in pyridine (3 ml) was added trimethylacetyl chloride (0.46 ml, 3.7 
mmol). The mixture was stirred at 0°C for 2h and then at room temperature 
for 20h. After that time, the mixture was diluted with ethyl acetate (30 ml) 
and washed with 1M aqueous hydrochloric acid (15 ml) and the aqueous layer 
was then further extracted with ethyl acetate (10 ml). The combined organic 
extracts were dried (Na2 S04) concentrated in vacuo and the residue purified 
by chromatography, using ethyl acetate-petrol as eluant, to afford the 
N-protected pyrrolidine (107). Recrystallisation from ethyl acetate-petrol 
afforded (107) (751 mg, 6 8 %). rap. 112-113°C [a]21D+56.9° (c 1.06 in 
methanol)(Found: C, 67.4; H, 7.83; N, 4.33. C18H25N04 requires C, 67.69; H,
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7.89; N, 4.38%); umax (nujol mull) 3020 (br) and 1725 cm'1; SH 1.27 (9H, s, 
COCMe3), 1.93-2.09 (2H, m), 2.19-2.32 (2H, m), 3.57-3.70 ( 1 H, m), 3.82-3.94 
(2H, m), 4.13-4.22 (1H, m), 4.49-4.60 (2H, m, PhCH2 0), 7.24-7.39 (5H, m, 
Ph), (1 x OH not seen); m/z (CL) 320 (M+ + H, 100%), 274 (10), 212 (24), 
200 (18), 91 (47).
l-rN-(l-oxo-2,2-Dimethylpropvl)1-(2R)-Methvlbenzvl ether-N- 
-(phenylmethoxv)-(2S)-pyrrolidinecarboxamide (108)
Pyrrolidine (107) (319 mg, 0.98 mmol) in dichloromethane ( 6  ml) was coupled 
to O-benzylhydroxylamine (124 mg, 1.0 mmol) in the presence of
1-hydroxybenzotriazole hydrate (178 mg, 1.3 mmol) and dicyclohexyl- 
carbodiimide (274 mg, 1.3 mmol) as described for the conversion of (62) to 
(80) and pyrrolidinecarboxamide (108) (248 mg, 60%) was isolated as a 
colourless oil (Found: M+ + H, 425.2440, C2 5 H3 3 N2 O4  requires 425.2440); 
Umax in film) 3270 (br), 1670 and 1625 cm'1; 8 h 1.22 (9H, s, COCMe3), 
1.78-1.99 (2H, m), 2.05-2.21 (2H, m), 3.53 (1H, d, J 9.2 Hz, part of AB 
system), 3.57-3.64 (1H, m), 3.76-3.85 (1H, m), 4.23 (1H, d, J 9  Hz, part of AB 
system), 4.34 (1H, d, J 11.7 Hz, part of A'B' system), 4.42 (1H, d, J 11.7 Hz, 
part of A'B' system), 4.86 (1H, d, J  11.2 Hz, part of A"B" system), 4.94 (1H, 
d, J 11.4 Hz, part of A"B" system), 7.12-7.19 (2H, m), 7.26-7.39 (6 H, m), 
7.41-7.46 (2H, m), 9.57 (1H, s, NH); 8 C 24.3 (CH2), 27.2 (CMeQ, 33.2 (CH2),
39.2 (CMe3), 49.8 (CH2), 70.4 (2-Cqualemary), 70.8 (CH2), 77.8 (CH2), 
127.5-129.3 ( P h C H ) ,  135.6 ( P h C q u a te rn a ry )>  137.3 ( P h C q U a te m a ry )>  170.5 
(C=0),178.5 (NC=0); m/z (+FAB) 425 (M+ + H, 37%), 302 (87), 91 (100); 




To a solution of O-benzylhydroxamic acid (108) (62 mg, 0.14 mmol) in 
methanol (3 ml) was added 10% palladium over charcoal catalyst (17 mg) and 
the mixture was then subjected to atmospheric hydrogenation for 1.45h. After 
that time, the catalyst was removed by filtration through celite and the solids 
washed with methanol (15 ml). The filtrate was evaporated under reduced 
pressure to give an oil which was purified by chromatography, using ethyl 
acetate-petrol (1:1 v/v) as eluant, to give hydroxamic acid (109) (34 mg, 72%) 
as a colourless oil (Found: M+ + H, 335.1971. C18H2 7 N2 0 4  requires 
335.1970); \)max (thin film) 3250 (br), 1660 and 1615 (br); 8 H 1.24 (9H, s, 
COCMe3), 1.81-2.05 (2H, m), 2.16-2.28 (2H, m), 3.61 (1H, d, J  9 Hz, part of 
AB system), 3.61-3.69 (1H, m), 3.81-3.90 (1H, m), 4.25 (1H, d, /  9 Hz, part of 
AB system), 4.47 (1H, d, J 12 Hz, part of A'B' system), 4.63 (1H, d, J 12 Hz, 
part of A'B' system), 7.28-7.42 (5H, m, Ph), 7.79-8.20 (1H, s (br), OH), 9.70 
(1H, s, NH); 5C 24.4 (CH2), 27.2 (CMeQ, 33.3 (CH2), 39.3 (CMe3), 49.9 
(CH2), 70.3 (CH2), 71.4 (2-Cquaternaiy), 73.4 (CH2), 127.6-128.4 (PhCH), 137.3 
(Phcquatemary). 171.9 (0=0), 177.1 (NOO); m/z (+FAB) 335 (M+ + H, 
54%),302 (100), 374 (54), 190 (22), 91 (77). (-FAB) 333 (M+ - H, 100%), 311 
(25), 227 (28), 135 (73), 106 (8 8 ).
l-rN-(l-oxo-2.2-Dimethyl- l-oxopropy)1-(2R)-Methvlbenzvl ether-(2S)- 
-pyrrolinecarboxamide (1 1 0 )
To a solution of N-(hydroxy)-(2S)-pyirolidinecarboxamide (109) ( 8 8  mg, 0.26 
mmol) in methanol (4 ml) was added ammonium formate (80 mg, 1.2 mmol) 
and 10% palladium over charcoal catalyst (46 mg). The mixture was stirred at 
room temperature for lh and then heated at 70-75°C for 2h. After that time,
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the catalyst was removed by filtration through celite and washed with 
methanol (10 ml). The filtrate was evaporated under reduced pressure to give 
an oil which was dissolved in ethyl acetate (15 ml) and washed with brine (3 
ml). The ethyl acetate extract was dried (Na2 S04) and concentrated in vacuo 
to give an oil which was purified by chromatography, using ethyl 
acetate-petrol (7:3 v/v) as eluant, to afford amide (110) (30 mg, 36%) as a 
colourless solid, m.p. 126-128°C (ethyl acetate-petrol) (Found: M+ + H, 
319.2022. C1 8H2 7 N2 O3  requires 319.2021); \)max (nujol mull) 3460, 3280, 
1685 and 1615 cm'1; 8 H 1.25 (9H, s, COCMe3), 1.82-2.02 (2H, m), 2.08-2.24 
(2H, m), 3.54 (1H, d, /  9 Hz, part of AB system), 3.64 (1H, td, /  9.8 and 7 Hz), 
3.87 (1H, td, J 9.9 and 6  Hz), 4.40 (1H, d, J 9 Hz, part of AB system), 4.49 
(1H, d, J 11.9 Hz, part of A'B' system), 4.63 (1H, d, J 11.9 Hz, part of A'B' 
system), 5.22-5.29 (1H, m, NH), 6.82-6.98 (1H, s (br), NH), 7.30-7.38 (5H, m, 
Ph); 6 C 24.6 (CH2), 27.3 (CMe-Q, 33.5 (CH2), 39.2 (CMe3), 49.8 (CH2), 70.6 
(2-Cquatemary), 71.2 (CH2), 73.4 (CHJ,  127.6-128.5 (PhCH), 137.4 
(Phcquatemaiy). 175.1 (O O ), 177.3 (NC=0); m/z (C.I.) 319 (M+ + H, 11%), 
302 (100), 274 (58), 229 (30); (+ FAB) 319 (M+ + H, 100%), 302 (79), 274 
(83), 91 (70).
Further attempts to remove the O-benzyl residue in compound (109) using 
boron trifluroetherate and ethanethiol^125^  and dissolving metal reduction 
(Na/EtOH)^126^  were unsuccessful.
1 -fN-( 1 -oxo-2.2-dimethvlpropvl)1-(2R)-hvdroxvmethvl-(2S)-pyrrolidine- 
carboxylic acid (1 1 1 )
Pyrrolidine derivative (107) (188 mg, 0.59 mmol) in methanol (7 ml) was
O-debenzylated in the presence of 10% palladium over charcoal catalyst (42 
mg) under atmospheric hydrogenation conditions. The reaction took 1.45h to
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complete. The mixture was filtered through celite and the solids washed with 
methanol (20 ml). Evaporation of the filtrate under reduced pressure afforded 
the 2-(hydroxymethyl) derivative (111) (133 mg, 98%) as a colourless solid, 
m.p. 286-288°C (ethanol-ether) (Found: C, 57.4; H, 8.35; N, 5.93. CnH^NQ* 
requires C, 57.62; H, 8.35; N, 6.10%); omax (nujol mull) 3400 and 1725 cm"1; 
5h (Methanol-d4) 1.26 (9H, s, COCMe3), 1.93-2.08 (3H, m), 2.21-2.31 (1H, 
m), 3.61-3,70 (1H, m), 3.84 (1H, d, J  11.7 Hz, part of AB system), 3.94-4.05 
(1H, m), 4.13 (1H, d, /  11.3 Hz, part of AB system), (2 x OH not seen); m/z 
(CL) 230 (M+ + H, 100%), 212 (7), 198 (3).
l-rN-(l-oxo-2,2-DimethvlpropylYl-(2R)-(hvdroxvmethvl)-N- 
-(phenylmethoxv)-(2S)-pvrrolidinecarboxamide (112) and 
(2R)-rHvdroxvmethvl-(l,l-dimethvlpropanoate)1-2-(N-phenvlmethoxyl)- 
-(2S)-pyrrolidinecarboxamide (113)
The 2-(hydroxymethyl) derivative (111) (690 mg, 3.0 mmol) was suspended in 
dichloromethane (10 ml) and dimethylformamide (3 ml) and coupled to
O-benzylhydroxylamine (471 mg, 3.8 mmol) in the presence of 1-hydroxy- 
-benzotriazole hydrate (511 mg, 3.7 mmol) and dicyclohexylcarbodiimide 
(780 mg, 3.7 mmol) as described for the conversion of (61) to (80). The 
mixture was stirred at room temperature for 2 days. After that time, the 
dicyclohexylurea was removed by filtration and washed with ethyl acetate (25 
ml). The filtrate was evaporated under reduced pressure to give an oil which 
was dissolved in ethyl acetate (30 ml), washed with saturated aqueous 
ammonium chloride solution (5 ml), dried (Na2 S0 4) and concentrated in 
vacuo to give an oil. Purification by chromatography, using ethyl 
acetate-petrol as eluant, afforded 1,1-dimethylpropanoate derivative (113) (85 
mg, 8 %) followed by the N-(phenylmethoxy)-2-pyrrolidinecarboxamide (112) 
(301 mg, 30%) as colourless crystals.
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Compound (112) m.p. 156-5-157-5°C (ethyl acetate-petrol) (Found: C, 64.3; 
H, 7.83; N, 8.31. C18H2 6 N2 0 4  requires C, 64.65; H, 7.77; N, 8.36%); \)max 
(nujol mull) 3240, 1650 and 1620 cm 1; SH 1.25 (9H, s, COCMe3), 1.60-1.71 
(1H, m), 1.79-1.90 (1H, m), 2.05-2.19 (2H, m), 3.53-3.63 (1H, m), 3.70 (1H, d, 
J  12.5 Hz, part of AB system), 3.87 (1H, d, J 12.3 Hz, part of AB system), 
3.95-4.03 (1H, m), 4.89 (2H, s, NOCH2), 7.32-7.45 (5H, m, Ph), 7.76-7.81 
(1H, m, OH), 9.56 (1H, s, NH); m/z (Cl.) 335 (M+ + H, 8 %), 184 (100), 154 
93), 91 (62).
(113): isolated as a colourless oil (Found: M+ + H 335.1971. C1 8H2 7N2 0 4  
requires 335.1970); \)max (thin film) 3280, 3140 (br), 1725 and 1655 (br) cm'1; 
6 h 1.18 (9H, s, COCMe3), 1.72-1.83 (3H, m), 1.85-2.02 (1H s (br), NH), 
2.04-2.18 (1H, m), 2.76-2.85 (1H, m), 2.90-3.01 (1H, m), 4.12 (1H, d, J 11.2 
Hz, part of AB system), 4.42 (1H, d, J 11.2 Hz, part of AB system), 4.87 (1H, 
d, /  11.2 Hz, part of A'B' system), 4.98 (1H, d, /  11 Hz, part of A'B' system),
7.34-7.44 (5H, m, P h ) ,  9.82-10.02 (1H, s (br), NH); 8 C 25.0 (CH^, 27.0 
(CMe3 ), 33.4 (CH2 ), 38.7 (Cquatemary), 46.7 (CH2), 66.9 (CH2), 69.0 
( Q u a t e r n a r y ) ,  78.0 (CH2), 128.4-129.7 ( P h C H ) ,  135.0 ( P h c q u a t e m a r y ) ,  170.7 
(0=0), 178.1 (NC=0); m/z (C.I.) 335 (M+ + H, 10%), 184 (100), 91 (65).
Further attempts to increase the yield of compound (112) such as changing 
reaction conditions and using more reactive coupling agents, such as BOP-C1 
and BOP Reagent were unsuccessful {See Chapter 4; Table 8).
l-rN-(l-oxo-2,2-dimethvlpropvl)1-(2R)-(Hvdroxvmethyl)-N-(hvdroxv)-(2S)- 
-pyrrolidinecarboxamide (114)
Pyrrolidine (112) (99 mg, 0.29 mmol) in methanol (5 ml) was debenzylated in 
the presence of 10% palladium over charcoal catalyst (23 mg) under 
atmospheric hydrogenation for 3.5h. The catalyst was removed by filtration
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through celite and the solids washed with methanol (15 ml). The filtrate was 
evaporated under reduced pressure to give a solid. Recrystallisation from 
ethanol-ether afforded hydroxamic acid (114) (46mg, 65%) as a colourless 
needles m.p. 153.5-155.8°C (Found: C, 54.0; H, 8.34; N, 11.47. Cn H2oN20 4 
requires C, 54.08; H, 8.25; N, 11.46%); V)max (nujol mull) 3440, 3250, 3150, 
1620 cm'1; SH (Mcthanol-d4) 1.25 (9H, s, COCMe3), 1.94-2.05 (3H, m),
2.19-2.25 (1H, m), 3.70 (1H, td, J 9.9 and 6 . 8  Hz), 3.85 (1H, d, J  11 Hz, pan 
of AB system), 3.87-3.97 (1H, m), 4.05 (1H, d, /  11 Hz, part of AB system), 
4.89 (2H, s, NH and OH /  2 x OH), (1 x OH /  NH not seen); m/z (+FAB) 245 
(M+ + H, 50%), 212 (100), 184 (60); (-FAB) 243 (M+ - H, 100%), 182 (7), 153 
(17).
4-r(N-l-oxo-2<2-dimethvlpropvl)3-aminopropyll-4-isoxazoline-3-one (115)
To an ice-cooled solution of triphenylphosphine (47 mg, 0.18 mmol) and 
diethylazodicarboxylate (0.028 ml, 0.18 mmol) in THF (2 ml) was added 
hydroxamic acid (114) (26 mg, 0.1 mmol). The mixture was stirred at 0°C for 
2.5h and then at room temperature for 20h. On returning, the solvent was 
evaporated under reduced pressure to give an oil which was purified by 
chromatography, using dichloromethane-methanol (9:1 v/v) as eluant, to give 
isoxazoline-3-one (115) (13.5 mg, 55%) as a colourless oil (Found: M+ + H, 
227.1396. Cn H1 9N2 0 3  requires 227.1396); umax (CHC13) 3370 (br), 3190 (br), 
3020, 1740, 1630 cm 1; 8 H 1-20 (9H, s, COCMe3), 1.71-1.81 (2H, m), 2.34 
(2H, t, /  6 . 8  Hz), 3.34 (2H, q, /  6.5 Hz), 6.15-6.22 (1H, m, NH), 6.55 (1H, d, J
1.3 Hz), 10.18 (1H, s (br), NH); 6 C 20.3 (CHJ, 27.6 (CMe3), 29.3 (CH^, 38.1 
(CH2), 38.8 (CMe3), 124.1 (CH), 126.8 (Cquatemary), 157.0 (0=0), 179.8 
(0=0); m/z (C.I.) 227 (M+ + H, 100%), 169 (12.8), 85 (13).
NOTE: An alternative method for cyclisation of hydroxamic acid (114) to the 
sp/ro-bicycle (IV) using PPh3/CCBr4  was unsuccessful.
N-Chloromethoxyphthlalimide (118/ 134)
To a suspension of N-hydroxyphthalimide (104 mg 0.64 mmol) in 
bromochloromethane (4 ml) was added anhydrous silver(I) oxide (182 mg, 
0.78 mmol). The suspension was heated at 75-80°C for lh. On returning, the 
cooled mixture was filtered through celite and washed with methanol ( 1 0  ml). 
The filtrate was evaporated under reduced pressure to give 
N-chloromethoxyphthalimide (118) as a colourless solid (125 mg, 92%). 
Recrystallisation from ethyl acetate-petrol afford (118) (80 mg, 58%) as 
colourless needles, m.p. 129-130°C (lit./134) 126-128°C (from CHCl3 -petrol)); 
Umax (nujol mull) 1780 and 1730 cm'1; 5H 5.88 (2H, s, CH2 0), 7.79-7.83 (2H, 
m), 7.86-7.90 (2H, m); m/z (70eV E.I.) 211 (M+, 3%), 176 (15), 147 (27), 105 
(100). (Cl.) 212 (M+ + H, 100%), 214 (33), 176 (69), 148 (73), 105 (20).
Reaction of N-chloromethoxyphthalimide (118) with diethyl malonate (119)
To a cooled solution of diethyl malonate (329 mg, 2.0 mmol) in absolute 
ethanol (2 ml) was added sodium (52 mg, 2.3 mmol), followed by dropwise 
addition of a solution of N-chloromethoxyphthalimide (118) (226 mg, 1.0 
mmol) in absolute ethanol (2 ml). The mixture was then stirred at -15°C for 
24h. After that time the mixture was quenched with saturated ammonium 
chloride solution (5 ml) and extracted with ethyl acetate (4 x 15 ml). The 
combined ethereal layers were dried (Na2 S04) and concentrated in vacuo to 
give an oil. Purification by chromatography on silica gel using ethyl 
acetate-petrol as eluant, afforded N-ethyloxymethoxyphthalimide (121) (59 
mg, 25%) and 2-(ethoxymethoxyaminocarbonyl)benzoic acid, ethyl ester 
(122) (28 mg, 27%) as solids.
(121) was isolated as a colourless solid, m.p. 75-78°C(ether-petrol); \)max
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(nujol mull) 1720 cm' 1 and 1450 cm'1; $h (60 MHz) 1.25 (3H, t, /  7 Hz, 
CH2CH3 ), 4.00 (2H, q, /  7 Hz, CH2 CH3 ), 5.10 (2H, s, QCH0Q), 7.70 (5H, s, 
Ph); m/z (C.I.) 222 (M+ + H, 100%), 176 (28), 163 (37), 148 (73).
NOTE: Unsatisfactory microanalytical data was obtained for the above 
compound (1 2 1 ).
(122): Isolated as a colourless solid, m.p. 58-59°C (ether-petrol) (Found: C, 
58.3; H, 6.38; N, 5.15. C1 3H1 7N 0 5  requires C, 58.41; H, 6.41; N, 5.24%); vmax 
(nujol mull) 3140, 1710 and 1630 cm'1; 6 H (60 MHz) 1.05-1.45 (6 H, m, 
CH2 CH3  x2), 3.55-3.95 (4H, m, CH2 CH3 x2), 4.95 (2H, s, OCH2 0), 7.45 (4H, 
s, Ph), 9.15 (1H, s (br), NH); m/z (CI.) 268 (M+ + H, 4%), 177 (100).
NOTE: Compound (121) (19 mg, 16%) and (122) (56 mg, 40%) were 
similarly obtained by adding N-chloromethoxyphthalimide (118) (110 mg, 0.5 
mmol) in absolute ethanol ( 2  ml) to an ice-cooled solution of sodium ethoxide 
[from sodium (12 mg, 0.52 mmol)] in absolute ethanol (3 ml) and stirring the 
mixture at room temperature for 3h. The structures of (121) and (122) were 
confirmed by JH NMR and melting point with the samples obtained from the 
above experiment.
N-Phen ylthiomethoxyphthalimide (125)
To a suspension of potassium bicarbonate (11.1 g, 0.08 mol) in 
dichloromethane (20 ml) was added thiophenol (9.1 g, 0.08 mol). The mixture 
was stirred at room temperature for lh. After that time, a solution of 
N-chloromethoxyphthalimide (4.1 g, 0.02 mol) in dichloromethane (10 ml) 
was added. The resulting mixture was then stirred at 45°C for 3.5 days. On 
returning, the mixture was washed with saturated ammonium chloride solution 
(20 ml) and extracted with dichloromethane (3 x 25 ml). The combined 
dichloromethane extracts were dried (Na2 S 04) and evaporated under reduced
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pressure to give a colourless solid. Purification by chromatography using 
ethyl acetate-petrol as eluant, afforded a solid which was recrystallised from 
ethyl acetate-petrol to give (125) (4.4 g, 76%) as colourless needles, m.p. 
85-86°C (Found: C, 63.4; H, 3.8; N, 4.92. C15Hn N 03S requires C, 63.15; H, 
3.89; N, 4.91%); vmax (CHC13) 3020,1775,1710 and 1570 cm'1; SH (60 MHz) 
5.61 (2H, s, CH2 0), 7.30-7.50 (2H, m), 7.65-7.90 (7H, m); m/z (70eV E.I.) 
285 (M+, 3%), 147 (2). (C.I.) 286 (M+ + H, 3%), 176 (5), 163 (3), 148 (27).
N-Methoxvmethyphtalimide (126)
To an ice-cooled solution of potassium bicarbonate (53 mg, 0.94 mmol) in 
methanol (1.5 ml) was added dropwise thiophenol (72 mg, 0.65 mmol). The 
mixture was stirred at 0°C for 10 min. After that time a solution of 
N-chloromethoxyphthalimide (106 mg, 0.50 mmol) in methanol (2 ml) was 
added. The resulting mixture was stirred at 0°C for 6 h and then at room 
temperature for 1.5 days. On returning, the solvent was evaporated under 
reduced pressure to give an oil. The oil was redissolved in ethyl acetate (10 
ml) and washed with saturated ammonium chloride solution (2 ml). The 
organic extract was dried ( Na2 S04) and evaporated under reduced pressure to 
give a solid which was purified by chromatography, using ethyl acetate-petrol 
as eluant, to give (126) (64 mg, 62%) as a colourless solid, m.p. 116-118°C 
(ethyl acetate-petrol) (Found: C, 57.9; H, 4.3; N, 6.53. C^HgNC^ requires C, 
57.97; H, 4.38; N, 6.76%); uma* (nujol mull) 1700 cm'1; SH (60 MHz) 3.07 
(3H, s), 5.05 (2H, s), 7.80 (4H, s); m/z (C.I.) 208 (M+ + H, 100%), 176 (38), 
163 (23), 148 (81).
Benzylidene glycine ethyl ester (127) was prepared following literature 
procedures/140*
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Reaction between N-Chloromethoxyphthalimide and Imine (127)
To an ice-cooled suspension of potassium rm-butoxide (127 mg, 1.1 mmol) in 
THF (2 ml) at -78°C was added dropwise a solution of imine (127) (213 mg, 
1.1 mmol) in THF (2 ml) and the mixture was stirred at -78°C for 25 min. 
After that time, a solution of N-chloromethoxyphthalimide (197 mg, 0.9 
mmol) in THF (2 ml) was added to the mixture; the solution turned from red 
to yellow during the addition. The mixture was stirred at -78°C for 35 min 
before being quenched with saturated aqueous ammonium chloride solution (3 
ml). The mixture was then extracted with ethyl acetate ( 3 x 6  ml). The 
combined organic layers were dried (Na2 S04) and concentrated in vacuo to 
give a brown oil. This residue was redissolved in absolute ethanol (2 ml), 
cooled to 0°C and a suspension of sodium borohydride (38 mg, 1.1 mmol) in 
absolute ethanol (2 ml) was added. The mixture was stirred for 20 min at 0°C 
before being quenched with 2M aqueous hydrochloric acid (2 ml). The 
mixture was then neutralised to pH6  with 1M aqueous sodium hydrogen 
carbonate and extracted with ethyl acetate ( 3 x 5  ml). The organic layers were 
dried (Na2 S04) and evaporated under reduced pressure to give 
N-benzylglycine ethyl ester as a brown oil (200 mg, 94%); “Umax (thin film) 
3300 (br), 2980 and 1720 cm 1; 8 H (60 MHz) 1.33 (3H, t, CH?CH^, 2.34 (1H, 
s, NH), 3.52 (2H, s), 3.98 (2H, s), 4.37 (2H, q, CH2 CH3), 6.80 (5H, s, Ph); m/z 
(C.I.) 194 (M+ + H, 100%), 148 (45), 120 (33), 91 (90).
Synthesis of N-Iodomethoxyphthalimide(129)
To a suspension of N-chloromethoxyphthalimide (1.27 g, 6.0 mmol) in 
acetone (50 ml) was added anhydrous sodium iodide (10.5 g, 0.07 mol). The 
mixture was heated at reflux for 24h. After that time, the solvent was 
evaporated under reduced pressure to give a solid (998 mg). The solid was
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suspended in dichloromethane (30 ml) and washed with 5M aqueous sodium 
thiosulphate (10 ml). The aqueous layer was then further extracted with 
dichloromethane (3 x 25 ml). The combined organic extracts were dried 
(Na2 S04), filtered and concentrated in vacuo to give a solid. Purification by 
chromatography on silica gel using ethyl acetate-petrol as eluant afforded 
(129) as a solid. Recrystallisation from ethyl acetate-petrol gave (129) (709 
mg, 39%) as colourless needles, m.p. 115-118°C (Found: C, 35.85; H, 1.94; N, 
4.61. C ^IN C ^ requires C, 35.64; H, 1.98; N, 4.62%); vmax (nujol mull) 1710 
cm'1; 5h (60 MHz) 6.00 (2H, s, CB^O), 7.65 (4H, s, Ph); m/z (C.I.) 304 (M+ + 
H, 45%), 176 (100), 148 (47).
2-fr3-t-Butvl-5,6,7,7a-tetrahvdro-l-oxo-lH<3H-pvrrolon,2-cloxazol-7a-vn- 
-carbonyl]-N-(chloromethvoxv)benzamide (130)
To a solution of diisopropylamine (0.67 ml, 4.7 mmol) in THF (5 ml) at -78°C 
was added dropwise n-butyllithium (2.5M in hexane, 1.9 ml, 4.7 mmol). The 
resulting solution was stirred at -78°C for 20 min and then at room 
temperature for 5 min and recooled back to -78°C before a solution of bicycle 
acetal (102) (0.7 g, 3.8 mmol) in THF (2 ml) was added dropwise. The orange 
solution was then stirred at -78°C for 30 min. After that time, a solution of 
N-chloromethoxyphthalimide (118) ( 0.85 g, 4.0 mmol) in THF (5 ml) was 
added dropwise. The mixture was then stirred at -78°C to -30°C for 2.5h. On 
returning, the mixture was diluted with ether (30 ml) and acidified to pH6  with 
1M aqueous hydrochloric acid. The aqueous extract was washed with ether (2 
x 10 ml). The combine ethereal extracts were dried (Na2 S04), filtered and 
evaporated under reduced pressure to give an orange oil (2 g). Purification by 
chromatography on silica gel using ethyl acetate-petrol as eluant afforded 
starting material N-chloromethoxyphthalimide (118) (0.3 g, 35%) and then the 
ring opened phthalimide-adduct (130) (24 mg, 2%) as a solid.
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Recrystallisation from ethyl acetate-petrol afforded (130) as a pale straw 
crystalline solid, m.p. 157-159°C (dec.) (Found: C, 58.4; H, 6.15; N, 6.98. 
C1 9H2 3 N2O5 CI requires C, 57.79; H, 5.87; N, 7.98%); umax (nujol mull) 3300, 
1785, 1730 and 1715 cm4 ; 6 H 0.92 (9H,s, COCMeQ, 1.70-1.89 (2H, m),
2.20-2.37 (2H, m), 2.52-2.61 (1H, m), 2.74-2.81 (2H, m), 3.88 (1H, s(br), NH), 
4.10-4.14 (2H, m, CH20), 7.50-7.90 (4H, m); m/z (+FAB) 395 (M+ + H, 
36%), 397 (12.8), 359 (6 ), 315 (4), 182 (100). (-FAB) 393 (M+ - H, 100%), 
395 (40), 312 (13), 188(48).
N.N'-fBis-rgrr-butyloxvcarbonvP-O-benzylhvdroxvlamine (132)
To a stirred solution of O-benzylhydroxylamine (330 mg, 2.6 mmol) in 
dichloromethane ( 8  ml) was added 4-dimethylaminopyridine (39 mg, 0.32 
mmol) followed by dropwise addition of a solution of di-rm-butyldicarbonate 
(1.36 g, 6  mmol) in dichloromethane ( 8  ml). The yellow solution was then 
stirred at room temperature for 4h. After that time, another 1.4 equiv. of 
di-rm-butyldicarbonate (810 mg, 3.7 mmol) in dichloromethane (5 ml) and 
0.7 equiv. of 4-dimethylaminopyridine (22 mg, 0.18 mmol) was added and the 
mixture was left to stir at room temperature for 20h. On returning, the solvent 
was removed under reduced pressure to give an oil which was purified by 
chromatography, using ethyl acetate-petrol (2:98 v/v to 5:95 v/v) as eluant, to 
give the N,N'-(bis-rm-butyloxycarbonyl) derivative (132) (712 mg, 81%) as a 
colourless solid and further elution afforded the mono-rm-butyloxycarbonyl 
derivative (131) (111 mg, 18%) as a colourless oil.
(132): Isolated as a crystalline solid, m.p. 83-84°C (ethyl acetate-petrol) 
(Found: C, 63.0; H, 7.93; N, 4.25. C17H2 5 N0 5  requires C, 63.14; H, 7.79 N, 
4.33%); \)max (thin film) 2975, 2935 and 1740 cm4 ; 8 H 1.54 (18H, s, COCMe  ^
x 2), 4.90 (2H, s, OCH?). 7.34-7.46 (5H, m, Ph); m/z (+FAB) 324 (M+ + H, 
8 %), 91 (100).
-148-
(131): Isolated as a colourless oil; \)max (thin film) 2930, 1740 (br) cm"1; 8 H 
1.50 (9H, s, COCMe3), 4.19 (2H, s, OCH2), 7.32-7.47 (5H, m, Ph); 8 C 27.9 
(CM©,), 78.9 (CH2) 84.6 (CMe3), 128.4-129.7 (PhCH), 134.4 (PhCquatemaiy), 
150.6 (C=0); m/z (70eV E.I.) 223 (M+, 0.8%), 167 (4.6), 91 (75), 57 (100). 
This compound was not characterised further as it was of no major importance 
to us.
N,N'-(Bis-rgrr-Butvloxvcarbonvl)hvdroxylamine (133)
O-Benzylhydroxamte (132) (632 mg, 1.9 mmol) in methanol (25 ml) was 
debenzylated in the presence of 1 0 % palladium over charcoal catalyst (128 
mg) under atmospheric hydrogenation for 6.5h. After that time, the catalyst 
was removed by filtration through celite and the solids washed with methanol 
(40 ml). The filtrate was evaporated under reduced pressure to give a solid. 
Recrystallisation from ethyl acetate-petrol gave (133) (346 mg, 78%) as a 
colourless crystalline solid, m.p. 88.5-89.5°C (Found: C, 51.6; H, 8.39; N, 
5.89. CjqH^NOs requires C, 51.49; H, 8.21; N, 6.00%); *umax (nujol mull) 
3300 and 1755 cm"1; 8 H 1.54 (18H, s, COCMe3  x2), 6.80 (1H, s(br), OH); 8 C 
28.0 (CMeQ, 84.6 (CMe3), 151.0 (C=0); m/z (+FAB) 234 (M+ + H, 37%), 
178 (100); (-FAB) 232 (M+ - H, 100%), 216 (46), 131 (17).
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APPENDIX
X-Ray Data for l-[N-(Hvdrox\imino)-2-oxa-5-azabic\clo[2.2.11hevtane (95)
Azabicyclo (95) (Figure 27) was recrystallised from ethanol-ether in space group 
P2l2i2lt a = 5.669(2), b = 11.570(3), c = 15.435(3)A, U  = 1071.8A3 and Dc = 1.32 
gem"3  for Z = 4 at room temperature. The data were measured on a Hilger and
f
Watts Y290 four-circle diffractometer in the range of 2<0<24° and were corrected 
for Lorentz and polarization effects but not for absorption. The structure was 
resolved by Direct methods using 1015 reflections of which 721 were unique with 
7^3o(7) and refined using SHELX^141a,b^  suite of programs. In the final least 
squares cycles, the oxygen atoms and N 1 were allowed to vibrate anisotropically. 
All other atoms were treated isotropically. Hydrogen atoms were included at 
calculated positions. Final residuals after 10 cycles of least squares were R = 
0.0894, Rw = 0.0949. Maximum final shift/esd was 0.001. The maximum and 
minimum residual densities were 0.16 and -0 . 1 8 eA' 3  respectively. Final fractional 
atomic coordinates and isotropic thermal parameters, bond distances and angles are 
given in Tables 12,13,14,15,16,17 and 18 respectively.
Crystal Data
A crystal of approximate dimensions 0.3 x 0.3 x 0.3 mm was used for data 
collection.
Molecular Formular C1 0H16O3 N2, M = 212.3, orthorhombic.
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Fractional Atomic Coordinates and Thermal Parameters (A)
Atom X y z U i s o  o r  Ueq (***
N2 - 0 . 1 5 7 3  (18) 0 . 4 7 5 0 ( 7 ) 0 . 2 2 1 8 ( 5 ) 0 . 0 7 9 ( 6 )  ***
01 - 0 . 2 1 7 6 ( 1 3 ) 0 . 2 9 8 1 ( 4 ) 0 . 2 7 7 1 ( 3 ) 0 . 0 2 6 ( 4 )  ***
02 0 . 0 2 8 5 ( 1 2 ) 0 . 4 2 1 0 ( 5 ) 0 . 5 4 2 4 ( 3 ) 0 . 0 2 6 ( 4 )  ***
03 - 0 . 3 9 3 5 ( 1 5 ) 0 . 4 5 8 7 ( 7 ) 0 . 1 9 0 2 ( 5 ) 0 . 0 4 7 ( 5 )  ***
N1 0 . 0 7 4 5 ( 1 4 ) 0 . 3 7 4 7 ( 5 ) 0 . 4 0 4 4  (4) 0 . 0 6 0 ( 2 )
Cl 0 . 1 3 6 6 ( 1 8 ) 0 . 3 7 6 0 ( 7 ) 0 . 3 1 2 2 ( 5 ) 0 . 0 4 0 ( 2 )
C2 0 . 1 7 2 9 ( 2 1 ) 0 . 2 5 6 2 ( 8 ) 0 . 2 9 3 0 ( 7 ) 0 . 0 5 4 ( 3 )
C3 - 0 . 0 6 4 2 ( 1 9 ) 0 . 2 2 8 6 ( 7 ) 0 . 3 2 8 5 ( 5 ) 0 . 0 4 3 ( 2 )
C4 - 0 . 0 6 3 1 ( 1 9 ) 0 . 2 7 4 6 ( 7 ) 0 . 4 1 9 1 ( 5 ) 0 . 0 4 4 ( 2 )
C5 0 . 1 1 2 9 ( 1 7 ) 0 . 4 4 5 8 ( 7 ) 0 . 4 7 2 3 ( 5 ) 0 . 0 3 6 ( 2 )
C6 0 . 2 5 9 2 ( 1 6 ) 0 . 5 4 8 1 ( 7 ) 0 . 4 5 9 2 ( 5 ) 0 . 0 3 9 ( 2 )
C7 0 . 2 5 1 3 ( 2 3 ) 0 . 6 1 7 9 ( 1 0 ) 0 . 5 4 2 0 ( 7 ) 0 . 0 6 6 ( 3 )
C8 0 . 1 6 6 0 ( 2 2 ) 0 . 6 2 1 9 ( 8 ) 0 . 3 8 5 8 ( 6 ) 0 . 0 5 3 ( 3 )
C9 0 . 5 1 4 2 ( 2 6 ) 0 . 5 1 8 8 ( 1 1 ) 0 . 4 3 9 9 ( 8 ) 0 . 0 7 6 ( 4 )
CIO - 0 . 0 8 8 8 ( 1 8 ) 0 . 3 9 0 2 ( 7 ) 0 . 2 6 5 4 ( 5 ) 0 . 0 4 1 ( 2 )
Table 13
Fractional Atomic Coordinates for the Hydrogen Atoms
Atom X y z
H031 - 0 . 4 4 9 5 0 . 5 2 9 8 0 . 1 5 4 3
H032 - 0 . 5 1 1 4 0 . 4 4 5 6 0 . 2 4 4 1
H033 - 0 . 3 9 6 6 0 . 3 8 8 1 0 . 1 4 8 2
H l l 0 . 2 7 5 0 0 . 4 3 3 6 0 . 2 9 7 3
H21 0 . 3 1 7 2 0 . 2 2 0 1 0 . 3 2 8 6
H22 0 . 1 9 2 4 0 . 2 3 8 2 0 . 2 2 4 9
H31 - 0 . 1 0 9 6 0 . 1 4 3 0 0 . 3 2 7 6
H41 0 . 0 2 1 1 0 . 2 2 0 4 0 . 4 6 4 8
H42 - 0 . 2 3 9 8 0 . 2 9 2 8 0 . 4 4 1 0
H71 0 . 3 1 4 8 0 . 5 7 0 5 0 . 5 9 6 2
H72 0 . 0 7 2 0 0 . 6 4 3 3 0 . 5 5 4 3
H73 0 . 3 6 1 6 0 . 6 8 9 0 0 . 5 3 3 6
H81 0 . 1 6 7 1 0 . 5 7 7 0 0 . 3 2 5 5
H82 0 . 2 7 7 7 0 . 6 9 2 9 0 . 3 7 9 8
H83 - 0 . 0 1 2 0 0 . 6 4 7 3 0 . 4 0 0 5
H101 0 . 5 2 2 5 0 . 4 6 9 5 0 . 3 8 1 9
H102 0 . 5 8 6 2 0 . 4 7 3 3 0 . 4 9 3 7
H103 0 . 6 1 5 3 0 . 5 9 2 5 0 . 4 3 0 5
Table 17
Intermolecular Distances (A)
N2 . . . H 7 1 2 . 8 0
N2 . . . H 3 1 2 . 6 6
01  . . . H 2 1 2 . 9 1
01  . . . H 8 2 2 . 7 7
02  . . .H102 2 . 6 9
0 2  . . . 0 3 2 . 8 2
02  . . . H 0 3 1 1 . 8 8
02  . . . H 0 3 3 2 . 9 5
02  . . . H 2 1 2 . 9 0
02  . . . H 3 1 2 . 9 8
02  . . . H 4 2 2 . 9 4
0 3  . . . H l l 2 . 5 2
0 3  . . . H 7 1 2 . 8 2
0 3  . . . H72 2 . 6 4
H 0 3 1 . . . C 5 2 . 9 7
H 0 3 2 . . . C l 2 . 4 1
H 0 3 3 . . .C7 2 . 6 0
C4 . . . H 4 1 2 . 9 6
C4 . . . H 4 2 2 . 9 5
0 . 0 1 . 0 0 . 0
0 . 0 - 1 . 0 0 . 0
1 . 0 0 . 0 0 . 0
0 . 0 0 . 0 0 . 0
1 . 0 0 . 0 0 . 0
- 1 . 0 1 . 0
0H1
- 1 . 0 1 . 0 - 1 . 0
- 1 . 0 1 . 0 - 1 . 0
0 . 0 0 . 0 1 . 0
- 1 . 0 0 . 0 1 . 0
- 1 . 0 0 . 0 1 . 0
1 . 0 0 . 0 0 . 0
- 1 . 0 1 . 0 0 . 0
- 1 . 0 1 . 0 0 . 0
- 1 . 0 1 . 0 0 . 0
1 . 0 0 . 0
oo
- 1 . 0 1 . 0 0 . 0
0 . 0 0 . 0 1 . 0























HI ...01 2.73 HI .. .02 2.22
HI ...Hll 2.13 HI ...C2 2.32
HI ...H21 2.62 HI ...C3 2.28
HI ...H41 2.13 HI ...H42 2.12
HI . . .C6 2.52 HI ...H81 2.81
HI ...H101 2.81 HI ...CIO 2.34
H2 ...01 2.35 H2 ... H031 2.07
H2 ...H032 2.07 H2 ...H033 2.06
H2 ...Cl 2.49 H2 ...Hll 2.76
H2 . . . H81 2.74 01 ...03 2.S8
01 ...H032 2.51 Ol ...H033 2.49
01 ...Cl 2.29 01 --C2 2.29
01 . . . H22 2.S7 01 ...H31 2.14
01 ...C4 2.38 01 ...H42 2.53
02 ...C4 2.67 02 ...H41 2.73
02 ...H42 2.69 02 ...C6 2.40
02 ...C7 2.72 02 ...H71 2.58
02 ...H72 2.74 03 ...CIO 2.24
H032...CIO 2.SI H033I...C10 2.51
Cl ...H21 2.18 Cl ...H22 2.18
Cl ...C3 2.15 Cl ...C4 2.36
Cl ...CS 2.62 Cl ...H81 2.48
Cl ...H101 2.69 Hll ...C2 2.2S
Hll . ..CS 2.86 Hll . . .C6 2.87
Hll ...C8 2.75 Hll .. .C9 2.79
Hll ...CIO 2.19 C2 ...H31 2.18
C2 ...C4 2.37 C2 ...H41 2.82
C2 ...CIO 2.25 H21 ...C3 2.16
H21 . ..C4 2.65 H22 .. .C3 2.16
H22 ...CIO 2.53 C3 --H41 2.16
C3 ...H42 2.15 C3 ...CIO 2.21
H31 ...C4 2.16 C4 ...CS 2.46
C4 ...CIO 2.77 H41 ...cs 2.81
H42 ...cs 2.78 CS ...C7 2.49
cs ...H71 2.70 CS ...H72 2.74
C5 . ..C8 2.55 C5 ...H81 2.79
CS ...H83 2.80 C5 ...C9 2.49
C5 ...H101 2.72 CS ...H102 2.72
C6 ...H71 2.15 C6 ...H72 2.15
C6 ...H73 2.15 C6 ...H81 2.16
C6 ...H82 2.16 C6 ...H83 2.16
C6 ...H101 2.14 C6 ...H102 2.14
C6 ...H103 2.14 C7 .. .C8 2.46
C7 ...H82 2.67 C7 . ..H83 2.67
C7 . . .C9 2.48 C7 ...H102 2.70
C7 ...H103 2.70 H71 . . -C9 2.74
H72 . . . C8 2.67 H73 . . . C8 2.67
H73 . . .C9 2.68 ce ...C9 2.49
C8 ...H101 2.75 C8 . ..H103 2.66
H81 . . .C9 2.74 H81 ...CIO 2.86
H82 . . .C9 2.68
